qron_10q.htm

0001477932-23-003520.txt : 20230515 0001477932-23-003520.hdr.sgml : 20230515 20230515143705 ACCESSION NUMBER: 0001477932-23-003520 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Qrons Inc. CENTRAL INDEX KEY: 0001689084 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813623646 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55800 FILM NUMBER: 23921041 BUSINESS ADDRESS: STREET 1: 28-10 JACKSON AVENUE, #26N CITY: LONG ISLAND CITY STATE: NY ZIP: 11101 BUSINESS PHONE: 212-945-2080 MAIL ADDRESS: STREET 1: 28-10 JACKSON AVENUE, #26N CITY: LONG ISLAND CITY STATE: NY ZIP: 11101 FORMER COMPANY: FORMER CONFORMED NAME: BIOLABMART INC. DATE OF NAME CHANGE: 20161102 10-Q 1 qron_10q.htm FORM 10-Q qron_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

000-55800

(Commission File Number)

QRONS INC.

(Exact name of registrant as specified in its charter)

Wyoming		81-3623646
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

28-10 Jackson Avenue #26N Long Island City, New York		11101
(Address of principal executive offices)		(Zip Code)

(212)-945-2080

(Registrant’s telephone number, including area code)

______________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 15, 2023 there were 13,439,789 shares of the registrant’s common stock outstanding.

QRONS INC.

TABLE OF CONTENTS

		Page
	PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27

Item 4.	Controls and Procedures	27

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	28

Item 1A.	Risk Factors	28

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 3.	Defaults Upon Senior Securities	28

Item 4.	Mine Safety Disclosures	28

Item 5.	Other Information	28

Item 6.	Exhibits	29

	SIGNATURES	30

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

QRONS INC.

CONDENSED BALANCE SHEETS

(Unaudited)

	March 31, 2023			December 31, 2022

ASSETS
Current assets
Cash and cash equivalents	$	4,488		$	3,069
Total current assets		4,488			3,069

TOTAL ASSETS	$	4,488		$	3,069

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current liabilities
Accounts payable and accrued liabilities	$	146,141		$	128,285
Accounts payable and accrued liabilities – related party		54,276			42,671
Demand loans, related party		85,873			85,873
Advances from related party		373,500			358,500
Unsecured short-term advances		100,000			100,000
Convertible notes, net of debt discount		219,624			208,247
Derivative liabilities		372,814			358,775
Total current liabilities		1,352,228			1,282,351

Total liabilities		1,352,228			1,282,351

Stockholders’ deficit
Series A Preferred stock: $0.001 par value; 10,000 shares authorized; 2,000 shares issued and outstanding		2			2
Common stock, $0.0001 par value: 100,000,000 shares authorized; 13,439,789 shares issued and outstanding		1,344			1,344
Additional paid-in capital		8,254,316			8,254,316
Accumulated deficit		(9,603,402	)		(9,534,944	)
Total stockholders’ deficit		(1,347,740	)		(1,279,282	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	4,488		$	3,069

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

QRONS INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended
	March 31,
	2023			2022

Net sales	$	-		$	-

Operating expenses:
Research and development expenses		6,820			8,932
Professional fees		22,345			44,866
General and administrative expenses		7,777			9,758
Total operating expenses		36,942			63,556

Loss from operations		(36,942	)		(63,556	)

Other income (expense)
Interest expense		(17,477	)		(34,617	)
Change in derivative liabilities		(14,039	)		(165,955	)
Total other income (expense)		(31,516	)		(200,572	)

Net loss	$	(68,458	)	$	(264,128	)

Net loss per common shares (basic and diluted)	$	(0.01	)	$	(0.02	)

Weighted average shares outstanding
(basic and diluted)		13,439,789			13,289,789

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

QRONS INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

									Additional					Total
	Series A Preferred				Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit
Balance, December 31, 2022		2,000	$	2		13,439,789	$	1,344	$	8,254,316	$	(9,534,944	)	$	(1,279,282	)

Net loss for the period												(68,458	)		(68,458	)
Balance, March 31, 2023		2,000	$	2		13,439,789	$	1,344	$	8,254,316	$	(9,603,402	)	$	(1,347,740	)

	Series A Preferred				Common Stock				Additional Paid-in		Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit
Balance, December 31, 2021		2,000	$	2		13,289,789	$	1,329	$	7,697,351	$	(8,801,427	)	$	(1,102,745	)

Net loss for the period												(264,128	)		(264,128	)
Balance, March 31, 2022		2,000	$	2		13,289,789	$	1,329	$	7,697,351	$	(9,065,555	)	$	(1,366,873	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

QRONS INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Three Months ended March 31,
	2023			2022
Cash Flows From Operating Activities
Net loss	$	(68,458	)	$	(264,128	)
Adjustments to reconcile net loss to net cash used by operating activities:
Accretion of debt discount		11,377			29,291
Change in derivative liabilities		14,039			165,955
Changes in operating assets and liabilities:
(Increase) in prepaid expenses		-			(2,163	)
Increase in accounts payable and accrued liabilities		17,856			41,054
Increase in accounts payable and accrued liabilities - related party		11,605			580
Net cash used by operating activities		(13,581	)		(29,411	)

Cash Flows From Investing Activities
Net cash provided from (used by) investing activities		-			-

Cash Flows From Financing Activities
Proceeds from related party advances		15,000			-
Net cash provided from financing activities		15,000			-

Net increase (decrease) in cash and cash equivalents		1,419			(29,411	)

Cash at beginning of year		3,069			35,065
Cash at end of period	$	4,488		$	5,654

SUPPLEMENTAL DISCLOSURES
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 1 – Description of Business and Basis of Presentation

Organization and Nature of Business:

Qrons Inc. (“Qrons” or the “Company”) was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. and changed its name to Qrons Inc., effective August 8, 2017.

The Company’s common stock was approved by the Financial Industry Regulatory Authority (“FINRA”) for quotation on the OTC pink sheets under the symbol “BLMB” as of July 3, 2017. FINRA announced the Company’s name change to Qrons Inc. on August 9, 2017. The new name and symbol change to “QRON” for the OTC Market was effective August 10, 2017. The Company’s common stock commenced trading on the OTCQB Venture Market on August 12, 2019.

The Company is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases, which are an enormous social and economic burden on society. The Company seeks to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. The Company’s search is currently focused on researchers based in Israel, a country which is world-renowned for biotech innovations and where its President is located and where its research to date has been conducted.

The Company’s principal executive office is located at 28-10 Jackson Avenue, Long Island City, #26N, New York 11101.

Note 2 – Summary of Significant Accounting Policies

Financial Statements: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

Fiscal year end: The Company has selected December 31 as its fiscal year end.

Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Cash Equivalents: The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.

Research and Development Costs: The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and development costs were $6,820 for the three months ended March 31, 2023. Research and development costs were $8,932 for the three months ended March 31, 2022.

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 2 – Summary of Significant Accounting Policies (Continued)

Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred. The Company incurred no advertising and marketing costs during the three months ended March 31, 2023 and 2022.

Related Parties: For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

Stock Based Compensation and Other Share-Based Payments: The Company records stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation, using the fair value method of the award on grant date. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the equity instruments issued. The expense attributable to the Company’s directors is recognized over the period the amounts are earned and vested, and the expense attributable to the Company’s non-employees is recognized when vested, as described in Note 9, Stock Plan.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument.

The following table provides a summary of the fair value of the Company’s derivative liabilities as of March 31, 2023 and December 31, 2022:

	Fair value measurements on a recurring basis
	Level 1		Level 2		Level 3
As of March 31, 2023:
Liabilities
Derivative liabilities	$	-	$	-	$	372,814

As of December 31, 2022:
Liabilities
Derivative liabilities	$	-	$	-	$	358,775

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 2 – Summary of Significant Accounting Policies (Continued)

Warrants: The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC 815 Derivatives and Hedging, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. For warrants classified as equity instruments the Company applies the Black Scholes model and expenses the fair value as financing costs. For warrants classified as derivative financial instruments the Company applies the Monte Carlo model to value the warrants.

Income taxes: The Company has adopted ASC 740, Income Taxes, which requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Basic and Diluted Loss Per Share: In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common stock had been issued and if the additional shares of common stock were dilutive.

Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options.

The table below reflects the potentially dilutive securities outstanding during each reporting period:

	March 31, 2023		March 31, 2022
Research warrants at 3% of issued and outstanding shares		403,194		398,694
Convertible notes		702,213		723,751
Series A preferred shares		700		700
Stock options vested		4,328,332		4,098,332
Stock purchase warrants		295,000		295,000
Total		5,729,439		5,516,477

Recently Issued Accounting Pronouncements

Adopted

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 changes how entities account for convertible instruments and contracts in an entity’s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU 2020-06 also modifies the guidance on diluted earnings per share calculations. The Company elected to adopt this guidance in the year ended December 31, 2022. There was no material effect on the Company’s operations, financial position or cash flows as a result of the adoption.

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 3 – Going Concern

The Company has experienced net losses to date and has not generated revenues from operations. While the Company raised proceeds totaling $72,500 in unsecured advances from related parties in the year ended December 31, 2022 and a further $15,000 in unsecured advances from related parties during the current three months ended March 31, 2023, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the second quarter of 2023. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing, and continued support from its officers and directors. There can be no assurance that financing, whether debt or equity, will be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. In addition, if the Company is unable to obtain adequate financing from the capital markets, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Covid-19 Pandemic and Other Factors

While the World Health Organization has recently declared that the COVID-19 pandemic is no longer a public health emergency of international concern and the global economy is focused on recovery, the impact of COVID-19 could continue to have an adverse impact on the Company going forward. COVID-19 caused significant disruptions to the global financial markets, which may continue to impact the Company’s ability to raise additional capital and ongoing research and development of our product candidates. Research facilities at Dartmouth were subject to closures as well as laboratories at Ariel in Israel during the pandemic. This resulted in our discontinuing our research at these Universities and was part of our decision to adjust our research to be collaborative and to seek aligning with third parties to advance our expanded goals. We do not currently know the full extent of potential delays of research in the future and the ultimate impact on us and our research relationships is currently uncertain. Additional factors which may impact the Company’s ongoing operations include, but are not limited to, inflation, potential supply chain issues as a result of the aforementioned recovery from the COVID-19 pandemic, the recent war in the Ukraine and climate change. These events may have serious adverse impact on domestic and foreign economies which may impact the Company’s operations as a result of a variety of factors including the potential for difficulties obtaining additional capital. The Company is unable to predict the ongoing impact of these factors on the Company’s financial operations. There are no assurances that the Company will be able to meet its obligations, raise funds or conclude the acquisition of identified businesses.

Note 4 – Convertible Note – Related Party and Derivative Liabilities

On September 1, 2016, the Company entered into a convertible debenture agreement with Decagon LLC, doing business as CubeSquare, LLC (“CubeSquare”), of which the Company’s Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 (“Note 1”). Note 1 bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender’s option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.

On September 29, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; on November 6, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020; on October 30, 2020, the Company further amended Note 1 to extend the maturity date to September 1, 2021; and on October 7, 2021, the Company further amended Note 1 to extend the maturity date to September 1, 2022 under the same terms and conditions.

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 4 – Convertible Note – Related Party and Derivative Liabilities (Continued)

On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and was due on September 27, 2018. Interest accrues from September 27, 2017 and is payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date to September 27, 2019. On November 6, 2019, Note 2 was amended to extend the maturity date to September 27, 2020; on October 30, 2020 Note 2 was amended to extend the maturity date to September 27, 2021; and further on October 7, 2021 Note 2 was amended to extend the maturity date to September 27, 2022.

On September 27, 2022 the Board and the noteholder agreed to cancel the two convertible notes and in full satisfaction of such outstanding debt to issue a new 6% non-convertible promissory note to CubeSquare in the principal amount of $35,873 (the “New Note”), representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022.

The Company analyzed the amendment to Note 1 and Note 2 under ASC 815-10-15-83 and concluded that the conversion feature within these two convertible Notes meet the definition of a derivative. The Company estimated the fair value of the derivative at each report date using the Black-Scholes valuation model to value the derivative liability related to the variable conversion rate. There is no derivative liability associated with the New Note given the absence of a conversion feature.

The carrying value of these convertible notes is as follows:

	March 31, 2023		December 31, 2022
Face value of certain convertible notes	$	-	$	25,000
Convertible notes extinguish		-		(25,000	)
Carrying value	$	-	$	-

For Three Months Ended

March 31,

2023

2022

Interest on the convertible notes

493

As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities – related party was $0.

As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature is summarized as follows:

Balance at December 31, 2021	$	73,099
Change in fair value during three months period		(20,463	)
Balance at March 31, 2022	$	52,636

The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2022 and December 31, 2021 and the commitment date:

	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility	101%-103		%	181%-182		%	261%~280		%
Expected term	0.92 - 1 year			0.67 - 0.74 year			0.49 year
Risk free interest rate		1.33	%		1.06	%		1.06	%

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 5 – Convertible Note and Derivative Liabilities

(1) 8% Convertible notes with warrants issued in December 2019 and February 2020

In December 2019, we issued and sold in a private offering 8% convertible notes in the aggregate principal amount of $70,000. Such notes were due on December 31, 2021 and are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date of the notes to December 2022 upon initial maturity, and further extended the maturity date to December 2023 under the same terms and conditions during the year ended December 31, 2022.

On February 19, 2020 we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date to February 2023 upon initial maturity, and further extended the maturity date to February 2024 under the same terms and conditions during the year ended December 31, 2022.

The carrying value of these convertible notes is as follows:

March 31,

2023

December 31,

2022

Face value of certain convertible notes

80,000

Carrying value

80,000

Interest expenses associated with the convertible notes are as follows:

	For Three Months Ended
	March 31,
	2023		2022
Amortization on debt discount	$	-	$	541
Interest on the convertible notes		1,613		1,578
Total	$	1,613	$	2,119

As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities was $20,882 and $19,269, respectively.

The convertible notes qualify for derivative accounting and bifurcation under ASC 815. As of March 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows:

Balance at December 31, 2022	$	57,033
Change in fair value		38,089
Balance at March 31, 2023		95,122

The convertible notes qualify for derivative accounting and bifurcation under ASC 815. As of March 31, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows:

Balance at December 31, 2021	$	157,490
Change in fair value		(10,411	)
Balance at March 31, 2022	$	147,079

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 5 – Convertible Note and Derivative Liabilities (Continued)

The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2023 and December 31, 2022 and the commitment date:

	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility	154%-173		%	194.20%-201.98		%	96.37%-98.24		%
Expected term	2.10 years			1.08 - 1.22 years			0.83 ~ 0.97 years
Risk free interest rate	1.42-1.65		%		4.41	%		4.64	%

	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility	154% ~173		%	203%~301		%	228%~245		%
Expected term	2.10 years			1.08 ~ 1.22 years			0.83 ~ 0.97 years
Risk free interest rate	1.42 ~ 1.65		%		0.39	%		1.35	%

(2) 8% Convertible note with warrants issued on June 15, 2021

On June 15, 2021, the Company entered into a note purchase agreement with Quick Capital, LLC (“Quick Capital”) pursuant to which the Company issued a twelve-month convertible promissory note in the principal amount of $115,000 for a $100,000 investment (the “Quick Note”), which included an original issuance discount of 10% and a $3,500 credit for legal and transaction costs. In connection with the Quick Note issuance, Quick Capital was also issued a five-year warrant (the “Quick Warrant”) to purchase up to an aggregate of 115,000 shares of the Company’s common stock at an exercise price of $1.00 per share (the “Quick Warrant Shares”) subject to adjustments for dilutive issuances at lower prices.

The Quick Note is convertible into shares of common stock at a conversion price of $0.50 per share. If delivery of the conversion shares is not timely made, the Company is obligated to pay Quick Capital $2,000 for each day that the delivery is late as liquidated damages. The conversion price of the Quick Note will be reduced if the Company issues common stock or grants derivative securities for consideration at a price less than the conversion price to the amount of the consideration of such dilutive issuance. The Quick Note may not be prepaid.

The Company is subject to significant cash penalties if the Company defaults on the Quick Note or in the event shares are not issued in a timely manner when a notice of conversion is provided. If an event of default occurs, the Quick Note will become immediately due and payable in an amount equal to 150% of the then outstanding principal amount of the Quick Note plus any interest or amounts owing to Quick Capital. The default provisions are based on the type of default and include a penalty of 50% of the principal plus accrued interest due (the “Default Sum”) and a parity value of the Default Sum based on the effective conversion of the Quick Note on the date of payment of the default and the maximum stock value during the period between the default date and the payment date.

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 5 – Convertible Note and Derivative Liabilities (Continued)

(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)

The Note and accrued interest totaling $124,200 was not repaid on maturity, constituting an event of default increasing the repayment value of the note to an amount equal to 150% of the principal balance and accrued interest outstanding, or $186,300. On December 7, 2022, the Company and Quick Capital amended the Note to extend the maturity date thereof to June 15, 2023, and amended the Warrant maturity date to June 15, 2027. Further Quick Capital agreed to reduce the outstanding balance of the Note from $186,300 to $150,000 in consideration for the issuance of 150,000 shares of unregistered, restricted common stock valued at $76,350.

Details of the valuation of the 150,000 shares of common stock are set out below:

December 7, 2022:
Note Payable, original face value	$	115,000
Accrued interest and default penalty on default		71,300
Convertible Note Payable, amended		(150,000	)
Debt discount, day one, amended convertible note payable		24,436
Derivative Liability associated with warrants		(15,416	)
Change in Fair Value		31,030
Fair value of Common stock issued	$	76,350

The unpaid balance of the Note continues to accrue interest at 8% per annum.

The Company valued the embedded default derivative liability of the Quick Note and the Quick Warrant liability, including the full ratchet reset feature, using Monte Carlo models.

The fair value of the Quick Note and Quick Warrant embedded default derivatives liability has been valued as of March 31, 2023 and December 31, 2022.

The carrying value of the Quick Note is as follows:

	March 31, 2023			December 31, 2022
Face value of Quick Note	$	150,000		$	150,000
Less: unamortized discount		(10,376	)		(21,753	)
Carrying value	$	139,624		$	128,247

Interest expenses associated with the conversion feature is as follows:

	For the Three Months ended
	March 31,
	2023		2022
Amortization of debt discount	$	11,377	$	28,750
Interest on the convertible notes		2,959		2,268
Total	$	14,336	$	31,018

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 5 – Convertible Note and Derivative Liabilities (Continued)

(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)

As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities was $3,748 and $789, respectively.

As a result of the application of ASC 815 as of March 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows:

Balance at December 31, 2022	$	301,742
Change in fair value – convertible note		(10,740	)
Change in fair value – warrants		(13,310	)
Balance at March 31, 2023	$	277,692

As a result of the application of ASC 815 as of March 31, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows:

Balance at December 31, 2021	$	175,368
Change in fair value – convertible note		14,352
Change in fair value – warrants		182,477
Balance at March 31, 2022	$	372,197

Convertible note:	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility		307.10	%		119.70	%		119.70	%
Expected term	1 years			0.45 years			0.21 years
Risk free interest rate		0.18	%		4.37	%		4.37	%

Warrants:	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility		201.70	%		219.10	%		222.20	%
Expected term	5 years			4.45 years			4.21 years
Risk free interest rate		0.65	%		4.27	%		4.19	%

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 5 – Convertible Note and Derivative Liabilities (Continued)

(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)

Convertible note:	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility		307.10	%		215.70	%		336.80	%
Expected term	1 years			0.45 years			0.21 years
Risk free interest rate		0.18	%		0.43	%		1.37	%

Warrants:	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility		201.70	%		200.90	%		280.40	%
Expected term	5 years			4.45 years			4.20 years
Risk free interest rate		0.65	%		0.82	%		1.350	%

Note 6 – Unsecured Short-Term Advance from Third Party

On June 20, 2019, the Company received $100,000 from a third party in the form of an unsecured, demand, non-interest-bearing, short-term advance to meet its operating needs. The advance remains outstanding at March 31, 2023 and December 31, 2022.

Note 7 – Related Party Transactions

(1) Demand Loan from related party

On May 1, 2019, the Company issued a promissory note (the “Note”) to CubeSquare in the principal amount of $50,000. The Company’s Chief Executive Officer is the managing partner and the Company’s President is a 25% owner of CubeSquare. The Note bears interest at the rate of 8% per annum and is due and payable by the Company upon demand from CubeSquare. The Company recorded interest expenses of $997 and $986 for the three months ended March 31, 2023 and 2022, respectively

On September 27, 2022 the Board and the related party noteholder agreed to cancel two convertible notes issued to Cubesquare and in full satisfaction of such outstanding debt to issue a new 6% promissory note (Ref: Note 4) in the principal amount of $35,873, representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company recorded interest expenses of $531 and $0 for the three months ended March 31, 2023 and 2022, respectively.

As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities – related party in respect of the aforementioned notes was $16,763 and $15,234, respectively.

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 7 – Related Party Transactions (Continued)

(2) Advances from Related Parties

During the year ended December 31, 2019, the Company received $135,000 from Jonah Meer, its Chief Executive Officer, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $70,000 from Jonah Meer. An additional $72,500 in advances was received from Mr. Meer during the year ended December 31, 2022. An additional $15,000 in advances was received from Mr. Meer during the three months ended March 31, 2023.Mr. Meer is owed $292,500 and $277,500 in respect to these advances at March 31, 2023 and December 31, 2022, respectively.

On August 20, 2019, the Company received $50,000 from Ido Merfeld, its President, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $21,000 from Ido Merfeld. There were no additional advances from Mr. Merfeld during the years ended December 31, 2022 and 2021. Mr. Merfeld is owed $71,000 in respect to these advances at March 31, 2023 and December 31, 2022.

During the year ended December 31, 2020, the Company received $10,000 from CubeSquare in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs which amount is outstanding as of March 31, 2023 and December 31, 2022.

(3) Others

Jonah Meer, the Company’s Chief Executive Officer, made payments of $10,076 to various vendors during the three months ended March 31, 2023. The balance payable to Mr. Meer of $36,344 and $26,268 is reflected in accounts payable, related party as of March 31, 2023 and December 31, 2022, respectively.

During the year ended December 31, 2019, Ido Merfeld, the Company’s President, made payments to various vendors in the aggregate amount of $1,169. The balance payable to Mr. Merfeld of $1,169 is reflected in accounts payable, related party as of March 31, 2023 and December 31, 2022.

Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement

Dartmouth College – Intellectual Property License Agreement

On October 2, 2019, the Company entered into an intellectual property license agreement (the “Intellectual Property License Agreement”) pursuant to which Dartmouth granted the Company an exclusive world-wide license under the patent application entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement.

The Agreement provided for: (i) a $25,000 license issue fee; (ii) an annual license maintenance fee of $25,000, until the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales of licensed products and services by the Company or a sublicensee; (iv) 15% of consideration received by the Company under a sublicense; and (v) beginning in the first calendar year after the first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter. The Company will also reimburse Dartmouth for all patent preparation, filing, maintenance and defense costs.

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement (Continued)

Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law.

The Agreement may be terminated by Dartmouth if the Company is in material breach of the Agreement which is not cured after 30 days of notice thereof or if the Company becomes insolvent. Dartmouth may terminate the Agreement if the Company challenges a Dartmouth patent or does not terminate a sublicensee that challenges a Dartmouth patent, except in response to a valid court or governmental order. The Company may terminate the Agreement at any time upon six months written notice to Dartmouth.

If the Company or any sublicensee or affiliate institutes or participates in a licensed patent challenge, the then current earned royalty rate for licensed products covered by Dartmouth patents will automatically be increased to three times the then current earned royalty rate.

On March 23, 2021, the United States Patent and Trademark Office issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College, which is directed to mechanically interlocked, molecules-based materials for 3-D printing. The patent’s inventors are Professor Chenfeng Ke, a member of the Company’s Scientific Advisory Board and Qianming Lin, Professor Ke’s assistant. The patent grant is the culmination of the Intellectual Property License Agreement between the Company and Dartmouth with respect to an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health.

Dartmouth College – Intellectual Property License Agreement

The Company expensed $6,250 as license fees during each of the three months ended March 31, 2023 and 2022 with respect to such annual fee.

Note 9 – Stock Plan

2016 Stock Option and Stock Award

On December 14, 2016, the Board adopted the Company’s 2016 Stock Option and Stock Award Plan (the “Plan”). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Board. The Company has reserved 10 million shares for issuance under the Plan.

(a) Stock Options granted to Science Advisors and employees

On December 22, 2022, the Board granted a five-year option to purchase 325,000 shares of common stock to a scientific advisor. The options have an exercise price of $2.00 per share, are immediately exercisable and were expensed on issue date.

During the year ended December 31, 2022, various three-year stock options to purchase 145,000 shares of common stock of the Company previously granted to science advisors and employees expired unexercised.

Details of outstanding options for employees and scientific advisors at March 31, 2023 are below:

	Grant date	Vested		Unvested		Exercise price		Expiry
Scientific Advisor	12/10/18		145,000		-	$	2.00	12/10/23
	12/17/19		33,333		-	$	2.00	12/17/23
	12/17/19		33,333		-	$	2.00	12/17/24
	12/10/20		100,000		-	$	2.00	12/10/25
	12//22/21		325,000		-	$	2.00	12/22/26
	12/22/22		325,000		-	$	2.00	12/22/27

Employees	04/16/18		10,000		-	$	2.00	4/16/23
	08/15/18		6,667		-	$	2.00	08/15/23
	12/10/18		33,333		-	$	2.00	12/10/23
	07/01/19		33,333		-	$	2.00	07/01/23
	07/01/19		33,333		-	$	2.00	07/01/24

As of March 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods.

(b) Stock Options granted to Officers:

On December 4, 2022, a five-year stock option to purchase 600,000 shares of common stock of the Company previously granted to officers expired unexercised.

On December 22, 2022, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share, are immediately exercisable and were expensed on issue date.

Following are the details of stock options granted to our officers at March 31, 2023:

Name	Grant date	Exercisable		Exercise price		Expiry
Jonah Meer	12/10/18		325,000	$	2.00	12/10/2023
	12/17/19		325,000	$	2.00	12/17/24
	12/10/20		325,000	$	2.00	12/10/25
	12//22/21		325,000	$	2.00	12//22/26
	12/22/22		325,000	$	2.00	12/22/27

Ido Merfeld	12/10/18		325,000	$	2.00	12/10/2023
	12/17/19		325,000	$	2.00	12/17/24
	12/10/20		325,000	$	2.00	12/10/25
	12//22/21		325,000	$	2.00	12//22/26
	12/22/22		325,000	$	2.00	12/22/27

As of March 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods.

A summary of the activity for the Company’s stock options at March 31, 2023 and December 31, 2022, is as follows:

	March 31, 2023						December 31, 2022
			Weighted Average Exercise		Weighted Average Remaining Contractual Life					Weighted Average Exercise		Weighted Average Remaining Contractual Life
	Shares		Price		(in years)		Shares			Price		(in years)
Outstanding, beginning of period		4,328,332	$	2		2.78		4,098,332		$	2		3.08
Granted		-	$	2		-		975,000		$	2		-
Exercised		-	$	-		-		-		$	-		-
Canceled/forfeited		-	$	2		-		(745,000	)	$	2		-
Outstanding, end of period		4,328,332	$	2		2.78		4,328,332		$	2		3.03
Options exercisable, end of period		4,328,332	$	2		2.78		4,328,332		$	2		3.03
Weighted average fair value of options granted			$	2						$	2

Table of Contents

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

March 31, 2023 and 2022

Note 10 – Capital Stock

Authorized:

The Company has authorized 100,000,000 shares of common stock, par value $0.0001, and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001.

Series A Preferred Stock:

The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company’s common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding.

There were 2,000 shares of Series A Preferred Stock issued and outstanding as of March 31, 2023 and December 31, 2022.

Common Stock

In December 2022, the Company issued 150,000 shares of its common stock to Quick Capital LLC with a value of $76,350 related to a loan amendment (Note 5).

There were 13,439,789 shares of common stock issued and outstanding as of March 31, 2023 and December 31, 2022.

Common Stock Purchase Warrants

As of March 31, 2023 and December 31, 2022, the following common stock purchase warrants were outstanding:

	Warrants		Weighted Average Exercise Price
Outstanding – December 31, 2021		295,000	$	1.00
Granted		-		-
Canceled/forfeited		-		-
Exercised		-		-
Outstanding – December 31, 2022		295,000		1.00
Granted		-		-
Canceled/forfeited		-		-
Exercised		-		-
Outstanding – March 31, 2023		295,000	$	1.00

On June 15, 2021, the Company granted a convertible noteholder a warrant to purchase 115,000 shares of common stock at an exercise price of $1.00, subject to adjustments for full ratchet resets for dilutive issuances at lower prices. (See Note 5(2) above.)

Note 11 – Subsequent Events

The Company has evaluated events for the period through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains predictions, estimates and other forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “intends,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors including the risks set forth in the section entitled “Risk Factors” in our prospectus, as filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2022, that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.

Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Report. You should read this Report with the understanding that our actual future results may be materially different from what we expect.

All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made, except as required by federal securities and any other applicable law.

The management’s discussion and analysis of our financial condition and results of operations are based upon our condensed unaudited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

The following discussion of our financial condition and results of operations should be read in conjunction with the notes to the unaudited financial statements appearing elsewhere in this Report and the Company’s audited financial statements for the fiscal year ended December 31, 2022, as filed with the SEC in its Annual Report on Form 10-K on March 31, 2023, along with the accompanying notes. As used in this Quarterly Report, the terms “we,” “us,” “our” and the “Company” means Qrons Inc.

The Company has relied primarily on its two co-founders, Jonah Meer, Chief Executive Officer, and Ido Merfeld, President, who are its sole directors to manage its day-to-day business and has outsourced professional services to third parties in an effort to maintain lower operational costs.

Messrs. Meer and Merfeld, as the holders of the Company’s issued and outstanding shares of the Company’s Class A Preferred Stock, collectively have 66 2/3% of the voting rights of the Company. Acting together, they will be able to influence the outcome of all corporate actions requiring approval of our stockholders.

Plan of Operations

We are an innovative biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. The Company’s approach is to marshal and leverage its proprietary research with developing breakthrough technologies by seeking to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases, and such other indications that may make use of our technology. The Company’s search is focused on researchers based in Israel, a country which is world-renowned for biotech innovations and where our researchers are based.

Table of Contents

To date, the Company has collaborated with universities and scientists in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels to develop a treatment that integrates proprietary, engineer mesenchymal stem cells (“MSCs”), 3D printable implant, smart materials and a novel delivery system and has two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries, both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs.

In early 2022, the Company began collaborating with scientists at a leading University in Israel to conduct preliminary experiments to confirm that a combination of certain molecule compounds that they invented which contain immunomodulating properties when integrated with ingredients in our QS200™ product candidate may substantially improve its solubility and allow very high dosage treatments which we believe offers treatment options to diffused axonal injuries. These molecules are being tested for certain indication in various Phase II trials conducted by others.

We also believe that the improved dosage delivery may present a unique treatment option to patients who suffer from antibiotic resistant bacteria infection and Sepsis. We are looking to conduct such in vitro tests, which if successful we believe may provide an expedited pathway to human trials.

As a result of the Company's multidiscipline research effort in the field of supramolecular and polymeric materials chemistry and neuronal tissue engineering, on April 3, 2022, the Company filed a US provisional patent application for inventions of therapeutic polypseudorotaxane hydrogels, and on March 12, 2023 filed an International Patent Application at the International Bureau , thereby providing the Company with the option to, in the future, seek protection for these inventions globally. The patent application relates generally to the treatment of pathological central nervous system conditions such as traumatic injury or neurodegenerative disease and the applications of uses of hydrogels in the treatment of such conditions, as well as manufacturing techniques for such compositions,

On September 18, 2022 Ido Merfeld, our President and co-Founder was awarded his PhD in Molecular Biology and Neuroscience based on his submission of his paper entitled Mesenchymal Stem Cells integrated into Pseudopolyrotaxane hydrogels promote neuronal stem cells maturation and inhibits reactive Astrocytes and Activated Microglia after penetrating traumatic brain injury, based on the research done at Qrons.

We have not generated any revenue from the sale of products.

Results of Operations

Three Months Ended March 31, 2023 and March 31, 2022

Revenue

We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future.

Net Loss

We had a net loss of $68,458 in the three months ended March 31, 2023 compared to a net loss of $264,128 in the three months ended March 31, 2022, as follows:

	For the Three Months Ended
	March 31,
	2023			2022

Net sales	$	-		$	-

Operating expenses:
Research and development expenses		6,820			8,932
Professional fees		22,345			44,866
General and administrative expenses		7,777			9,758
Total operating expenses		36,942			63,556

Income (loss) from operations		(36,942	)		(63,556	)

Other income (expense)
Interest expense		(17,477	)		(34,617	)
Change in derivative liabilities		(14,039	)		(165,955	)
Total other income (expense)		(31,516	)		(200,572	)

Net (loss)	$	(68,458	)	$	(264,128	)

Table of Contents

Operating Expenses

Total operating expenses for the three months ended March 31, 2023 were $36,942 compared to total operating expenses of $63,556 for the three months ended March 31, 2022. The decrease in operating expenses during the three months ended March 31, 2023 is predominantly due to a decrease in professional fees from $44,866 for the three months ended March 31, 2022 to $22,345 for the three months ended March 31, 2022. The Company incurred additional professional fees during the three months ended March 31, 2022 as a result of the costs associated with filing a registration statement and prospectus. The Company also recorded decreases in research and development expenses from $8,932 for the three months ended March 31, 2022 to $6,820 for the three months ended March 31, 2023, and a decrease in general and administrative expenses from $9,758 during the three months ended March 31, 2022 to $7,777 for the three months ended March 31, 20223. During the three months ended March 31, 2023, the Company incurred $6,820 of research and development expenses which included technology licensing fees of $6,250 and lab supplies and expenses of $570, as compared to $8,932 in research and development fees for the three months ended March 31, 2022 which includes licensing fees of $6,250 and software license and equipment costs of $2,682.

Other Income (Expense)

Other expense in the three months ended March 31, 2023 was $31,516, which included a loss of $14,039 as a result of the change in value of derivative liabilities, and interest expense of $17,477 which is comprised of accretion of convertible notes of $11,377 and accrued interest on convertible notes payable of $6,100. Other expense in the three months ended March 31, 2022 was $200,572, which included a loss of $165,955 as a result of the change in value of derivative liabilities, and interest expense of $34,617 which is comprised of accretion of convertible notes of $29,291 and accrued interest on convertible notes payable of $5,326.

Operating Activities

Net Cash used in operating activities for the three months ended March 31, 2023 was primarily the result of net loss, offset by non-cash items including accretion of debt discount of $11,377, a loss from the change in derivative liabilities of $14,039 and changes to operating assets and liabilities, including an increase to accounts payable of $17,856 and an increase to accounts payable-related parties of $11,605. Net cash used in operating activities was $29,411 for the three months ended March 31, 2022 compared to $28,189 for the three months ended March 31, 2021. Net cash used in operating activities for the three months ended March 31, 2022 was primarily the result of net loss, offset by non-cash items, accretion of debt discount of $29,291, an increase in derivative liabilities of $165,955, and changes to operating assets and liabilities, including an increase to prepaid expenses of $2,163, an increase to accounts payable of $41,054 and an increase to accounts payable-related parties of $580.

Net Cash used in operating activities for the three months ended March 31, 2023 was the result of net loss, offset by non-cash items including accretion of debt discount of $11,377, a loss from the change in fair market value of derivative liabilities of $14,039 and changes to operating assets and liabilities, including an increase to accounts payable of $17,856 and an increase to accounts payable-related parties of $11,605. Net cash used in operating activities was $29,411 for the three months ended March 31, 2022 and was the result of net loss, offset by non-cash items including accretion of debt discount of $29,291, a loss from the change in fair market value of derivative liabilities of $165,955, and changes to operating assets and liabilities, including an increase to prepaid expenses of $2,163, an increase to accounts payable of $41,054 and an increase to accounts payable-related parties of $580.

Investing Activities

There were no investing activities during the three months ended March 31, 2023 and 2022.

Financing Activities

During the three months ended March 31, 2023 there was $15,000 of cash provided from financing activities consisting of advances from related parties. There were no financing activities during the three months ended March 31, 2022.

Table of Contents

Liquidity and Capital Resources

As of March 31, 2023, we had cash of $4,488. We are in the early stage of development and have experienced net losses to date and have not generated revenue from operations which raises substantial doubt about our ability to continue as a going concern. There are a number of conditions that we must satisfy before we will be able to commercialize potential products and generate revenue, including successful development of product candidates, which includes clinical trials, FDA approval, demonstration of effectiveness sufficient to generate commercial orders by customers, establishing production capabilities as well as effective marketing and sales capabilities for our product. We do not currently have sufficient resources to accomplish any of these conditions necessary for us to generate revenue and expect to incur increasing operating expenses. We will require substantial additional funds for operations, the service of debt and to fund our business objectives. There can be no assurance that financing, whether debt or equity, will be available to us in the amount required at any particular time or for any particular period or, if available, that it can be obtained on terms favorable to us. If additional funds are raised by the issuance of equity securities, such as through the issuance and exercise of warrants, then existing stockholders will experience dilution of their ownership interest. If additional funds are raised by the issuance of debt or other equity instruments, we may be subject to certain limitations in our operations, and issuance of such securities may have rights senior to those of the then existing stockholders. We currently have no agreements, arrangements or understandings with any person or entity to obtain funds through bank loans, lines of credit or any other sources.

We continue exploring sources of debt and equity financings as well as available grants. We are currently exploring and are in discussions for a potential strategic alliance in the biotechnology field which could advance our MSCs and neurodegenerative research. as well as treat other indications. There can be no assurance that we will reach agreement on this alliance or that the necessary financing will be available to implement the research under the alliance. In such event, we may explore other relationships with other third parties to develop or commercialize products or technologies that we have not previously sought to develop or commercialize, decide to exit our existing business, cease operations altogether or pursue an acquisition of our company. However, without additional financing, we do not believe our resources will be sufficient to meet our operating and capital needs beyond the second quarter of 2023.

Offering

The Company filed a registration statement on Form S-1 with the SEC on January 11, 2022, to offer and sell up to 2,500,000 shares of common stock in a self-underwritten primary offering at a fixed price of $0.70 per share which was declared effective on January 11, 2022. To date, no shares have been sold and there can be no assurance that the Company will be successful in selling any of the shares being offered.

Going Concern

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. Our report from our independent registered public accounting firm for the fiscal year ended December 31, 2022 includes an explanatory paragraph stating the Company has recurring losses and limited operations which raise substantial doubt about its ability to continue as a going concern. If the Company is unable to obtain adequate capital, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Table of Contents

COVID-19 Pandemic and other factors

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Critical Accounting Estimates

The financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses and related disclosures. We base our estimates on historical experience, as appropriate, and on various other assumptions that we believe are reasonable under the circumstances. Changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ significantly from the estimates made by our management. We evaluate our estimates and assumptions on an ongoing basis. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. Our significant accounting policies are more fully discussed in Note 2 to our unaudited condensed financial statements contained herein.

Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The estimates used for, but not limited to, the fair value of financial instruments, stock based compensation and warrants could be impacted. We have assessed the impact and are not aware of any specific events or circumstances that required an update to our estimates and assumptions or materially affected the carrying value of our assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

Estimates

Recent Accounting Pronouncements

Adopted

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company and are not required to provide this information.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, as of March 31, 2023, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and principal financial officer have concluded that, based on the material weaknesses discussed below, our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act were recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Act Commission’s rules and forms and that our disclosure controls are not effectively designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our internal controls and procedures are not effective for the following reasons: (i) there is an inadequate segregation of duties consistent with control objectives as management is comprised of only two persons, one of which is the Company’s principal executive officer and principal financial officer and, (ii) the Company does not have a formal audit committee with a financial expert, and thus the Company lacks the board oversight role within the financial reporting process.

In order to mitigate the foregoing material weakness, we have engaged an outside accounting consultant with significant experience in the preparation of financial statements in conformity with GAAP to assist us in the preparation of our financial statements to ensure that these financial statements are prepared in conformity with GAAP. We will continue to monitor the effectiveness of this action and make any changes that our management deems appropriate.

We would need to hire additional staff to provide greater segregation of duties. Currently, it is not feasible to hire additional staff to obtain optimal segregation of duties. Management will continue to reassess this matter to determine whether improvement in segregation of duty is feasible. In addition, we would need to expand our board to include independent members.

Going forward, we intend to evaluate our processes and procedures and, where practicable and resources permit, implement changes in order to have more effective controls over financial reporting.

Changes in Internal Control over Financial Reporting

During the period covered by this report, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.

ITEM 1A. RISK FACTORS

The Company is a smaller reporting company and is not required to provide this information.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no sales of equity securities during the period covered by this Report that were not registered under the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5. OTHER INFORMATION

None

Table of Contents

ITEM 6. EXHIBITS

Exhibit Number		Exhibit
31		Certification of the Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32		Certification of the Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)
101.INS		XBRL INSTANCE DOCUMENT
101.SCH		XBRL TAXONOMY EXTENSION SCHEMA
101.CAL		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB		XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	QRONS INC.

Date: May 15, 2023	By:	/s/ Jonah Meer
		Jonah Meer
		Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

EX-31 2 qron_ex31.htm CERTIFICATION qron_ex31.htm

EXHIBIT 31

Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended

I, Jonah Meer (Principal Executive Officer and Principal Financial and Accounting Officer), certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Qrons Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

As the registrant’s certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15 (f) for the registrant and I have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5.	As the registrant’s certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2023	By:	/s/ Jonah Meer
		Jonah Meer
		Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

EX-32 3 qron_ex32.htm CERTIFICATION qron_ex32.htm

EXHIBIT 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Jonah Meer, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) of Qrons Inc. (the “Company”), certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350) that, to his knowledge, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Report”):

(1)

fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Jonah Meer
Jonah Meer
Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

Date: May 15, 2023

EX-101.SCH 4 qron-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Convertible Note Related Party and Derivative Liabilities link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Convertible Note and Derivative Liabilities link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Unsecured Short-Term Advance from Third Party link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Intellectual Property License Agreement and Sponsored Research Agreement link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Stock Plan link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Convertible Note and Derivative Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Stock Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Capital Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 1) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 2) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 3) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Convertible Note and Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Convertible Note and Derivative Liabilities (Details 1) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - Convertible Note and Derivative Liabilities (Details 2) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - Convertible Note and Derivative Liabilities (Details 3) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - Convertible Note and Derivative Liabilities (Details 4) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - Convertible Note and Derivative Liabilities (Details 5) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - Convertible Note and Derivative Liabilities (Details 6) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - Convertible Note and Derivative Liabilities (Details 7) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - Convertible Note and Derivative Liabilities (Details 8) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - Convertible Note and Derivative Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - Unsecured ShortTerm Advance from Third Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000046 - Disclosure - Stock Plan (Details) link:presentationLink link:calculationLink link:definitionLink 000047 - Disclosure - Stock Plan (Details 1) link:presentationLink link:calculationLink link:definitionLink 000048 - Disclosure - Stock Plan (Details 2) link:presentationLink link:calculationLink link:definitionLink 000049 - Disclosure - Stock Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000050 - Disclosure - Capital Stock (Details) link:presentationLink link:calculationLink link:definitionLink 000051 - Disclosure - Capital Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 qron-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Entity Interactive Data Current CONDENSED BALANCE SHEETS ASSETS Current assets Cash and cash equivalents Total current assets [Assets, Current] TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities Accounts payable and accrued liabilities - related party Demand loans, related party Advances from related party Unsecured short-term advances Convertible notes, net of debt discount Derivative liabilities Total current liabilities [Liabilities, Current] Total liabilities [Liabilities] Stockholders' deficit Series A Preferred stock: $0.001 par value; 10,000 shares authorized; 2,000 shares issued and outstanding Common stock, $0.0001 par value: 100,000,000 shares authorized; 13,439,789 shares issued and outstanding Additional paid-in capital Accumulated deficit Total stockholders' deficit [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT [Liabilities and Equity] Series A Preferred Shares, par value Series A Preferred Shares, authorized Series A Preferred Shares, shares issued Series A Preferred Shares, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Net sales Operating expenses: Research and development expenses Professional fees General and administrative expenses Total operating expenses [Operating Expenses] Loss from operations [Operating Income (Loss)] Other income (expense) Interest expense [Interest Expense] Change in derivative liabilities Total other income (expense) [Other Nonoperating Income (Expense)] Net loss [Net Income (Loss) Attributable to Parent] Net loss per common shares (basic and diluted) Weighted average shares outstanding (basic and diluted) CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited) Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Preferred Stock Series A [Member] Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Balance, shares [Shares, Issued] Balance, amount Net loss for the period Balance, shares Balance, amount CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Cash Flows From Operating Activities Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used by operating activities: Accretion of debt discount Change in derivative liabilities [Change in derivative liabilities] Changes in operating assets and liabilities: (Increase) in prepaid expenses [Increase (Decrease) in Prepaid Expense] Increase in accounts payable and accrued liabilities Increase in accounts payable and accrued liabilities - related party Net cash used by operating activities [Net Cash Provided by (Used in) Operating Activities] Cash Flows From Investing Activities Net cash provided from (used by) investing activities Cash Flows From Financing Activities Proceeds from related party advances Net cash provided from financing activities [Net Cash Provided by (Used in) Financing Activities] Net increase (decrease) in cash and cash equivalents [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] Cash at beginning of year [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] Cash at end of period SUPPLEMENTAL DISCLOSURES Interest paid Income taxes paid Description of Business and Basis of Presentation Description of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Summary of Significant Accounting Policies Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Going Concern Going Concern Substantial Doubt about Going Concern [Text Block] Convertible Note Related Party and Derivative Liabilities Convertible Note Related Party and Derivative Liabilities Disclosure of Credit Derivatives [Table Text Block] Convertible Note and Derivative Liabilities Convertible Note and Derivative Liabilities [Convertible Note and Derivative Liabilities] Unsecured Short-Term Advance from Third Party Term Advance from Third Party Related Party Transactions Related Party Transactions Related Party Transactions Disclosure [Text Block] Intellectual Property License Agreement and Sponsored Research Agreement Intellectual Property License Agreement and Sponsored Research Agreement [Intellectual Property License Agreement and Sponsored Research Agreement] Stock Plan Stock Plan Schedule of Stock by Class [Table Text Block] Capital Stock Capital Stock [Capital Stock] Subsequent Events Subsequent Events Subsequent Events [Text Block] Financial Statement Presentation: Fiscal Year End: Use of Estimates: Cash Equivalents: Research and Development Costs: Advertising and Marketing Costs: Related Parties: Stock Based Compensation and Other Share-Based Payments: Fair Value of Financial Instruments Warrants: Income taxes: Basic and Diluted Loss Per Share Recently Issued Accounting Pronouncements Table below reflects the potentially dilutive securities at each reporting period The carrying value of these convertible notes is as follows Schedule of intrest on the convertible note Schedule of derivative liability associated with the conversion Schedule of derivative liability based upon management assumptions carrying value of these convertible notes Interest expenses associated with the convertible notes the fair value of the derivative liability associated with the conversion feature the commitment and re-measurement dates Details of the valuation shares of common stock The carrying value of the Quick Note is as follows Interest expenses associated with the conversion fair value at the commitment and re-measurement dates for the Company's derivative liabilities the fair value of the derivative liability associated with the conversion feature is summarized as follows Summary of the activity for the Company's stock options Following are the details of stock options granted to our officers Details of outstanding options for employees and scientific advisors the following common stock purchase warrants were outstanding Fair Value By Fair Value Hierarchy Level Axis Level 1 [Member] Level 2 [Member] Level 3 [Member] Liabilities Derivative liabilities [Derivative Liability] Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis Award Type Axis Research Warrants at 3% of issued and outstanding shares [Member] Convertible Note [Member] Series A Preferred Shares [Member] Stock options vested [Member] Stock purchase warrants [Member] Potentially dilutive securities net loss per share Research and development costs Advertising or marketing costs EX-101.CAL 6 qron-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 qron-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 qron-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	May 15, 2023
Cover [Abstract]
Entity Registrant Name	QRONS INC.
Entity Central Index Key	0001689084
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		13,439,789
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-55800
Entity Incorporation State Country Code	WY
Entity Tax Identification Number	81-3623646
Entity Address Address Line 1	28-10 Jackson Avenue #26N
Entity Address City Or Town	Long Island City
Entity Address State Or Province	NY
Entity Address Postal Zip Code	11101
City Area Code	212
Local Phone Number	945-2080
Entity Interactive Data Current	Yes

XML 10 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 4,488	$ 3,069
Total current assets	4,488	3,069
TOTAL ASSETS	4,488	3,069
Current liabilities
Accounts payable and accrued liabilities	146,141	128,285
Accounts payable and accrued liabilities - related party	54,276	42,671
Demand loans, related party	85,873	85,873
Advances from related party	373,500	358,500
Unsecured short-term advances	100,000	100,000
Convertible notes, net of debt discount	219,624	208,247
Derivative liabilities	372,814	358,775
Total current liabilities	1,352,228	1,282,351
Total liabilities	1,352,228	1,282,351
Stockholders' deficit
Series A Preferred stock: $0.001 par value; 10,000 shares authorized; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: 100,000,000 shares authorized; 13,439,789 shares issued and outstanding	1,344	1,344
Additional paid-in capital	8,254,316	8,254,316
Accumulated deficit	(9,603,402)	(9,534,944)
Total stockholders' deficit	(1,347,740)	(1,279,282)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 4,488	$ 3,069

XML 11 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
CONDENSED BALANCE SHEETS
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,439,789	13,439,789
Common stock, shares outstanding	13,439,789	13,439,789

XML 12 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CONDENSED STATEMENTS OF OPERATIONS (Unaudited)
Net sales	$ 0	$ 0
Operating expenses:
Research and development expenses	6,820	8,932
Professional fees	22,345	44,866
General and administrative expenses	7,777	9,758
Total operating expenses	36,942	63,556
Loss from operations	(36,942)	(63,556)
Other income (expense)
Interest expense	(17,477)	(34,617)
Change in derivative liabilities	(14,039)	(165,955)
Total other income (expense)	(31,516)	(200,572)
Net loss	$ (68,458)	$ (264,128)
Net loss per common shares (basic and diluted)	$ (0.01)	$ (0.02)
Weighted average shares outstanding
(basic and diluted)	13,439,789	13,289,789

XML 13 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited) - USD ($)	Total	Common Stock	Preferred Stock Series A [Member]	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2021		13,289,789	2,000
Balance, amount at Dec. 31, 2021	$ (1,102,745)	$ 1,329	$ 2	$ 7,697,351	$ (8,801,427)
Net loss for the period	(264,128)				(264,128)
Balance, shares at Mar. 31, 2022		13,289,789	2,000
Balance, amount at Mar. 31, 2022	(1,366,873)	$ 1,329	$ 2	7,697,351	(9,065,555)
Balance, shares at Dec. 31, 2022		13,439,789	2,000
Balance, amount at Dec. 31, 2022	(1,279,282)	$ 1,344	$ 2	8,254,316	(9,534,944)
Net loss for the period	(68,458)				(68,458)
Balance, shares at Mar. 31, 2023		13,439,789	2,000
Balance, amount at Mar. 31, 2023	$ (1,347,740)	$ 1,344	$ 2	$ 8,254,316	$ (9,603,402)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 14 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flows From Operating Activities
Net loss	$ (68,458)	$ (264,128)
Adjustments to reconcile net loss to net cash used by operating activities:
Accretion of debt discount	11,377	29,291
Change in derivative liabilities	14,039	165,955
Changes in operating assets and liabilities:
(Increase) in prepaid expenses	0	(2,163)
Increase in accounts payable and accrued liabilities	17,856	41,054
Increase in accounts payable and accrued liabilities - related party	11,605	580
Net cash used by operating activities	(13,581)	(29,411)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities	0	0
Cash Flows From Financing Activities
Proceeds from related party advances	15,000	0
Net cash provided from financing activities	15,000	0
Net increase (decrease) in cash and cash equivalents	1,419	(29,411)
Cash at beginning of year	3,069	35,065
Cash at end of period	4,488	5,654
SUPPLEMENTAL DISCLOSURES
Interest paid	0	0
Income taxes paid	$ 0	$ 0

XML 15 R7.htm IDEA: XBRL DOCUMENT

Description of Business and Basis of Presentation

3 Months Ended

Mar. 31, 2023

Description of Business and Basis of Presentation

Description of Business and Basis of Presentation

Note 1 – Description of Business and Basis of Presentation

Organization and Nature of Business:

The Company’s principal executive office is located at 28-10 Jackson Avenue, Long Island City, #26N, New York 11101.

XML 16 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Fiscal year end: The Company has selected December 31 as its fiscal year end.

Cash Equivalents: The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.

Fair Value of Financial Instruments

Level 1 – Quoted prices in active markets for identical assets or liabilities.

The following table provides a summary of the fair value of the Company’s derivative liabilities as of March 31, 2023 and December 31, 2022:

	Fair value measurements on a recurring basis
	Level 1		Level 2		Level 3
As of March 31, 2023:
Liabilities
Derivative liabilities	$	-	$	-	$	372,814

As of December 31, 2022:
Liabilities
Derivative liabilities	$	-	$	-	$	358,775

The table below reflects the potentially dilutive securities outstanding during each reporting period:

	March 31, 2023		March 31, 2022
Research warrants at 3% of issued and outstanding shares		403,194		398,694
Convertible notes		702,213		723,751
Series A preferred shares		700		700
Stock options vested		4,328,332		4,098,332
Stock purchase warrants		295,000		295,000
Total		5,729,439		5,516,477

Recently Issued Accounting Pronouncements

Adopted

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

XML 17 R9.htm IDEA: XBRL DOCUMENT

Going Concern

3 Months Ended

Mar. 31, 2023

Going Concern

Going Concern

Note 3 – Going Concern

Covid-19 Pandemic and Other Factors

XML 18 R10.htm IDEA: XBRL DOCUMENT

Convertible Note Related Party and Derivative Liabilities

3 Months Ended

Mar. 31, 2023

Convertible Note Related Party and Derivative Liabilities

Convertible Note Related Party and Derivative Liabilities

Note 4 – Convertible Note – Related Party and Derivative Liabilities

The carrying value of these convertible notes is as follows:

	March 31, 2023		December 31, 2022
Face value of certain convertible notes	$	-	$	25,000
Convertible notes extinguish		-		(25,000	)
Carrying value	$	-	$	-

For Three Months Ended

March 31,

2023

2022

Interest on the convertible notes

493

As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities – related party was $0.

As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature is summarized as follows:

Balance at December 31, 2021	$	73,099
Change in fair value during three months period		(20,463	)
Balance at March 31, 2022	$	52,636

	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility	101%-103		%	181%-182		%	261%~280		%
Expected term	0.92 - 1 year			0.67 - 0.74 year			0.49 year
Risk free interest rate		1.33	%		1.06	%		1.06	%

- Definition

Tabular disclosure of credit derivatives which includes information by sellers of credit derivatives, about each credit derivative, or each group of similar credit derivatives, including (a) the nature of the credit derivative - its term, how it arose, the events or circumstances that would require the seller to perform under the credit derivative, and the current status of the payment/performance risk of the credit derivative; (b) the maximum potential amount of future payments (undiscounted) the seller could be required to make under the credit derivative; (c) the current fair value of the credit derivative; and (d) the nature of any recourse provisions under the credit derivative, and any assets held either as collateral or by third parties. A credit derivative is a derivative instrument (1) in which one or more of its underlyings are related to the credit risk of a specified entity (or a group of entities) or an index based on the credit risk of a group of entities and (2) that exposes the seller to potential loss from credit-risk-related events specified in the contract. Examples of credit derivatives within the scope of this paragraph include, but are not limited to, credit default swaps, credit spread options, and credit index products; also includes a hybrid instrument that has an embedded credit derivative (for example, but not limited to, a credit-linked note).

+ References + Details

XML 19 R11.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities

3 Months Ended

Mar. 31, 2023

Convertible Note and Derivative Liabilities

Convertible Note and Derivative Liabilities

Note 5 – Convertible Note and Derivative Liabilities

(1) 8% Convertible notes with warrants issued in December 2019 and February 2020

The carrying value of these convertible notes is as follows:

March 31,

2023

December 31,

2022

Face value of certain convertible notes

80,000

Carrying value

80,000

Interest expenses associated with the convertible notes are as follows:

	For Three Months Ended
	March 31,
	2023		2022
Amortization on debt discount	$	-	$	541
Interest on the convertible notes		1,613		1,578
Total	$	1,613	$	2,119

As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities was $20,882 and $19,269, respectively.

Balance at December 31, 2022	$	57,033
Change in fair value		38,089
Balance at March 31, 2023		95,122

Balance at December 31, 2021	$	157,490
Change in fair value		(10,411	)
Balance at March 31, 2022	$	147,079

	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility	154%-173		%	194.20%-201.98		%	96.37%-98.24		%
Expected term	2.10 years			1.08 - 1.22 years			0.83 ~ 0.97 years
Risk free interest rate	1.42-1.65		%		4.41	%		4.64	%

	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility	154% ~173		%	203%~301		%	228%~245		%
Expected term	2.10 years			1.08 ~ 1.22 years			0.83 ~ 0.97 years
Risk free interest rate	1.42 ~ 1.65		%		0.39	%		1.35	%

(2) 8% Convertible note with warrants issued on June 15, 2021

(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)

Details of the valuation of the 150,000 shares of common stock are set out below:

December 7, 2022:
Note Payable, original face value	$	115,000
Accrued interest and default penalty on default		71,300
Convertible Note Payable, amended		(150,000	)
Debt discount, day one, amended convertible note payable		24,436
Derivative Liability associated with warrants		(15,416	)
Change in Fair Value		31,030
Fair value of Common stock issued	$	76,350

The unpaid balance of the Note continues to accrue interest at 8% per annum.

The Company valued the embedded default derivative liability of the Quick Note and the Quick Warrant liability, including the full ratchet reset feature, using Monte Carlo models.

The fair value of the Quick Note and Quick Warrant embedded default derivatives liability has been valued as of March 31, 2023 and December 31, 2022.

The carrying value of the Quick Note is as follows:

	March 31, 2023			December 31, 2022
Face value of Quick Note	$	150,000		$	150,000
Less: unamortized discount		(10,376	)		(21,753	)
Carrying value	$	139,624		$	128,247

Interest expenses associated with the conversion feature is as follows:

	For the Three Months ended
	March 31,
	2023		2022
Amortization of debt discount	$	11,377	$	28,750
Interest on the convertible notes		2,959		2,268
Total	$	14,336	$	31,018

(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)

As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities was $3,748 and $789, respectively.

As a result of the application of ASC 815 as of March 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows:

Balance at December 31, 2022	$	301,742
Change in fair value – convertible note		(10,740	)
Change in fair value – warrants		(13,310	)
Balance at March 31, 2023	$	277,692

As a result of the application of ASC 815 as of March 31, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows:

Balance at December 31, 2021	$	175,368
Change in fair value – convertible note		14,352
Change in fair value – warrants		182,477
Balance at March 31, 2022	$	372,197

Convertible note:	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility		307.10	%		119.70	%		119.70	%
Expected term	1 years			0.45 years			0.21 years
Risk free interest rate		0.18	%		4.37	%		4.37	%

Warrants:	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility		201.70	%		219.10	%		222.20	%
Expected term	5 years			4.45 years			4.21 years
Risk free interest rate		0.65	%		4.27	%		4.19	%

(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)

Convertible note:	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility		307.10	%		215.70	%		336.80	%
Expected term	1 years			0.45 years			0.21 years
Risk free interest rate		0.18	%		0.43	%		1.37	%

Warrants:	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility		201.70	%		200.90	%		280.40	%
Expected term	5 years			4.45 years			4.20 years
Risk free interest rate		0.65	%		0.82	%		1.350	%

XML 20 R12.htm IDEA: XBRL DOCUMENT

Unsecured Short-Term Advance from Third Party

3 Months Ended

Mar. 31, 2023

Unsecured Short-Term Advance from Third Party

Term Advance from Third Party

Note 6 – Unsecured Short-Term Advance from Third Party

XML 21 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2023

Related Party Transactions

Related Party Transactions

Note 7 – Related Party Transactions

(1) Demand Loan from related party

(2) Advances from Related Parties

(3) Others

XML 22 R14.htm IDEA: XBRL DOCUMENT

Intellectual Property License Agreement and Sponsored Research Agreement

3 Months Ended

Mar. 31, 2023

Intellectual Property License Agreement and Sponsored Research Agreement

Intellectual Property License Agreement and Sponsored Research Agreement

Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement

Dartmouth College – Intellectual Property License Agreement

Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law.

Dartmouth College – Intellectual Property License Agreement

The Company expensed $6,250 as license fees during each of the three months ended March 31, 2023 and 2022 with respect to such annual fee.

XML 23 R15.htm IDEA: XBRL DOCUMENT

Stock Plan

3 Months Ended

Mar. 31, 2023

Stock Plan

Stock Plan

Note 9 – Stock Plan

2016 Stock Option and Stock Award

(a) Stock Options granted to Science Advisors and employees

Details of outstanding options for employees and scientific advisors at March 31, 2023 are below:

	Grant date	Vested		Unvested		Exercise price		Expiry
Scientific Advisor	12/10/18		145,000		-	$	2.00	12/10/23
	12/17/19		33,333		-	$	2.00	12/17/23
	12/17/19		33,333		-	$	2.00	12/17/24
	12/10/20		100,000		-	$	2.00	12/10/25
	12//22/21		325,000		-	$	2.00	12/22/26
	12/22/22		325,000		-	$	2.00	12/22/27

Employees	04/16/18		10,000		-	$	2.00	4/16/23
	08/15/18		6,667		-	$	2.00	08/15/23
	12/10/18		33,333		-	$	2.00	12/10/23
	07/01/19		33,333		-	$	2.00	07/01/23
	07/01/19		33,333		-	$	2.00	07/01/24

As of March 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods.

(b) Stock Options granted to Officers:

On December 4, 2022, a five-year stock option to purchase 600,000 shares of common stock of the Company previously granted to officers expired unexercised.

Following are the details of stock options granted to our officers at March 31, 2023:

Name	Grant date	Exercisable		Exercise price		Expiry
Jonah Meer	12/10/18		325,000	$	2.00	12/10/2023
	12/17/19		325,000	$	2.00	12/17/24
	12/10/20		325,000	$	2.00	12/10/25
	12//22/21		325,000	$	2.00	12//22/26
	12/22/22		325,000	$	2.00	12/22/27

Ido Merfeld	12/10/18		325,000	$	2.00	12/10/2023
	12/17/19		325,000	$	2.00	12/17/24
	12/10/20		325,000	$	2.00	12/10/25
	12//22/21		325,000	$	2.00	12//22/26
	12/22/22		325,000	$	2.00	12/22/27

As of March 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods.

A summary of the activity for the Company’s stock options at March 31, 2023 and December 31, 2022, is as follows:

	March 31, 2023						December 31, 2022
			Weighted Average Exercise		Weighted Average Remaining Contractual Life					Weighted Average Exercise		Weighted Average Remaining Contractual Life
	Shares		Price		(in years)		Shares			Price		(in years)
Outstanding, beginning of period		4,328,332	$	2		2.78		4,098,332		$	2		3.08
Granted		-	$	2		-		975,000		$	2		-
Exercised		-	$	-		-		-		$	-		-
Canceled/forfeited		-	$	2		-		(745,000	)	$	2		-
Outstanding, end of period		4,328,332	$	2		2.78		4,328,332		$	2		3.03
Options exercisable, end of period		4,328,332	$	2		2.78		4,328,332		$	2		3.03
Weighted average fair value of options granted			$	2						$	2

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

XML 24 R16.htm IDEA: XBRL DOCUMENT

Capital Stock

3 Months Ended

Mar. 31, 2023

Capital Stock

Capital Stock

Note 10 – Capital Stock

Authorized:

The Company has authorized 100,000,000 shares of common stock, par value $0.0001, and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001.

Series A Preferred Stock:

There were 2,000 shares of Series A Preferred Stock issued and outstanding as of March 31, 2023 and December 31, 2022.

Common Stock

In December 2022, the Company issued 150,000 shares of its common stock to Quick Capital LLC with a value of $76,350 related to a loan amendment (Note 5).

There were 13,439,789 shares of common stock issued and outstanding as of March 31, 2023 and December 31, 2022.

Common Stock Purchase Warrants

As of March 31, 2023 and December 31, 2022, the following common stock purchase warrants were outstanding:

	Warrants		Weighted Average Exercise Price
Outstanding – December 31, 2021		295,000	$	1.00
Granted		-		-
Canceled/forfeited		-		-
Exercised		-		-
Outstanding – December 31, 2022		295,000		1.00
Granted		-		-
Canceled/forfeited		-		-
Exercised		-		-
Outstanding – March 31, 2023		295,000	$	1.00

XML 25 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2023

Subsequent Events

Subsequent Events

Note 11 – Subsequent Events

The Company has evaluated events for the period through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.

XML 26 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Financial Statement Presentation:

Fiscal Year End:

Fiscal year end: The Company has selected December 31 as its fiscal year end.

Use of Estimates:

Cash Equivalents:

Cash Equivalents: The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.

Research and Development Costs:

Advertising and Marketing Costs:

Fair Value of Financial Instruments

Level 1 – Quoted prices in active markets for identical assets or liabilities.

The following table provides a summary of the fair value of the Company’s derivative liabilities as of March 31, 2023 and December 31, 2022:

	Fair value measurements on a recurring basis
	Level 1		Level 2		Level 3
As of March 31, 2023:
Liabilities
Derivative liabilities	$	-	$	-	$	372,814

As of December 31, 2022:
Liabilities
Derivative liabilities	$	-	$	-	$	358,775

Warrants:

Income taxes:

Basic and Diluted Loss Per Share

The table below reflects the potentially dilutive securities outstanding during each reporting period:

	March 31, 2023		March 31, 2022
Research warrants at 3% of issued and outstanding shares		403,194		398,694
Convertible notes		702,213		723,751
Series A preferred shares		700		700
Stock options vested		4,328,332		4,098,332
Stock purchase warrants		295,000		295,000
Total		5,729,439		5,516,477

Recently Issued Accounting Pronouncements

Adopted

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

XML 27 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Table below reflects the potentially dilutive securities at each reporting period

	March 31, 2023		March 31, 2022
Research warrants at 3% of issued and outstanding shares		403,194		398,694
Convertible notes		702,213		723,751
Series A preferred shares		700		700
Stock options vested		4,328,332		4,098,332
Stock purchase warrants		295,000		295,000
Total		5,729,439		5,516,477

XML 28 R20.htm IDEA: XBRL DOCUMENT

Convertible Note Related Party and Derivative Liabilities (Tables)

3 Months Ended

Mar. 31, 2023

Convertible Note Related Party and Derivative Liabilities

The carrying value of these convertible notes is as follows

	March 31, 2023		December 31, 2022
Face value of certain convertible notes	$	-	$	25,000
Convertible notes extinguish		-		(25,000	)
Carrying value	$	-	$	-

Schedule of intrest on the convertible note

For Three Months Ended

March 31,

2023

2022

Interest on the convertible notes

493

Schedule of derivative liability associated with the conversion

Balance at December 31, 2021	$	73,099
Change in fair value during three months period		(20,463	)
Balance at March 31, 2022	$	52,636

Schedule of derivative liability based upon management assumptions

	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility	101%-103		%	181%-182		%	261%~280		%
Expected term	0.92 - 1 year			0.67 - 0.74 year			0.49 year
Risk free interest rate		1.33	%		1.06	%		1.06	%

XML 29 R21.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Tables)

3 Months Ended

Mar. 31, 2023

Convertible Note and Derivative Liabilities

carrying value of these convertible notes

March 31,

2023

December 31,

2022

Face value of certain convertible notes

80,000

Carrying value

80,000

Interest expenses associated with the convertible notes

	For Three Months Ended
	March 31,
	2023		2022
Amortization on debt discount	$	-	$	541
Interest on the convertible notes		1,613		1,578
Total	$	1,613	$	2,119

the fair value of the derivative liability associated with the conversion feature

Balance at December 31, 2022	$	57,033
Change in fair value		38,089
Balance at March 31, 2023		95,122

Balance at December 31, 2021	$	157,490
Change in fair value		(10,411	)
Balance at March 31, 2022	$	147,079

the commitment and re-measurement dates

	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility	154%-173		%	194.20%-201.98		%	96.37%-98.24		%
Expected term	2.10 years			1.08 - 1.22 years			0.83 ~ 0.97 years
Risk free interest rate	1.42-1.65		%		4.41	%		4.64	%

	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility	154% ~173		%	203%~301		%	228%~245		%
Expected term	2.10 years			1.08 ~ 1.22 years			0.83 ~ 0.97 years
Risk free interest rate	1.42 ~ 1.65		%		0.39	%		1.35	%

Details of the valuation shares of common stock

December 7, 2022:
Note Payable, original face value	$	115,000
Accrued interest and default penalty on default		71,300
Convertible Note Payable, amended		(150,000	)
Debt discount, day one, amended convertible note payable		24,436
Derivative Liability associated with warrants		(15,416	)
Change in Fair Value		31,030
Fair value of Common stock issued	$	76,350

The carrying value of the Quick Note is as follows

	March 31, 2023			December 31, 2022
Face value of Quick Note	$	150,000		$	150,000
Less: unamortized discount		(10,376	)		(21,753	)
Carrying value	$	139,624		$	128,247

Interest expenses associated with the conversion

	For the Three Months ended
	March 31,
	2023		2022
Amortization of debt discount	$	11,377	$	28,750
Interest on the convertible notes		2,959		2,268
Total	$	14,336	$	31,018

fair value at the commitment and re-measurement dates for the Company's derivative liabilities

Convertible note:	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility		307.10	%		119.70	%		119.70	%
Expected term	1 years			0.45 years			0.21 years
Risk free interest rate		0.18	%		4.37	%		4.37	%

Warrants:	Commitment Date			December 31, 2022			March 31, 2023
Expected dividends		0			0			0
Expected volatility		201.70	%		219.10	%		222.20	%
Expected term	5 years			4.45 years			4.21 years
Risk free interest rate		0.65	%		4.27	%		4.19	%

Convertible note:	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility		307.10	%		215.70	%		336.80	%
Expected term	1 years			0.45 years			0.21 years
Risk free interest rate		0.18	%		0.43	%		1.37	%

Warrants:	Commitment Date			December 31, 2021			March 31, 2022
Expected dividends		0			0			0
Expected volatility		201.70	%		200.90	%		280.40	%
Expected term	5 years			4.45 years			4.20 years
Risk free interest rate		0.65	%		0.82	%		1.350	%

the fair value of the derivative liability associated with the conversion feature is summarized as follows

Balance at December 31, 2022	$	301,742
Change in fair value – convertible note		(10,740	)
Change in fair value – warrants		(13,310	)
Balance at March 31, 2023	$	277,692

Balance at December 31, 2021	$	175,368
Change in fair value – convertible note		14,352
Change in fair value – warrants		182,477
Balance at March 31, 2022	$	372,197

XML 30 R22.htm IDEA: XBRL DOCUMENT

Stock Plan (Tables)

3 Months Ended

Mar. 31, 2023

Stock Plan

Summary of the activity for the Company's stock options

	March 31, 2023						December 31, 2022
			Weighted Average Exercise		Weighted Average Remaining Contractual Life					Weighted Average Exercise		Weighted Average Remaining Contractual Life
	Shares		Price		(in years)		Shares			Price		(in years)
Outstanding, beginning of period		4,328,332	$	2		2.78		4,098,332		$	2		3.08
Granted		-	$	2		-		975,000		$	2		-
Exercised		-	$	-		-		-		$	-		-
Canceled/forfeited		-	$	2		-		(745,000	)	$	2		-
Outstanding, end of period		4,328,332	$	2		2.78		4,328,332		$	2		3.03
Options exercisable, end of period		4,328,332	$	2		2.78		4,328,332		$	2		3.03
Weighted average fair value of options granted			$	2						$	2

Following are the details of stock options granted to our officers

Name	Grant date	Exercisable		Exercise price		Expiry
Jonah Meer	12/10/18		325,000	$	2.00	12/10/2023
	12/17/19		325,000	$	2.00	12/17/24
	12/10/20		325,000	$	2.00	12/10/25
	12//22/21		325,000	$	2.00	12//22/26
	12/22/22		325,000	$	2.00	12/22/27

Ido Merfeld	12/10/18		325,000	$	2.00	12/10/2023
	12/17/19		325,000	$	2.00	12/17/24
	12/10/20		325,000	$	2.00	12/10/25
	12//22/21		325,000	$	2.00	12//22/26
	12/22/22		325,000	$	2.00	12/22/27

Details of outstanding options for employees and scientific advisors

	Grant date	Vested		Unvested		Exercise price		Expiry
Scientific Advisor	12/10/18		145,000		-	$	2.00	12/10/23
	12/17/19		33,333		-	$	2.00	12/17/23
	12/17/19		33,333		-	$	2.00	12/17/24
	12/10/20		100,000		-	$	2.00	12/10/25
	12//22/21		325,000		-	$	2.00	12/22/26
	12/22/22		325,000		-	$	2.00	12/22/27

Employees	04/16/18		10,000		-	$	2.00	4/16/23
	08/15/18		6,667		-	$	2.00	08/15/23
	12/10/18		33,333		-	$	2.00	12/10/23
	07/01/19		33,333		-	$	2.00	07/01/23
	07/01/19		33,333		-	$	2.00	07/01/24

XML 31 R23.htm IDEA: XBRL DOCUMENT

Capital Stock (Tables)

3 Months Ended

Mar. 31, 2023

Capital Stock

the following common stock purchase warrants were outstanding

	Warrants		Weighted Average Exercise Price
Outstanding – December 31, 2021		295,000	$	1.00
Granted		-		-
Canceled/forfeited		-		-
Exercised		-		-
Outstanding – December 31, 2022		295,000		1.00
Granted		-		-
Canceled/forfeited		-		-
Exercised		-		-
Outstanding – March 31, 2023		295,000	$	1.00

XML 32 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Level 1 [Member]
Liabilities
Derivative liabilities	$ 0	$ 0
Level 2 [Member]
Liabilities
Derivative liabilities	0	0
Level 3 [Member]
Liabilities
Derivative liabilities	$ 372,814	$ 358,775

XML 33 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Potentially dilutive securities net loss per share	5,729,439	5,516,477
Series A Preferred Shares [Member]
Potentially dilutive securities net loss per share	700	700
Research Warrants at 3% of issued and outstanding shares [Member]
Potentially dilutive securities net loss per share	403,194	398,694
Convertible Note [Member]
Potentially dilutive securities net loss per share	702,213	723,751
Stock options vested [Member]
Potentially dilutive securities net loss per share	4,328,332	4,098,332
Stock purchase warrants [Member]
Potentially dilutive securities net loss per share	295,000	295,000

XML 34 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Summary of Significant Accounting Policies
Research and development costs	$ 6,820	$ 8,932
Advertising or marketing costs	$ 0	$ 0

XML 35 R27.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
Going Concern (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Going Concern
Proceeds from loan	$ 15,000	$ 72,500

XML 36 R28.htm IDEA: XBRL DOCUMENT

Convertible Note Related Party and Derivative Liabilities (Details) - Related Party Debt [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Carrying value	$ 0	$ 0
Face value of certain convertible notes	0	25,000
Convertible notes extinguish	$ 0	$ (25,000)

XML 37 R29.htm IDEA: XBRL DOCUMENT

Convertible Note Related Party and Derivative Liabilities (Details 1) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Interest on the convertible notes	$ 2,959	$ 2,268
Related Party Debt [Member]
Interest on the convertible notes	$ 0		$ 493

XML 38 R30.htm IDEA: XBRL DOCUMENT

Convertible Note Related Party and Derivative Liabilities (Details 2) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Beganing balance	$ 358,775
Changes in Fair Value	38,089	$ (10,411)
Ending balance	$ 372,814
Derivative Liabilities [Member]
Beganing balance		73,099
Changes in Fair Value		(20,463)
Ending balance		$ 52,636

XML 39 R31.htm IDEA: XBRL DOCUMENT

Convertible Note Related Party and Derivative Liabilities (Details 3)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Minimum [Member]
Expected term	9 months 29 days	9 months 29 days	1 year 29 days	1 year 29 days
Maximum [Member]
Expected term	11 months 19 days	11 months 19 days	1 year 2 months 19 days	1 year 2 months 19 days
Related Party Debt [Member]
Expected dividends		0.00%		0.00%
Risk free interest rate				1.06%
Expected term		5 months 26 days
Related Party Debt [Member] \| Minimum [Member]
Expected volatility		261.00%		181.00%
Expected term				8 months 1 day
Related Party Debt [Member] \| Maximum [Member]
Expected volatility		280.00%		182.00%
Expected term				8 months 26 days
Related Party Debt [Member] \| Commitment Date [Member]
Expected dividends		0.00%
Risk free interest rate		1.33%
Related Party Debt [Member] \| Commitment Date [Member] \| Minimum [Member]
Expected volatility		101.00%
Expected term		11 months 1 day
Related Party Debt [Member] \| Commitment Date [Member] \| Maximum [Member]
Expected volatility		103.00%
Expected term		1 year

XML 40 R32.htm IDEA: XBRL DOCUMENT

Convertible Note Related Party and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended
	Sep. 27, 2022	Sep. 27, 2017	Sep. 01, 2016	Mar. 31, 2023	Dec. 31, 2022
Principal amount - related party convertible note modified to 6% promissory note	$ 35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	10,873
Cubesquare Llc [Member]
Convertible debenture agreement		$ 15,000	$ 10,000
Ownership percentage			25.00%
Interest rate per annum		8.00%	8.00%	8.00%	8.00%
Conversion, description		any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare	$0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender
Accounts payable and accrued liabilities related party				$ 0	$ 0
Principal amount - related party convertible note modified to 6% promissory note	35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	$ 10,873

XML 41 R33.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details) - Derivative Liabilities [Member] - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Face value of certain convertible notes	$ 80,000	$ 80,000
Carrying value	$ 80,000	$ 80,000

XML 42 R34.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total	$ 14,336	$ 31,018
Warrants [Member]
Interest on the convertible notes	1,613	1,578
Amortization on debt discount	0	541
Total	$ 1,613	$ 2,119

XML 43 R35.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details 2) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Convertible Note and Derivative Liabilities
Balance at beginnings	$ 57,033	$ 157,490
Change in fair value	38,089	(10,411)
Balance at ending	$ 95,122	$ 147,079

XML 44 R36.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details 3)	3 Months Ended		12 Months Ended
Convertible Note and Derivative Liabilities (Details 3)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Minimum [Member]
Expected volatility	96.37%	228.00%	194.20%	203.00%
Expected term	9 months 29 days	9 months 29 days	1 year 29 days	1 year 29 days
Maximum [Member]
Expected volatility	98.24%	245.00%	201.98%	301.00%
Expected term	11 months 19 days	11 months 19 days	1 year 2 months 19 days	1 year 2 months 19 days
Commitment Date [Member]
Expected dividend	0.00%	0.00%	0.00%	0.00%
Risk free interest	4.64%	1.35%	4.41%	0.39%
Expected term			2 years 1 month 6 days	2 years 1 month 6 days
Commitment Dates Minimum [Member]
Expected dividend	0.00%	0.00%
Risk free interest			1.42%	1.42%
Expected volatility			154.00%	154.00%
Commitment Dates Maximum [Member]
Risk free interest			1.65%	1.65%
Expected volatility			173.00%	173.00%

XML 45 R37.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details 4)	Dec. 07, 2022 USD ($)
Convertible Note and Derivative Liabilities
Note Payable, original face value	$ 115,000
Accrued interest and default penalty on default	71,300
Convertible Note Payable, amended	(150,000)
Debt discount, day one, amended convertible note payable	24,436
Derivative Liability associated with warrants	(15,416)
Change in Fair Value 1	31,030
Fair value of Common stock issued	$ 76,350

XML 46 R38.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details 5) - Quick Note [Member] - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Face value of Quick Note	$ 150,000	$ 150,000
Less: unamortized discount	(10,376)	(21,753)
Carrying value	$ 139,624	$ 128,247

XML 47 R39.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details 6) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Convertible Note and Derivative Liabilities
Amortization of debt discount	$ 11,377	$ 28,750
Interest on the convertible notes	2,959	2,268
Total	$ 14,336	$ 31,018

XML 48 R40.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details 7) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Balance at ending	$ 95,122	$ 147,079
Warrants [Member] \| Convertible Note June [Member]
Balance at beginnings	301,742	175,368
Change in fair value - convertible note	(10,740)	14,352
Change in fair value - warrants	(13,310)	182,477
Balance at ending	$ 277,692	$ 372,197

XML 49 R41.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details 8)	3 Months Ended		12 Months Ended
Convertible Note and Derivative Liabilities (Details 8)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Commitment DateConvertible Note [Member]
Expected dividend	0.00%	0.00%
Risk free interest	0.18%	0.18%
Expected volatility	307.10%	307.10%
Expected term	1 year	1 year
Warrants [Member]
Expected dividend	0.00%	0.00%	0.00%	0.00%
Risk free interest	4.19%	1.35%	4.27%	0.82%
Expected volatility	222.20%	280.40%	219.10%	200.90%
Expected term	4 years 2 months 15 days	4 years 2 months 12 days	4 years 5 months 12 days	4 years 5 months 12 days
Commitment And Warrants [Member]
Expected dividend	0.00%	0.00%
Risk free interest	0.65%	0.65%
Expected volatility	201.70%	201.70%
Expected term	5 years	5 years
Convertible Note [Member]
Expected dividend	0.00%	0.00%	0.00%	0.00%
Risk free interest	4.37%	1.37%	4.37%	0.43%
Expected volatility	119.70%	336.80%	119.70%	215.70%
Expected term	2 months 15 days	2 months 15 days	5 months 12 days	5 months 12 days

XML 50 R42.htm IDEA: XBRL DOCUMENT

Convertible Note and Derivative Liabilities (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 19, 2020	Jun. 15, 2021	Mar. 31, 2023	Dec. 31, 2019	Dec. 31, 2022
Accounts payable and accrued liabilities			$ 3,748		$ 789
Accrued interest			124,200
Accrued interest outstanding			186,300
Restricted common stock valued			76,350
Issuance of common stock shares			50,000
Derivative Liabilities [Member]
Conversion, description	we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance			are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00
Interest rate per annum	8.00%			8.00%
Accounts payable and accrued liabilities related party			$ 20,882		$ 19,269
Investment		$ 100,000
Legal and transaction expences		3,500
Principal amount	$ 10,000	$ 115,000		$ 70,000
Discount rate		10.00%
Aggregate purchase of common stock		115,000
Exercise price		$ 1
Conversion price of common stock		$ 0.50
Liquidated damages payment, daily		$ 2,000
Interest due penalty		50.00%

XML 51 R43.htm IDEA: XBRL DOCUMENT

Unsecured ShortTerm Advance from Third Party (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Unsecured ShortTerm Advance from Third Party (Details Narrative)
Unsecured short-term advances	$ 100,000	$ 100,000

XML 52 R44.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 27, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2019	Sep. 27, 2017	Sep. 01, 2016
Unpaid interest		$ 16,763		$ 15,234
Interest expense		$ 531	$ 0
Principal amount - related party convertible note modified to 6% promissory note	$ 35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	10,873
Cubesquare Llc [Member]
Due to related party				$ 50,000	$ 10,000
Interest percentage		8.00%		8.00%			8.00%	8.00%
Ownership percentage		25.00%
Interest expense		$ 997	$ 986
Principal amount - related party convertible note modified to 6% promissory note	35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	$ 10,873
Jonah Meer [Member]
Due to related party		15,000		$ 72,500	70,000	$ 135,000
Accounts payable and accrued liabilities		36,344		26,268
Additional advances received		10,076
Advances amount		292,500		277,500
Payment of advances		1,169		1,169
Ido Merfeld [Member]
Due to related party		50,000			$ 21,000	$ 1,169
Accounts payable and accrued liabilities		1,169
Advances amount		$ 71,000		$ 71,000

XML 53 R45.htm IDEA: XBRL DOCUMENT

Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Intellectual Property License Agreement and Sponsored Research Agreement
License fee	$ 25,000
License fees	6,250	$ 6,250
Royalty expense	500,000
Licence expense	$ 25,000
Description of consideration received	first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter
Royalty percentage of net sales	2.00%

XML 54 R46.htm IDEA: XBRL DOCUMENT

Stock Plan (Details)	3 Months Ended
Stock Plan (Details)	Mar. 31, 2023 $ / shares shares
Scientific Advisor \| Grant
Expiry	Dec. 10, 2023
Exercise price \| $ / shares	$ 2.00
Vested \| shares	145,000
Grant date	Dec. 10, 2018
Scientific Advisor \| Grant 1
Expiry	Dec. 17, 2023
Exercise price \| $ / shares	$ 2.00
Vested \| shares	33,333
Grant date	Dec. 17, 2019
Scientific Advisor \| Grant 2
Expiry	Dec. 17, 2024
Exercise price \| $ / shares	$ 2.00
Vested \| shares	33,333
Grant date	Dec. 17, 2019
Scientific Advisor \| Grant 3
Expiry	Dec. 10, 2025
Exercise price \| $ / shares	$ 2.00
Vested \| shares	100,000
Grant date	Dec. 10, 2020
Scientific Advisor \| Grant 4
Expiry	Dec. 22, 2026
Exercise price \| $ / shares	$ 2.00
Vested \| shares	325,000
Grant date	Dec. 22, 2021
Scientific Advisor \| Grant 5
Expiry	Dec. 22, 2027
Exercise price \| $ / shares	$ 2.00
Vested \| shares	325,000
Grant date	Dec. 22, 2022
Employees \| Grant
Expiry	Apr. 16, 2023
Exercise price \| $ / shares	$ 2.00
Vested \| shares	10,000
Grant date	Apr. 16, 2018
Employees \| Grant 1
Expiry	Aug. 15, 2023
Exercise price \| $ / shares	$ 2.00
Vested \| shares	6,667
Grant date	Aug. 15, 2018
Employees \| Grant 2
Expiry	Dec. 10, 2023
Exercise price \| $ / shares	$ 2.00
Vested \| shares	33,333
Grant date	Dec. 10, 2018
Employees \| Grant 3
Expiry	Jul. 01, 2023
Exercise price \| $ / shares	$ 2.00
Vested \| shares	33,333
Grant date	Jul. 01, 2019
Employees \| Grant 4
Expiry	Jul. 01, 2024
Exercise price \| $ / shares	$ 2.00
Vested \| shares	33,333
Grant date	Jul. 01, 2019

XML 55 R47.htm IDEA: XBRL DOCUMENT

Stock Plan (Details 1)	3 Months Ended
Stock Plan (Details 1)	Mar. 31, 2023 $ / shares shares
Jonah Meer \| Grant
Expiry	Dec. 10, 2023
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 10, 2018
Jonah Meer \| Grant 1
Expiry	Dec. 17, 2024
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 17, 2019
Jonah Meer \| Grant 2
Expiry	Dec. 10, 2025
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 10, 2020
Jonah Meer \| Grant 3
Expiry	Dec. 22, 2026
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 22, 2021
Jonah Meer \| Grant 4
Expiry	Dec. 22, 2027
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 22, 2022
Ido Merfeld \| Grant
Expiry	Dec. 10, 2023
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 10, 2018
Ido Merfeld \| Grant 1
Expiry	Dec. 17, 2024
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 17, 2019
Ido Merfeld \| Grant 2
Expiry	Dec. 10, 2025
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 10, 2020
Ido Merfeld \| Grant 3
Expiry	Dec. 22, 2026
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 22, 2021
Ido Merfeld \| Grant 4
Expiry	Dec. 22, 2027
Exercise price \| $ / shares	$ 2.00
Exercisable \| shares	325,000
Grant date	Dec. 22, 2022

XML 56 R48.htm IDEA: XBRL DOCUMENT

Stock Plan (Details 2) - $ / shares	3 Months Ended	12 Months Ended
Stock Plan (Details 2) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Stock Plan
Number of Options begining balance	4,328,332	4,098,332
Number of Options Granted		975,000
Number of Options Canceled, forfeited, or expired		(745,000)
Number of Options ending balance	4,328,332	4,328,332
Numbeer of Options exercisable	4,328,332	4,328,332
Weighted Average Exercise Price begining	$ 2	$ 2
Weighted Average Exercise Price Granted	2	2
Weighted Average Exercise Price Exercised	0	0
Weighted Average Exercise Price Canceled, forfeited, or expired	2	2
Weighted Average Exercise Price ending balance	2	2
Weighted Average Exercise Price exercisable	2	2
Weighted average fair value of options granted	$ 2	$ 2
Remaining Contract term begining	2 years 9 months 10 days	3 years 29 days
Remaining Contract term Ending	2 years 9 months 10 days	3 years 10 days
Remaining Contract term exercisable	2 years 9 months 10 days	3 years 10 days

XML 57 R49.htm IDEA: XBRL DOCUMENT

Stock Plan (Details Narrative) - $ / shares		1 Months Ended	12 Months Ended
Stock Plan (Details Narrative) - $ / shares	Dec. 04, 2022	Dec. 22, 2022	Dec. 31, 2022
Stock Options Granted To Science Advisor And Business Advisors [Member]
Granted an option to purchase of common stock		325,000	145,000
Weighted average excercise price		$ 2.00
Stock Options Granted To Officers [Member]
Granted an option to purchase of common stock	600,000	325,000
Weighted average excercise price		$ 2.00

XML 58 R50.htm IDEA: XBRL DOCUMENT

Capital Stock (Details) - $ / shares	3 Months Ended	12 Months Ended
Capital Stock (Details) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Capital Stock
Warrants Outstanding beganing	295,000	295,000
Warrants Outstanding Ending	295,000	295,000
Weighted Average Exercise Price Outstanding beganing	$ 1.00	$ 1.00
Weighted Average Exercise Price Granted	0	0
Weighted Average Exercise Price Canceled/Forfeited	0	0
Weighted Average Exercise Price Exercised	0	0
Weighted Average Exercise Price Outstanding Ending	$ 1.00	$ 1.00

XML 59 R51.htm IDEA: XBRL DOCUMENT

Capital Stock (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Capital Stock (Details Narrative) - USD ($)	Jun. 15, 2021	Mar. 31, 2023	Dec. 31, 2022
Common Stock, Shares Authorized		100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Common stock exercise price per share	$ 1.00
Common Stock, Shares Issued		13,439,789	13,439,789
Common Stock, value		$ 1,344	$ 1,344
Common Stock, Shares, Outstanding		13,439,789	13,439,789
Number of common shares issued for warrants	115,000
Preferred Stock, Shares Authorized		10,000	10,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Preferred Stock, Shares Issued		2,000	2,000
Preferred Stock, Shares Outstanding		2,000	2,000
Series A, Preferred Stock
Preferred Stock, Shares Authorized		10,000	10,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Preferred Stock, Shares Issued		2,000	2,000
Preferred Stock, Shares Outstanding		2,000	2,000
Redemption description		The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”)
Quick Capital LLC [Member]
Common Stock, Shares Issued			150,000
Common Stock, value			$ 76,350

XML 60 qron_10q_htm.xml IDEA: XBRL DOCUMENT 0001689084 2023-01-01 2023-03-31 0001689084 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0001689084 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001689084 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001689084 2021-06-01 2021-06-15 0001689084 qron:QuickCapitalLLCMember 2022-12-31 0001689084 2021-06-15 0001689084 qron:StockOptionsGrantedToScienceAdvisorAndBusinessAdvisorsMember 2022-01-01 2022-12-31 0001689084 qron:StockOptionsGrantedToScienceAdvisorAndBusinessAdvisorsMember 2022-12-22 0001689084 qron:StockOptionsGrantedToOfficersMember 2022-12-01 2022-12-04 0001689084 qron:StockOptionsGrantedToOfficersMember 2022-12-01 2022-12-22 0001689084 qron:StockOptionsGrantedToOfficersMember 2022-12-22 0001689084 qron:StockOptionsGrantedToScienceAdvisorAndBusinessAdvisorsMember 2022-12-01 2022-12-22 0001689084 qron:GrantFourMember qron:IdoMerfeldMember 2023-01-01 2023-03-31 0001689084 qron:GrantThreeMember qron:IdoMerfeldMember 2023-01-01 2023-03-31 0001689084 qron:GrantTwoMember qron:IdoMerfeldMember 2023-01-01 2023-03-31 0001689084 qron:GrantOneMember qron:IdoMerfeldMember 2023-01-01 2023-03-31 0001689084 us-gaap:GrantMember qron:IdoMerfeldMember 2023-01-01 2023-03-31 0001689084 qron:GrantFourMember qron:JonahMeerMember 2023-01-01 2023-03-31 0001689084 qron:GrantThreeMember qron:JonahMeerMember 2023-01-01 2023-03-31 0001689084 qron:GrantTwoMember qron:JonahMeerMember 2023-01-01 2023-03-31 0001689084 qron:GrantOneMember qron:JonahMeerMember 2023-01-01 2023-03-31 0001689084 us-gaap:GrantMember qron:JonahMeerMember 2023-01-01 2023-03-31 0001689084 qron:GrantFourMember qron:EmployeesMember 2023-01-01 2023-03-31 0001689084 qron:GrantThreeMember qron:EmployeesMember 2023-01-01 2023-03-31 0001689084 qron:GrantTwoMember qron:EmployeesMember 2023-01-01 2023-03-31 0001689084 qron:GrantOneMember qron:EmployeesMember 2023-01-01 2023-03-31 0001689084 us-gaap:GrantMember qron:EmployeesMember 2023-01-01 2023-03-31 0001689084 qron:GrantFiveMember qron:ScientificAdvisorMember 2023-01-01 2023-03-31 0001689084 qron:GrantFourMember qron:ScientificAdvisorMember 2023-01-01 2023-03-31 0001689084 qron:GrantThreeMember qron:ScientificAdvisorMember 2023-01-01 2023-03-31 0001689084 qron:GrantTwoMember qron:ScientificAdvisorMember 2023-01-01 2023-03-31 0001689084 qron:GrantOneMember qron:ScientificAdvisorMember 2023-01-01 2023-03-31 0001689084 us-gaap:GrantMember qron:ScientificAdvisorMember 2023-01-01 2023-03-31 0001689084 qron:IdoMerfeldMember 2022-01-01 2022-12-31 0001689084 qron:IdoMerfeldMember 2023-01-01 2023-03-31 0001689084 qron:JonahMeerMember 2022-01-01 2022-12-31 0001689084 qron:JonahMeerMember 2023-01-01 2023-03-31 0001689084 2022-09-01 2022-09-27 0001689084 qron:CubesquareLlcMember 2022-01-01 2022-03-31 0001689084 qron:CubesquareLlcMember 2023-01-01 2023-03-31 0001689084 qron:IdoMerfeldMember 2019-12-31 0001689084 qron:CubesquareLlcMember 2020-12-31 0001689084 qron:IdoMerfeldMember 2020-12-31 0001689084 qron:IdoMerfeldMember 2023-03-31 0001689084 qron:JonahMeerMember 2023-03-31 0001689084 qron:JonahMeerMember 2020-12-31 0001689084 qron:JonahMeerMember 2019-12-31 0001689084 qron:JonahMeerMember 2022-12-31 0001689084 qron:DerivativeLiabilitieMember 2021-06-01 2021-06-15 0001689084 qron:DerivativeLiabilitieMember 2021-06-15 0001689084 qron:DerivativeLiabilitieMember 2020-02-19 0001689084 qron:DerivativeLiabilitieMember 2019-12-31 0001689084 qron:DerivativeLiabilitieMember 2020-02-18 2020-02-19 0001689084 qron:DerivativeLiabilitieMember 2019-01-12 2019-12-31 0001689084 qron:CommitmentDateConvertibleNoteMember 2022-01-01 2022-03-31 0001689084 qron:CommitmentDateConvertibleNoteMember 2023-01-01 2023-03-31 0001689084 qron:WarrantsMember 2022-01-01 2022-12-31 0001689084 qron:WarrantsMember 2021-01-01 2021-12-31 0001689084 qron:ConvertibleNotesMember 2022-01-01 2022-12-31 0001689084 qron:ConvertibleNotesMember 2021-01-01 2021-12-31 0001689084 qron:CommitmentAndWarrantsMember 2022-01-01 2022-03-31 0001689084 qron:CommitmentAndWarrantsMember 2023-01-01 2023-03-31 0001689084 qron:WarrantsMember qron:ConvertibleNoteJuneMember 2023-03-31 0001689084 qron:WarrantsMember qron:ConvertibleNoteJuneMember 2022-03-31 0001689084 qron:WarrantsMember qron:ConvertibleNoteJuneMember 2023-01-01 2023-03-31 0001689084 qron:WarrantsMember qron:ConvertibleNoteJuneMember 2022-01-01 2022-03-31 0001689084 qron:QuickNoteMember 2023-03-31 0001689084 qron:QuickNoteMember 2022-12-31 0001689084 2022-12-07 0001689084 qron:CommitmentDatesMinimumMember 2023-01-01 2023-03-31 0001689084 srt:MaximumMember 2022-01-01 2022-12-31 0001689084 srt:MinimumMember 2022-01-01 2022-12-31 0001689084 srt:MaximumMember 2021-01-01 2021-12-31 0001689084 srt:MaximumMember 2022-01-01 2022-03-31 0001689084 srt:MaximumMember 2023-01-01 2023-03-31 0001689084 srt:MinimumMember 2021-01-01 2021-12-31 0001689084 srt:MinimumMember 2022-01-01 2022-03-31 0001689084 srt:MinimumMember 2023-01-01 2023-03-31 0001689084 qron:CommitmentDateMember 2023-01-01 2023-03-31 0001689084 qron:CommitmentDateMember 2021-01-01 2021-12-31 0001689084 qron:CommitmentDatesMaximumMember 2021-01-01 2021-12-31 0001689084 qron:CommitmentDatesMaximumMember 2022-01-01 2022-12-31 0001689084 qron:CommitmentDatesMinimumMember 2021-01-01 2021-12-31 0001689084 qron:CommitmentDatesMinimumMember 2022-01-01 2022-12-31 0001689084 qron:CommitmentDateMember 2022-01-01 2022-03-31 0001689084 qron:CommitmentDatesMinimumMember 2022-01-01 2022-03-31 0001689084 qron:CommitmentDateMember 2022-01-01 2022-12-31 0001689084 qron:WarrantsMember 2022-01-01 2022-03-31 0001689084 qron:WarrantsMember 2023-01-01 2023-03-31 0001689084 qron:DerivativeLiabilitieMember 2023-03-31 0001689084 qron:DerivativeLiabilitieMember 2022-12-31 0001689084 qron:CubesquareLlcMember 2022-09-01 2022-09-27 0001689084 qron:CubesquareLlcMember 2023-03-31 0001689084 qron:CubesquareLlcMember 2022-12-31 0001689084 qron:CubesquareLlcMember 2017-09-27 0001689084 qron:CubesquareLlcMember 2016-09-01 0001689084 qron:CubesquareLlcMember 2017-09-01 2017-09-27 0001689084 qron:CubesquareLlcMember 2016-08-10 2016-09-01 0001689084 srt:MaximumMember qron:RelatedPartyDebtMember 2022-01-01 2022-03-31 0001689084 srt:MaximumMember qron:RelatedPartyDebtMember 2021-01-01 2021-12-31 0001689084 srt:MinimumMember qron:RelatedPartyDebtMember 2022-01-01 2022-03-31 0001689084 srt:MinimumMember qron:RelatedPartyDebtMember 2021-01-01 2021-12-31 0001689084 srt:MaximumMember qron:CommitmentDateMember qron:RelatedPartyDebtMember 2022-01-01 2022-03-31 0001689084 srt:MinimumMember qron:CommitmentDateMember qron:RelatedPartyDebtMember 2022-01-01 2022-03-31 0001689084 qron:CommitmentDateMember qron:RelatedPartyDebtMember 2022-01-01 2022-03-31 0001689084 qron:RelatedPartyDebtMember 2022-01-01 2022-03-31 0001689084 qron:RelatedPartyDebtMember 2021-01-01 2021-12-31 0001689084 qron:DerivativeLiabilitieMember 2022-03-31 0001689084 qron:DerivativeLiabilitieMember 2022-01-01 2022-03-31 0001689084 qron:DerivativeLiabilitieMember 2021-12-31 0001689084 qron:RelatedPartyDebtMember 2022-01-01 2022-12-31 0001689084 qron:RelatedPartyDebtMember 2023-01-01 2023-03-31 0001689084 qron:RelatedPartyDebtMember 2023-03-31 0001689084 qron:RelatedPartyDebtMember 2022-12-31 0001689084 2022-01-01 2022-12-31 0001689084 qron:StockPurchaseWarrantsMember 2022-01-01 2022-03-31 0001689084 qron:StockPurchaseWarrantsMember 2023-01-01 2023-03-31 0001689084 qron:StockOptionsVestedMember 2022-01-01 2022-03-31 0001689084 qron:StockOptionsVestedMember 2023-01-01 2023-03-31 0001689084 qron:SeriesAPreferredSharesMember 2022-01-01 2022-03-31 0001689084 qron:SeriesAPreferredSharesMember 2023-01-01 2023-03-31 0001689084 qron:ConvertibleNotesMember 2022-01-01 2022-03-31 0001689084 qron:ConvertibleNotesMember 2023-01-01 2023-03-31 0001689084 qron:ResearchWarrantsMember 2022-01-01 2022-03-31 0001689084 qron:ResearchWarrantsMember 2023-01-01 2023-03-31 0001689084 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001689084 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001689084 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001689084 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001689084 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001689084 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001689084 us-gaap:RetainedEarningsMember 2023-03-31 0001689084 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001689084 us-gaap:CommonStockMember 2023-03-31 0001689084 qron:PreferredStockSeriesAMember 2023-03-31 0001689084 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001689084 us-gaap:RetainedEarningsMember 2022-12-31 0001689084 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001689084 us-gaap:CommonStockMember 2022-12-31 0001689084 qron:PreferredStockSeriesAMember 2022-12-31 0001689084 2022-03-31 0001689084 us-gaap:RetainedEarningsMember 2022-03-31 0001689084 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001689084 us-gaap:CommonStockMember 2022-03-31 0001689084 qron:PreferredStockSeriesAMember 2022-03-31 0001689084 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001689084 2021-12-31 0001689084 us-gaap:RetainedEarningsMember 2021-12-31 0001689084 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001689084 us-gaap:CommonStockMember 2021-12-31 0001689084 qron:PreferredStockSeriesAMember 2021-12-31 0001689084 2022-01-01 2022-03-31 0001689084 2022-12-31 0001689084 2023-03-31 0001689084 2023-05-15 iso4217:USD shares iso4217:USD shares pure 0001689084 false --12-31 Q1 2023

0.001

10000

2000

0.0001

100000000

13439789

0.08

10000

100000

0.08

71000

1169 1169

6250

500000

10000

0.001

2000

10-Q true 2023-03-31 false 000-55800 QRONS INC. WY 81-3623646 28-10 Jackson Avenue #26N Long Island City NY 11101 212 945-2080 Yes Yes Non-accelerated Filer true false false 13439789

4488

3069

4488

3069

4488

3069

146141

128285

54276

42671

85873

373500 358500

100000

219624

208247

372814

358775

1352228

1282351

1352228

1282351

0.001

10000

2000

0.0001

100000000

13439789

1344

8254316

-9603402

-9534944

-1347740

-1279282

4488

3069

6820

8932

22345

44866

7777

9758

36942

63556

-36942

-63556

17477

34617

-14039 -165955

-31516

-200572

-68458

-264128

-0.01 -0.02 13439789 13289789

2000

13439789

1344

8254316

-9534944

-1279282

-68458

2000

13439789

1344

8254316

-9603402

-1347740

2000

13289789

1329

7697351

-8801427

-1102745

-264128

2000

13289789

1329

7697351

-9065555

-1366873

68458

264128

11377

29291

14039 165955

2163

17856

41054

11605

580

-13581

-29411

15000

1419

-29411

3069

35065

4488

5654

Note 1 – Description of Business and Basis of Presentation Organization and Nature of Business: Qrons Inc. (“Qrons” or the “Company”) was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. and changed its name to Qrons Inc., effective August 8, 2017. The Company’s common stock was approved by the Financial Industry Regulatory Authority (“FINRA”) for quotation on the OTC pink sheets under the symbol “BLMB” as of July 3, 2017. FINRA announced the Company’s name change to Qrons Inc. on August 9, 2017. The new name and symbol change to “QRON” for the OTC Market was effective August 10, 2017. The Company’s common stock commenced trading on the OTCQB Venture Market on August 12, 2019. The Company is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases, which are an enormous social and economic burden on society. The Company seeks to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. The Company’s search is currently focused on researchers based in Israel, a country which is world-renowned for biotech innovations and where its President is located and where its research to date has been conducted. The Company’s principal executive office is located at 28-10 Jackson Avenue, Long Island City, #26N, New York 11101.

Note 2 – Summary of Significant Accounting Policies Financial Statements: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Fiscal year end: The Company has selected December 31 as its fiscal year end. Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates. Cash Equivalents: The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents. Research and Development Costs: The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and development costs were $6,820 for the three months ended March 31, 2023. Research and development costs were $8,932 for the three months ended March 31, 2022. Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred. The Company incurred no advertising and marketing costs during the three months ended March 31, 2023 and 2022. Related Parties: For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities. Stock Based Compensation and Other Share-Based Payments: The Company records stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation, using the fair value method of the award on grant date. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the equity instruments issued. The expense attributable to the Company’s directors is recognized over the period the amounts are earned and vested, and the expense attributable to the Company’s non-employees is recognized when vested, as described in Note 9, Stock Plan. Fair Value of Financial Instruments ASC 820, Fair Value Measurements, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of March 31, 2023 and December 31, 2022: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair value measurements on a recurring basis</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">As of March 31, 2023:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">372,814</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">As of December 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">358,775</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>Warrants: The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC 815 Derivatives and Hedging, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. For warrants classified as equity instruments the Company applies the Black Scholes model and expenses the fair value as financing costs. For warrants classified as derivative financial instruments the Company applies the Monte Carlo model to value the warrants. Income taxes: The Company has adopted ASC 740, Income Taxes, which requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Basic and Diluted Loss Per Share: In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common stock had been issued and if the additional shares of common stock were dilutive. Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The table below reflects the potentially dilutive securities outstanding during each reporting period: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research warrants at 3% of issued and outstanding shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">403,194</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">398,694</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">702,213</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">723,751</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series A preferred shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock options vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,328,332</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,098,332</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock purchase warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">295,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">295,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,729,439</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,516,477</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Recently Issued Accounting Pronouncements AdoptedIn August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 changes how entities account for convertible instruments and contracts in an entity’s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU 2020-06 also modifies the guidance on diluted earnings per share calculations. The Company elected to adopt this guidance in the year ended December 31, 2022. There was no material effect on the Company’s operations, financial position or cash flows as a result of the adoption. There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

Financial Statements: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

Fiscal year end: The Company has selected December 31 as its fiscal year end.

Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Cash Equivalents: The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.

Research and Development Costs: The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and development costs were $6,820 for the three months ended March 31, 2023. Research and development costs were $8,932 for the three months ended March 31, 2022.

6820

8932

Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred. The Company incurred no advertising and marketing costs during the three months ended March 31, 2023 and 2022.

Related Parties: For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

Stock Based Compensation and Other Share-Based Payments: The Company records stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation, using the fair value method of the award on grant date. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the equity instruments issued. The expense attributable to the Company’s directors is recognized over the period the amounts are earned and vested, and the expense attributable to the Company’s non-employees is recognized when vested, as described in Note 9, Stock Plan.

ASC 820, Fair Value Measurements, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of March 31, 2023 and December 31, 2022: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair value measurements on a recurring basis</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">As of March 31, 2023:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">372,814</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">As of December 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">358,775</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

372814

358775

Warrants: The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC 815 Derivatives and Hedging, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. For warrants classified as equity instruments the Company applies the Black Scholes model and expenses the fair value as financing costs. For warrants classified as derivative financial instruments the Company applies the Monte Carlo model to value the warrants.

Income taxes: The Company has adopted ASC 740, Income Taxes, which requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Basic and Diluted Loss Per Share: In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common stock had been issued and if the additional shares of common stock were dilutive. Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The table below reflects the potentially dilutive securities outstanding during each reporting period: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research warrants at 3% of issued and outstanding shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">403,194</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">398,694</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">702,213</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">723,751</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series A preferred shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock options vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,328,332</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,098,332</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock purchase warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">295,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">295,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,729,439</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,516,477</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

403194

398694

702213

723751

700

4328332

4098332

295000

5729439

5516477

AdoptedIn August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 changes how entities account for convertible instruments and contracts in an entity’s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU 2020-06 also modifies the guidance on diluted earnings per share calculations. The Company elected to adopt this guidance in the year ended December 31, 2022. There was no material effect on the Company’s operations, financial position or cash flows as a result of the adoption. There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

Note 3 – Going Concern The Company has experienced net losses to date and has not generated revenues from operations. While the Company raised proceeds totaling $72,500 in unsecured advances from related parties in the year ended December 31, 2022 and a further $15,000 in unsecured advances from related parties during the current three months ended March 31, 2023, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the second quarter of 2023. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing, and continued support from its officers and directors. There can be no assurance that financing, whether debt or equity, will be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. In addition, if the Company is unable to obtain adequate financing from the capital markets, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty. Covid-19 Pandemic and Other Factors While the World Health Organization has recently declared that the COVID-19 pandemic is no longer a public health emergency of international concern and the global economy is focused on recovery, the impact of COVID-19 could continue to have an adverse impact on the Company going forward. COVID-19 caused significant disruptions to the global financial markets, which may continue to impact the Company’s ability to raise additional capital and ongoing research and development of our product candidates. Research facilities at Dartmouth were subject to closures as well as laboratories at Ariel in Israel during the pandemic. This resulted in our discontinuing our research at these Universities and was part of our decision to adjust our research to be collaborative and to seek aligning with third parties to advance our expanded goals. We do not currently know the full extent of potential delays of research in the future and the ultimate impact on us and our research relationships is currently uncertain. Additional factors which may impact the Company’s ongoing operations include, but are not limited to, inflation, potential supply chain issues as a result of the aforementioned recovery from the COVID-19 pandemic, the recent war in the Ukraine and climate change. These events may have serious adverse impact on domestic and foreign economies which may impact the Company’s operations as a result of a variety of factors including the potential for difficulties obtaining additional capital. The Company is unable to predict the ongoing impact of these factors on the Company’s financial operations. There are no assurances that the Company will be able to meet its obligations, raise funds or conclude the acquisition of identified businesses.

72500

15000

Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with Decagon LLC, doing business as CubeSquare, LLC (“CubeSquare”), of which the Company’s Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 (“Note 1”). Note 1 bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender’s option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender. On September 29, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; on November 6, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020; on October 30, 2020, the Company further amended Note 1 to extend the maturity date to September 1, 2021; and on October 7, 2021, the Company further amended Note 1 to extend the maturity date to September 1, 2022 under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and was due on September 27, 2018. Interest accrues from September 27, 2017 and is payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date to September 27, 2019. On November 6, 2019, Note 2 was amended to extend the maturity date to September 27, 2020; on October 30, 2020 Note 2 was amended to extend the maturity date to September 27, 2021; and further on October 7, 2021 Note 2 was amended to extend the maturity date to September 27, 2022. On September 27, 2022 the Board and the noteholder agreed to cancel the two convertible notes and in full satisfaction of such outstanding debt to issue a new 6% non-convertible promissory note to CubeSquare in the principal amount of $35,873 (the “New Note”), representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company analyzed the amendment to Note 1 and Note 2 under ASC 815-10-15-83 and concluded that the conversion feature within these two convertible Notes meet the definition of a derivative. The Company estimated the fair value of the derivative at each report date using the Black-Scholes valuation model to value the derivative liability related to the variable conversion rate. There is no derivative liability associated with the New Note given the absence of a conversion feature. The carrying value of these convertible notes is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Face value of certain convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible notes extinguish</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(25,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Carrying value</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">For Three Months EndedMarch 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest on the convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">493</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities – related party was $0. As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature is summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,099</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value during three months period</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20,463 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at March 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">52,636</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2022 and December 31, 2021 and the commitment date: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">101%-103</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">181%-182</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">261%~280</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.92 - 1 year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.67 - 0.74 year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.49 year</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.06</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.06</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>

0.25

10000

$0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender

15000

0.08

any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare

35873 25000 10873

25000

-25000

493

73099

-20463

52636

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">101%-103</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">181%-182</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">261%~280</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.92 - 1 year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.67 - 0.74 year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.49 year</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.06</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.06</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> 0 0 0 1.01 1.03 1.81 1.82 2.61 2.80 P0Y11M1D P1Y P0Y8M1D P0Y8M26D P0Y5M26D 0.0133 0.0106 Note 5 – Convertible Note and Derivative Liabilities (1) 8% Convertible notes with warrants issued in December 2019 and February 2020 In December 2019, we issued and sold in a private offering 8% convertible notes in the aggregate principal amount of $70,000. Such notes were due on December 31, 2021 and are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date of the notes to December 2022 upon initial maturity, and further extended the maturity date to December 2023 under the same terms and conditions during the year ended December 31, 2022. On February 19, 2020 we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date to February 2023 upon initial maturity, and further extended the maturity date to February 2024 under the same terms and conditions during the year ended December 31, 2022. The carrying value of these convertible notes is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Face value of certain convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Carrying value</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">80,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">80,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Interest expenses associated with the convertible notes are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;">For Three Months Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization on debt discount</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">541</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Interest on the convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,613</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,578</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,613</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,119</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities was $20,882 and $19,269, respectively. The convertible notes qualify for derivative accounting and bifurcation under ASC 815. As of March 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">57,033</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,089</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">95,122</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The convertible notes qualify for derivative accounting and bifurcation under ASC 815. As of March 31, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">157,490</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(10,411 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at March 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,079</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2023 and December 31, 2022 and the commitment date: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">154%-173</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">194.20%-201.98</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">96.37%-98.24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">2.10 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1.08 - 1.22 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.83 ~ 0.97 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1.42-1.65</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.41</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.64</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2022 and December 31, 2021 and the commitment date: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">154% ~173</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">203%~301</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">228%~245</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">2.10 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1.08 ~ 1.22 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.83 ~ 0.97 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1.42 ~ 1.65</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.39</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.35</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> (2) 8% Convertible note with warrants issued on June 15, 2021 On June 15, 2021, the Company entered into a note purchase agreement with Quick Capital, LLC (“Quick Capital”) pursuant to which the Company issued a twelve-month convertible promissory note in the principal amount of $115,000 for a $100,000 investment (the “Quick Note”), which included an original issuance discount of 10% and a $3,500 credit for legal and transaction costs. In connection with the Quick Note issuance, Quick Capital was also issued a five-year warrant (the “Quick Warrant”) to purchase up to an aggregate of 115,000 shares of the Company’s common stock at an exercise price of $1.00 per share (the “Quick Warrant Shares”) subject to adjustments for dilutive issuances at lower prices. The Quick Note is convertible into shares of common stock at a conversion price of $0.50 per share. If delivery of the conversion shares is not timely made, the Company is obligated to pay Quick Capital $2,000 for each day that the delivery is late as liquidated damages. The conversion price of the Quick Note will be reduced if the Company issues common stock or grants derivative securities for consideration at a price less than the conversion price to the amount of the consideration of such dilutive issuance. The Quick Note may not be prepaid. The Company is subject to significant cash penalties if the Company defaults on the Quick Note or in the event shares are not issued in a timely manner when a notice of conversion is provided. If an event of default occurs, the Quick Note will become immediately due and payable in an amount equal to 150% of the then outstanding principal amount of the Quick Note plus any interest or amounts owing to Quick Capital. The default provisions are based on the type of default and include a penalty of 50% of the principal plus accrued interest due (the “Default Sum”) and a parity value of the Default Sum based on the effective conversion of the Quick Note on the date of payment of the default and the maximum stock value during the period between the default date and the payment date.(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d) The Note and accrued interest totaling $124,200 was not repaid on maturity, constituting an event of default increasing the repayment value of the note to an amount equal to 150% of the principal balance and accrued interest outstanding, or $186,300. On December 7, 2022, the Company and Quick Capital amended the Note to extend the maturity date thereof to June 15, 2023, and amended the Warrant maturity date to June 15, 2027. Further Quick Capital agreed to reduce the outstanding balance of the Note from $186,300 to $150,000 in consideration for the issuance of 150,000 shares of unregistered, restricted common stock valued at $76,350. Details of the valuation of the 150,000 shares of common stock are set out below: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">December 7, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Note Payable, original face value</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">115,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued interest and default penalty on default</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible Note Payable, amended</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(150,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Debt discount, day one, amended convertible note payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,436</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative Liability associated with warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,416 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in Fair Value</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">31,030</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of Common stock issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">76,350</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The unpaid balance of the Note continues to accrue interest at 8% per annum. The Company valued the embedded default derivative liability of the Quick Note and the Quick Warrant liability, including the full ratchet reset feature, using Monte Carlo models. The fair value of the Quick Note and Quick Warrant embedded default derivatives liability has been valued as of March 31, 2023 and December 31, 2022. The carrying value of the Quick Note is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Face value of Quick Note</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: unamortized discount</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(10,376 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,753 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Carrying value</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">139,624</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">128,247</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Interest expenses associated with the conversion feature is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;">For the Three Months ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization of debt discount</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,377</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,750</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Interest on the convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,959</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,268</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,336</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">31,018</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d) As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities was $3,748 and $789, respectively. As a result of the application of ASC 815 as of March 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">301,742</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value – convertible note</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(10,740 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in fair value – warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(13,310 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">277,692</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> As a result of the application of ASC 815 as of March 31, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">175,368</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value – convertible note</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,352</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in fair value – warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,477</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at March 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">372,197</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2023 and December 31, 2022 and the commitment date: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Convertible note:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307.10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">119.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">119.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.45 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.21 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.18</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Warrants:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">219.10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">222.20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">5 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.45 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.21 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.65</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.27</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.19</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d) The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2022 and December 31, 2021 and the commitment date: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Convertible note:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307.10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">215.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.45 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.21 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.18</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.43</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Warrants:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200.90</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">280.40</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">5 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.45 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.20 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.65</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.82</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.350</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>

0.08

70000

are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00

we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance

80000

1613

1578

1613 2119

20882

19269

38089

95122 157490

-10411

147079 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">154%-173</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">194.20%-201.98</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">96.37%-98.24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">2.10 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1.08 - 1.22 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.83 ~ 0.97 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1.42-1.65</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.41</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.64</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">154% ~173</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">203%~301</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">228%~245</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">2.10 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1.08 ~ 1.22 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.83 ~ 0.97 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1.42 ~ 1.65</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">% </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.39</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.35</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> 0 0 0 1.54 1.73 1.9420 2.0198 0.9637 0.9824 P2Y1M6D P1Y29D P1Y2M19D P0Y9M29D P0Y11M19D 0.0142 0.0165 0.0441 0.0464 0 0 0 1.54 1.73 2.03 3.01 2.28 2.45 P2Y1M6D P1Y29D P1Y2M19D P0Y9M29D P0Y11M19D 0.0142 0.0165 0.0039 0.0135 115000

100000

0.10

3500

115000

0.50

2000

0.50

124200

186300

50000

76350

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">December 7, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Note Payable, original face value</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">115,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued interest and default penalty on default</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible Note Payable, amended</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(150,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Debt discount, day one, amended convertible note payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,436</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative Liability associated with warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,416 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in Fair Value</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">31,030</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of Common stock issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">76,350</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

115000 71300 -150000 24436 -15416 31030 76350 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Face value of Quick Note</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: unamortized discount</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(10,376 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,753 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Carrying value</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">139,624</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">128,247</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

150000

10376

21753

139624

128247

11377

28750

2959

2268

14336 31018

3748

789

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">301,742</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value – convertible note</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(10,740 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in fair value – warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(13,310 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">277,692</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">175,368</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value – convertible note</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,352</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in fair value – warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,477</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at March 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">372,197</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 301742 -10740 -13310 277692 175368 14352 182477 372197 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Convertible note:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307.10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">119.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">119.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.45 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.21 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.18</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Warrants:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">219.10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">222.20</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">5 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.45 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.21 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.65</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.27</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.19</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Convertible note:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307.10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">215.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">1 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.45 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.21 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.18</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.43</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Warrants:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">CommitmentDate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividends</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200.90</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">280.40</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected term</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">5 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.45 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.20 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.65</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.82</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.350</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> 0 0 0 3.0710 1.1970 1.1970 P1Y P0Y5M12D P0Y2M15D 0.0018 0.0437 0.0437 0 0 0 2.0170 2.1910 2.2220 P5Y P4Y5M12D P4Y2M15D 0.0065 0.0427 0.0419 0 0 0 3.0710 2.1570 3.3680 P1Y P0Y5M12D P0Y2M15D 0.0018 0.0043 0.0137 0 0 0 2.0170 2.0090 2.8040 P5Y P4Y5M12D P4Y2M12D 0.0065 0.0082 0.01350

Note 6 – Unsecured Short-Term Advance from Third Party On June 20, 2019, the Company received $100,000 from a third party in the form of an unsecured, demand, non-interest-bearing, short-term advance to meet its operating needs. The advance remains outstanding at March 31, 2023 and December 31, 2022.

100000

Note 7 – Related Party Transactions (1) Demand Loan from related party On May 1, 2019, the Company issued a promissory note (the “Note”) to CubeSquare in the principal amount of $50,000. The Company’s Chief Executive Officer is the managing partner and the Company’s President is a 25% owner of CubeSquare. The Note bears interest at the rate of 8% per annum and is due and payable by the Company upon demand from CubeSquare. The Company recorded interest expenses of $997 and $986 for the three months ended March 31, 2023 and 2022, respectively On September 27, 2022 the Board and the related party noteholder agreed to cancel two convertible notes issued to Cubesquare and in full satisfaction of such outstanding debt to issue a new 6% promissory note (Ref: Note 4) in the principal amount of $35,873, representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company recorded interest expenses of $531 and $0 for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities – related party in respect of the aforementioned notes was $16,763 and $15,234, respectively.(2) Advances from Related Parties During the year ended December 31, 2019, the Company received $135,000 from Jonah Meer, its Chief Executive Officer, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $70,000 from Jonah Meer. An additional $72,500 in advances was received from Mr. Meer during the year ended December 31, 2022. An additional $15,000 in advances was received from Mr. Meer during the three months ended March 31, 2023.Mr. Meer is owed $292,500 and $277,500 in respect to these advances at March 31, 2023 and December 31, 2022, respectively. On August 20, 2019, the Company received $50,000 from Ido Merfeld, its President, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $21,000 from Ido Merfeld. There were no additional advances from Mr. Merfeld during the years ended December 31, 2022 and 2021. Mr. Merfeld is owed $71,000 in respect to these advances at March 31, 2023 and December 31, 2022. During the year ended December 31, 2020, the Company received $10,000 from CubeSquare in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs which amount is outstanding as of March 31, 2023 and December 31, 2022. (3) Others Jonah Meer, the Company’s Chief Executive Officer, made payments of $10,076 to various vendors during the three months ended March 31, 2023. The balance payable to Mr. Meer of $36,344 and $26,268 is reflected in accounts payable, related party as of March 31, 2023 and December 31, 2022, respectively. During the year ended December 31, 2019, Ido Merfeld, the Company’s President, made payments to various vendors in the aggregate amount of $1,169. The balance payable to Mr. Merfeld of $1,169 is reflected in accounts payable, related party as of March 31, 2023 and December 31, 2022.

50000

0.25

0.08

997

986

35873 25000 10873

531

16763

15234

135000

70000

72500

15000

292500

277500

50000

21000

71000

10000

10076 36344 26268

1169

1169 Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement Dartmouth College – Intellectual Property License Agreement On October 2, 2019, the Company entered into an intellectual property license agreement (the “Intellectual Property License Agreement”) pursuant to which Dartmouth granted the Company an exclusive world-wide license under the patent application entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement. The Agreement provided for: (i) a $25,000 license issue fee; (ii) an annual license maintenance fee of $25,000, until the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales of licensed products and services by the Company or a sublicensee; (iv) 15% of consideration received by the Company under a sublicense; and (v) beginning in the first calendar year after the first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter. The Company will also reimburse Dartmouth for all patent preparation, filing, maintenance and defense costs.Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law. The Agreement may be terminated by Dartmouth if the Company is in material breach of the Agreement which is not cured after 30 days of notice thereof or if the Company becomes insolvent. Dartmouth may terminate the Agreement if the Company challenges a Dartmouth patent or does not terminate a sublicensee that challenges a Dartmouth patent, except in response to a valid court or governmental order. The Company may terminate the Agreement at any time upon six months written notice to Dartmouth. If the Company or any sublicensee or affiliate institutes or participates in a licensed patent challenge, the then current earned royalty rate for licensed products covered by Dartmouth patents will automatically be increased to three times the then current earned royalty rate. On March 23, 2021, the United States Patent and Trademark Office issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College, which is directed to mechanically interlocked, molecules-based materials for 3-D printing. The patent’s inventors are Professor Chenfeng Ke, a member of the Company’s Scientific Advisory Board and Qianming Lin, Professor Ke’s assistant. The patent grant is the culmination of the Intellectual Property License Agreement between the Company and Dartmouth with respect to an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health. Dartmouth College – Intellectual Property License Agreement The Company expensed $6,250 as license fees during each of the three months ended March 31, 2023 and 2022 with respect to such annual fee. 25000 25000

0.02

first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter

6250

Note 9 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company’s 2016 Stock Option and Stock Award Plan (the “Plan”). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Board. The Company has reserved 10 million shares for issuance under the Plan. (a) Stock Options granted to Science Advisors and employees On December 22, 2022, the Board granted a five-year option to purchase 325,000 shares of common stock to a scientific advisor. The options have an exercise price of $2.00 per share, are immediately exercisable and were expensed on issue date. During the year ended December 31, 2022, various three-year stock options to purchase 145,000 shares of common stock of the Company previously granted to science advisors and employees expired unexercised. Details of outstanding options for employees and scientific advisors at March 31, 2023 are below: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Grant date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Vested </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Unvested </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise price </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiry </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Scientific Advisor</td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">145,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/24</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/20</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/25</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/21</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/26</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/22</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/27</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Employees </td><td style="width:1%;white-space: nowrap;"> </td><td>04/16/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>4/16/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>08/15/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>08/15/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>07/01/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>07/01/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>07/01/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>07/01/24</td><td style="width:1%;"> </td></tr></tbody></table> As of March 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods. (b) Stock Options granted to Officers: On December 4, 2022, a five-year stock option to purchase 600,000 shares of common stock of the Company previously granted to officers expired unexercised. On December 22, 2022, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share, are immediately exercisable and were expensed on issue date. Following are the details of stock options granted to our officers at March 31, 2023: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Name </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Grant date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercisable </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise price </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiry </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Jonah Meer </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/24</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/20</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/25</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/21</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/26</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/22</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/27</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ido Merfeld </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/24</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/20</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/25</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/21</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/26</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/22</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/27</td><td style="width:1%;"> </td></tr></tbody></table> As of March 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods. A summary of the activity for the Company’s stock options at March 31, 2023 and December 31, 2022, is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">March 31, 2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">December 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;">Weighted Average Remaining Contractual Life</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:6%;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;">Weighted Average Remaining Contractual Life</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">(in years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">(in years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, beginning of period</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">4,328,332</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">2.78</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">4,098,332</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">3.08</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">975,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Canceled/forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(745,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, end of period</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">4,328,332</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2.78</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">4,328,332</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">3.03</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable, end of period</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">4,328,332</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2.78</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">4,328,332</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">3.03</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average fair value of options granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

325000

2.00

145000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Grant date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Vested </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Unvested </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise price </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiry </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Scientific Advisor</td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">145,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/24</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/20</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/25</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/21</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/26</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/22</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/27</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Employees </td><td style="width:1%;white-space: nowrap;"> </td><td>04/16/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>4/16/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>08/15/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>08/15/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>07/01/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>07/01/23</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>07/01/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,333</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>07/01/24</td><td style="width:1%;"> </td></tr></tbody></table>

2018-12-10

145000

2.00

2023-12-10

2019-12-17

33333

2.00

2023-12-17

2019-12-17

33333

2.00

2024-12-17

2020-12-10

100000

2.00

2025-12-10

2021-12-22

325000

2.00

2026-12-22

2022-12-22

325000

2.00

2027-12-22

2018-04-16

10000

2.00

2023-04-16

2018-08-15

6667

2.00

2023-08-15

2018-12-10

33333

2.00

2023-12-10

2019-07-01

33333

2.00

2023-07-01

2019-07-01

33333

2.00

2024-07-01

600000 325000

2.00

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Name </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Grant date </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercisable </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise price </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiry </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Jonah Meer </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/24</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/20</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/25</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/21</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/26</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/22</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/27</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ido Merfeld </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/17/24</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/20</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/10/25</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/21</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12//22/26</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/22</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/22/27</td><td style="width:1%;"> </td></tr></tbody></table>

2018-12-10

325000

2.00

2023-12-10

2019-12-17

325000

2.00

2024-12-17

2020-12-10

325000

2.00

2025-12-10

2021-12-22

325000

2.00

2026-12-22

2022-12-22

325000

2.00

2027-12-22

2018-12-10

325000

2.00

2023-12-10

2019-12-17

325000

2.00

2024-12-17

2020-12-10

325000

2.00

2025-12-10

2021-12-22

325000

2.00

2026-12-22

2022-12-22

325000

2.00

2027-12-22

4328332 2 P2Y9M10D 4098332 2 P3Y29D 2 975000 2 0 0 2 -745000 2 4328332 2 P2Y9M10D 4328332 2 P3Y10D 4328332 2 P2Y9M10D 4328332 2 P3Y10D 2 2 Note 10 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, par value $0.0001, and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001. Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company’s common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding. There were 2,000 shares of Series A Preferred Stock issued and outstanding as of March 31, 2023 and December 31, 2022. Common Stock In December 2022, the Company issued 150,000 shares of its common stock to Quick Capital LLC with a value of $76,350 related to a loan amendment (Note 5). There were 13,439,789 shares of common stock issued and outstanding as of March 31, 2023 and December 31, 2022. Common Stock Purchase Warrants As of March 31, 2023 and December 31, 2022, the following common stock purchase warrants were outstanding: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">WeightedAverageExercisePrice</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding – December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">295,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.00</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Canceled/forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding – December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">295,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Canceled/forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding – March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">295,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> On June 15, 2021, the Company granted a convertible noteholder a warrant to purchase 115,000 shares of common stock at an exercise price of $1.00, subject to adjustments for full ratchet resets for dilutive issuances at lower prices. (See Note 5(2) above.)

100000000

0.0001

10000

0.001

2000

150000

76350

13439789

295000

1.00 0 0 0

295000

1.00 0 0 0

295000

1.00

115000

1.00

Note 11 – Subsequent Events The Company has evaluated events for the period through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.

EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 156 221 1 false 41 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://f10qqrons.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED BALANCE SHEETS Sheet http://f10qqrons.com/role/CondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited) Sheet http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited) Statements 5 false false R6.htm 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - Description of Business and Basis of Presentation Sheet http://f10qqrons.com/role/DescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 7 false false R8.htm 000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://f10qqrons.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 000009 - Disclosure - Going Concern Sheet http://f10qqrons.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 000010 - Disclosure - Convertible Note Related Party and Derivative Liabilities Sheet http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilities Convertible Note Related Party and Derivative Liabilities Notes 10 false false R11.htm 000011 - Disclosure - Convertible Note and Derivative Liabilities Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilities Convertible Note and Derivative Liabilities Notes 11 false false R12.htm 000012 - Disclosure - Unsecured Short-Term Advance from Third Party Sheet http://f10qqrons.com/role/UnsecuredShortTermAdvanceFromThirdParty Unsecured Short-Term Advance from Third Party Notes 12 false false R13.htm 000013 - Disclosure - Related Party Transactions Sheet http://f10qqrons.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 000014 - Disclosure - Intellectual Property License Agreement and Sponsored Research Agreement Sheet http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreement Intellectual Property License Agreement and Sponsored Research Agreement Notes 14 false false R15.htm 000015 - Disclosure - Stock Plan Sheet http://f10qqrons.com/role/StockPlan Stock Plan Notes 15 false false R16.htm 000016 - Disclosure - Capital Stock Sheet http://f10qqrons.com/role/CapitalStock Capital Stock Notes 16 false false R17.htm 000017 - Disclosure - Subsequent Events Sheet http://f10qqrons.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://f10qqrons.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 000019 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://f10qqrons.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 000020 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Tables) Sheet http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables Convertible Note Related Party and Derivative Liabilities (Tables) Tables http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilities 20 false false R21.htm 000021 - Disclosure - Convertible Note and Derivative Liabilities (Tables) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables Convertible Note and Derivative Liabilities (Tables) Tables http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilities 21 false false R22.htm 000022 - Disclosure - Stock Plan (Tables) Sheet http://f10qqrons.com/role/StockPlanTables Stock Plan (Tables) Tables http://f10qqrons.com/role/StockPlan 22 false false R23.htm 000023 - Disclosure - Capital Stock (Tables) Sheet http://f10qqrons.com/role/CapitalStockTables Capital Stock (Tables) Tables http://f10qqrons.com/role/CapitalStock 23 false false R24.htm 000024 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 000025 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 000027 - Disclosure - Going Concern (Details Narrative) Sheet http://f10qqrons.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://f10qqrons.com/role/GoingConcern 27 false false R28.htm 000028 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details) Sheet http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails Convertible Note Related Party and Derivative Liabilities (Details) Details http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 28 false false R29.htm 000029 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 1) Sheet http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails1 Convertible Note Related Party and Derivative Liabilities (Details 1) Details http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 29 false false R30.htm 000030 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 2) Sheet http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2 Convertible Note Related Party and Derivative Liabilities (Details 2) Details http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 30 false false R31.htm 000031 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 3) Sheet http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3 Convertible Note Related Party and Derivative Liabilities (Details 3) Details http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 31 false false R32.htm 000032 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details Narrative) Sheet http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative Convertible Note Related Party and Derivative Liabilities (Details Narrative) Details http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 32 false false R33.htm 000033 - Disclosure - Convertible Note and Derivative Liabilities (Details) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails Convertible Note and Derivative Liabilities (Details) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 33 false false R34.htm 000034 - Disclosure - Convertible Note and Derivative Liabilities (Details 1) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1 Convertible Note and Derivative Liabilities (Details 1) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 34 false false R35.htm 000035 - Disclosure - Convertible Note and Derivative Liabilities (Details 2) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails2 Convertible Note and Derivative Liabilities (Details 2) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 35 false false R36.htm 000036 - Disclosure - Convertible Note and Derivative Liabilities (Details 3) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3 Convertible Note and Derivative Liabilities (Details 3) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 36 false false R37.htm 000037 - Disclosure - Convertible Note and Derivative Liabilities (Details 4) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4 Convertible Note and Derivative Liabilities (Details 4) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 37 false false R38.htm 000038 - Disclosure - Convertible Note and Derivative Liabilities (Details 5) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5 Convertible Note and Derivative Liabilities (Details 5) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 38 false false R39.htm 000039 - Disclosure - Convertible Note and Derivative Liabilities (Details 6) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails6 Convertible Note and Derivative Liabilities (Details 6) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 39 false false R40.htm 000040 - Disclosure - Convertible Note and Derivative Liabilities (Details 7) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7 Convertible Note and Derivative Liabilities (Details 7) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 40 false false R41.htm 000041 - Disclosure - Convertible Note and Derivative Liabilities (Details 8) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8 Convertible Note and Derivative Liabilities (Details 8) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 41 false false R42.htm 000042 - Disclosure - Convertible Note and Derivative Liabilities (Details Narrative) Sheet http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative Convertible Note and Derivative Liabilities (Details Narrative) Details http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables 42 false false R43.htm 000043 - Disclosure - Unsecured ShortTerm Advance from Third Party (Details Narrative) Sheet http://f10qqrons.com/role/UnsecuredShorttermAdvanceFromThirdPartyDetailsNarrative Unsecured ShortTerm Advance from Third Party (Details Narrative) Details 43 false false R44.htm 000044 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://f10qqrons.com/role/RelatedPartyTransactions 44 false false R45.htm 000045 - Disclosure - Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative) Sheet http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementDetailsNarrative Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative) Details http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreement 45 false false R46.htm 000046 - Disclosure - Stock Plan (Details) Sheet http://f10qqrons.com/role/StockPlanDetails Stock Plan (Details) Details http://f10qqrons.com/role/StockPlanTables 46 false false R47.htm 000047 - Disclosure - Stock Plan (Details 1) Sheet http://f10qqrons.com/role/StockPlanDetails1 Stock Plan (Details 1) Details http://f10qqrons.com/role/StockPlanTables 47 false false R48.htm 000048 - Disclosure - Stock Plan (Details 2) Sheet http://f10qqrons.com/role/StockPlanDetails2 Stock Plan (Details 2) Details http://f10qqrons.com/role/StockPlanTables 48 false false R49.htm 000049 - Disclosure - Stock Plan (Details Narrative) Sheet http://f10qqrons.com/role/StockPlanDetailsNarrative Stock Plan (Details Narrative) Details http://f10qqrons.com/role/StockPlanTables 49 false false R50.htm 000050 - Disclosure - Capital Stock (Details) Sheet http://f10qqrons.com/role/CapitalStockDetails Capital Stock (Details) Details http://f10qqrons.com/role/CapitalStockTables 50 false false R51.htm 000051 - Disclosure - Capital Stock (Details Narrative) Sheet http://f10qqrons.com/role/CapitalStockDetailsNarrative Capital Stock (Details Narrative) Details http://f10qqrons.com/role/CapitalStockTables 51 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. qron_10q.htm 1 [dq-0542-Deprecated-Concept] Concept DueToOtherRelatedPartiesClassifiedCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. qron_10q.htm 1 [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesNoncurrent in us-gaap/2022 used in 9 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. qron_10q.htm 1 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 29 fact(s) appearing in ix:hidden were eligible for transformation: qron:PaymentOfAdvances, qron:PrincipalAmount, us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent, us-gaap:CommercialPaper, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentInterestRateStatedPercentage, us-gaap:MarketingAndAdvertisingExpense, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:PrepaymentFeesOnAdvancesNet, us-gaap:RoyaltyExpense, us-gaap:TaxesAndLicenses - qron_10q.htm 1 qron_10q.htm qron-20230331.xsd qron-20230331_cal.xml qron-20230331_def.xml qron-20230331_lab.xml qron-20230331_pre.xml qron_ex31.htm qron_ex32.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "qron_10q.htm": { "axisCustom": 0, "axisStandard": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 341, "http://xbrl.sec.gov/dei/2022": 26 }, "contextCount": 156, "dts": { "calculationLink": { "local": [ "qron-20230331_cal.xml" ] }, "definitionLink": { "local": [ "qron-20230331_def.xml" ] }, "inline": { "local": [ "qron_10q.htm" ] }, "labelLink": { "local": [ "qron-20230331_lab.xml" ] }, "presentationLink": { "local": [ "qron-20230331_pre.xml" ] }, "schema": { "local": [ "qron-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 325, "entityCount": 1, "hidden": { "http://f10qqrons.com/20230331": 3, "http://fasb.org/us-gaap/2022": 26, "http://xbrl.sec.gov/dei/2022": 5, "total": 34 }, "keyCustom": 82, "keyStandard": 139, "memberCustom": 29, "memberStandard": 10, "nsprefix": "qron", "nsuri": "http://f10qqrons.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://f10qqrons.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCreditDerivativesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Convertible Note Related Party and Derivative Liabilities", "menuCat": "Notes", "order": "10", "role": "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilities", "shortName": "Convertible Note Related Party and Derivative Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCreditDerivativesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Convertible Note and Derivative Liabilities", "menuCat": "Notes", "order": "11", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilities", "shortName": "Convertible Note and Derivative Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Unsecured Short-Term Advance from Third Party", "menuCat": "Notes", "order": "12", "role": "http://f10qqrons.com/role/UnsecuredShortTermAdvanceFromThirdParty", "shortName": "Unsecured Short-Term Advance from Third Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "13", "role": "http://f10qqrons.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Intellectual Property License Agreement and Sponsored Research Agreement", "menuCat": "Notes", "order": "14", "role": "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreement", "shortName": "Intellectual Property License Agreement and Sponsored Research Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Stock Plan", "menuCat": "Notes", "order": "15", "role": "http://f10qqrons.com/role/StockPlan", "shortName": "Stock Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:CapitalStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Capital Stock", "menuCat": "Notes", "order": "16", "role": "http://f10qqrons.com/role/CapitalStock", "shortName": "Capital Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:CapitalStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "17", "role": "http://f10qqrons.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "18", "role": "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "19", "role": "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://f10qqrons.com/role/CondensedBalanceSheets", "shortName": "CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Tables)", "menuCat": "Tables", "order": "20", "role": "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables", "shortName": "Convertible Note Related Party and Derivative Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:ScheduleOfConvertibleNotesDerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Convertible Note and Derivative Liabilities (Tables)", "menuCat": "Tables", "order": "21", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables", "shortName": "Convertible Note and Derivative Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:ScheduleOfConvertibleNotesDerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Stock Plan (Tables)", "menuCat": "Tables", "order": "22", "role": "http://f10qqrons.com/role/StockPlanTables", "shortName": "Stock Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "qron:CapitalStockTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Capital Stock (Tables)", "menuCat": "Tables", "order": "23", "role": "http://f10qqrons.com/role/CapitalStockTables", "shortName": "Capital Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "qron:CapitalStockTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "qron:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31_us-gaap_FairValueInputsLevel1Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "24", "role": "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31_us-gaap_FairValueInputsLevel1Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Summary of Significant Accounting Policies (Details 1)", "menuCat": "Details", "order": "25", "role": "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1", "shortName": "Summary of Significant Accounting Policies (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ResearchAndDevelopmentExpensePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLoans", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Going Concern (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://f10qqrons.com/role/GoingConcernDetailsNarrative", "shortName": "Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLoans", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31_qron_RelatedPartyDebtMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details)", "menuCat": "Details", "order": "28", "role": "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails", "shortName": "Convertible Note Related Party and Derivative Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31_qron_RelatedPartyDebtMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfConvertibleNotesInterestExpenseWarrants", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestOnConvertibleDebtNetOfTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 1)", "menuCat": "Details", "order": "29", "role": "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails1", "shortName": "Convertible Note Related Party and Derivative Liabilities (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ConvertibleNoteInterestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_RelatedPartyDebtMember", "decimals": "0", "lang": null, "name": "us-gaap:InterestOnConvertibleDebtNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 2)", "menuCat": "Details", "order": "30", "role": "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2", "shortName": "Convertible Note Related Party and Derivative Liabilities (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueOfConversionFeatureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2021-12-31_qron_DerivativeLiabilitieMember", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueAtCommitmentAndRemeasurementDatesDerivativeLiabilities", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "qron:FairValueAssumptionExpectedTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details 3)", "menuCat": "Details", "order": "31", "role": "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3", "shortName": "Convertible Note Related Party and Derivative Liabilities (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfDerivativeLiabilityBasedUponManagementAssumptions", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2022-01-01to2022-03-31_qron_RelatedPartyDebtMember", "decimals": "INF", "lang": null, "name": "qron:FairValueAssumptionExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2022-09-01to2022-09-27", "decimals": "0", "first": true, "lang": null, "name": "qron:PrincipalAmountRelatedPartyConvertibleNoteModifiedTo6PromissoryNote", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Convertible Note Related Party and Derivative Liabilities (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "shortName": "Convertible Note Related Party and Derivative Liabilities (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2017-09-01to2017-09-27_qron_CubesquareLlcMember", "decimals": "0", "lang": null, "name": "us-gaap:RepaymentsOfConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfConvertibleNotesDerivativeLiabilities", "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31_qron_DerivativeLiabilitieMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Convertible Note and Derivative Liabilities (Details)", "menuCat": "Details", "order": "33", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails", "shortName": "Convertible Note and Derivative Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfConvertibleNotesDerivativeLiabilities", "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31_qron_DerivativeLiabilitieMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfConvertibleNotesInterestExpenseWarrants", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "qron:InterestExpenseNetAmortizationDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Convertible Note and Derivative Liabilities (Details 1)", "menuCat": "Details", "order": "34", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1", "shortName": "Convertible Note and Derivative Liabilities (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ConvertibleNoteDerivativeLiabilitiesInterestExpenseTableTextBlock", "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_WarrantsMember", "decimals": "0", "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueOfConversionFeatureDerivativeLiabilities", "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "qron:DerivativeLiabilitiesConvertibleNoteCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Convertible Note and Derivative Liabilities (Details 2)", "menuCat": "Details", "order": "35", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails2", "shortName": "Convertible Note and Derivative Liabilities (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueOfConversionFeatureDerivativeLiabilities", "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "qron:DerivativeLiabilitiesConvertibleNoteCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueAtCommitmentAndRemeasurementDatesDerivativeLiabilities", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_srt_MinimumMember", "decimals": "INF", "first": true, "lang": null, "name": "qron:FairValueAssumptionExpectedVolatilityConvertibleNoteRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - Convertible Note and Derivative Liabilities (Details 3)", "menuCat": "Details", "order": "36", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "shortName": "Convertible Note and Derivative Liabilities (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueAtCommitmentAndRemeasurementDatesDerivativeLiabilities", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_srt_MinimumMember", "decimals": "INF", "first": true, "lang": null, "name": "qron:FairValueAssumptionExpectedVolatilityConvertibleNoteRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2022-12-07", "decimals": "0", "first": true, "lang": null, "name": "qron:NotePayableOriginalFaceValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Convertible Note and Derivative Liabilities (Details 4)", "menuCat": "Details", "order": "37", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4", "shortName": "Convertible Note and Derivative Liabilities (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2022-12-07", "decimals": "0", "first": true, "lang": null, "name": "qron:NotePayableOriginalFaceValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfConvertibleNotesWarrantsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31_qron_QuickNoteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - Convertible Note and Derivative Liabilities (Details 5)", "menuCat": "Details", "order": "38", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5", "shortName": "Convertible Note and Derivative Liabilities (Details 5)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfConvertibleNotesWarrantsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31_qron_QuickNoteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfConvertibleNotesInterestExpenseWarrants", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - Convertible Note and Derivative Liabilities (Details 6)", "menuCat": "Details", "order": "39", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails6", "shortName": "Convertible Note and Derivative Liabilities (Details 6)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfConvertibleNotesInterestExpenseWarrants", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited", "shortName": "CONDENSED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueOfConversionFeatureDerivativeLiabilities", "qron:ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "qron:DerivativeLiabilitiesConvertibleNoteCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - Convertible Note and Derivative Liabilities (Details 7)", "menuCat": "Details", "order": "40", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7", "shortName": "Convertible Note and Derivative Liabilities (Details 7)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueOfConversionFeatureWarrants", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_WarrantsMember_qron_ConvertibleNoteJuneMember", "decimals": "0", "lang": null, "name": "qron:BalanceAtBeginnings", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueAtCommitmentRemeasurementDatesWarrants", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_CommitmentDateConvertibleNoteMember", "decimals": "INF", "first": true, "lang": null, "name": "qron:FairValueAssumptionExpectedDividendConvertibleNoteRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - Convertible Note and Derivative Liabilities (Details 8)", "menuCat": "Details", "order": "41", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "shortName": "Convertible Note and Derivative Liabilities (Details 8)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfFairValueAtCommitmentRemeasurementDatesWarrants", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_CommitmentDateConvertibleNoteMember", "decimals": "INF", "first": true, "lang": null, "name": "qron:FairValueAssumptionExpectedDividendConvertibleNoteRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherAccountsPayableAndAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - Convertible Note and Derivative Liabilities (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "shortName": "Convertible Note and Derivative Liabilities (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherAccountsPayableAndAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommercialPaper", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - Unsecured ShortTerm Advance from Third Party (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://f10qqrons.com/role/UnsecuredShorttermAdvanceFromThirdPartyDetailsNarrative", "shortName": "Unsecured ShortTerm Advance from Third Party (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommercialPaper", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepositLiabilitiesAccruedInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepositLiabilitiesAccruedInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "qron:IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "qron:LicenceFee", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative)", "menuCat": "Details", "order": "45", "role": "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementDetailsNarrative", "shortName": "Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "qron:IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "qron:LicenceFee", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "qron:DetailsOfOutstandingOptionsForEmployeesAndScientificAdvisorsTableTextBlock", "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_ScientificAdvisorMember_us-gaap_GrantMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - Stock Plan (Details)", "menuCat": "Details", "order": "46", "role": "http://f10qqrons.com/role/StockPlanDetails", "shortName": "Stock Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "qron:DetailsOfOutstandingOptionsForEmployeesAndScientificAdvisorsTableTextBlock", "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_ScientificAdvisorMember_us-gaap_GrantMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "qron:FollowingAreTheDetailsOfStockOptionsGrantedToOurOfficersTableTextblock", "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_JonahMeerMember_us-gaap_GrantMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - Stock Plan (Details 1)", "menuCat": "Details", "order": "47", "role": "http://f10qqrons.com/role/StockPlanDetails1", "shortName": "Stock Plan (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "qron:FollowingAreTheDetailsOfStockOptionsGrantedToOurOfficersTableTextblock", "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31_qron_JonahMeerMember_us-gaap_GrantMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "qron:NumberOfOptionsBeginingBalance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - Stock Plan (Details 2)", "menuCat": "Details", "order": "48", "role": "http://f10qqrons.com/role/StockPlanDetails2", "shortName": "Stock Plan (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "qron:NumberOfOptionsBeginingBalance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2022-12-01to2022-12-22_qron_StockOptionsGrantedToScienceAdvisorAndBusinessAdvisorsMember", "decimals": "0", "first": true, "lang": null, "name": "qron:OptionToPurchaseSharesOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - Stock Plan (Details Narrative)", "menuCat": "Details", "order": "49", "role": "http://f10qqrons.com/role/StockPlanDetailsNarrative", "shortName": "Stock Plan (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfStockByClassTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2022-12-01to2022-12-22_qron_StockOptionsGrantedToScienceAdvisorAndBusinessAdvisorsMember", "decimals": "0", "first": true, "lang": null, "name": "qron:OptionToPurchaseSharesOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited", "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock", "qron:CapitalStockTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - Capital Stock (Details)", "menuCat": "Details", "order": "50", "role": "http://f10qqrons.com/role/CapitalStockDetails", "shortName": "Capital Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "qron:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock", "qron:CapitalStockTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "qron:CapitalStockTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - Capital Stock (Details Narrative)", "menuCat": "Details", "order": "51", "role": "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "shortName": "Capital Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "qron:CapitalStockTextBlock", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "AsOf2021-06-15", "decimals": "INF", "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Description of Business and Basis of Presentation", "menuCat": "Notes", "order": "7", "role": "http://f10qqrons.com/role/DescriptionOfBusinessAndBasisOfPresentation", "shortName": "Description of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://f10qqrons.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Going Concern", "menuCat": "Notes", "order": "9", "role": "http://f10qqrons.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "qron_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 41, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://f10qqrons.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "qron_AccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Accounts payable and accrued liabilities]", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilities", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_AccruedInterestAndDefaultPenaltyOnDefault": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accrued interest and default penalty on default" } } }, "localname": "AccruedInterestAndDefaultPenaltyOnDefault", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4" ], "xbrltype": "monetaryItemType" }, "qron_AccruedInterestOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued interest outstanding" } } }, "localname": "AccruedInterestOutstanding", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_AccruedInterestPayableRelatedPartyConvertibleNoteModifiedTo6PromissoryNote1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued interest payable - related party convertible note modified to 6% promissory note", "verboseLabel": "Accrued interest payable - related party convertible note modified to 6% promissory note" } } }, "localname": "AccruedInterestPayableRelatedPartyConvertibleNoteModifiedTo6PromissoryNote1", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_AdditionalAdvancesReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Additional advances received" } } }, "localname": "AdditionalAdvancesReceived", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_AdvancesFromRelatedParty": { "auth_ref": [], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances from related party" } } }, "localname": "AdvancesFromRelatedParty", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "qron_AggregatePrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate principal amount - related party convertible note modified to 6% promissory note", "verboseLabel": "Aggregate principal amount - related party convertible note modified to 6% promissory note" } } }, "localname": "AggregatePrincipalAmount", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_AggregatePurchaseOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aggregate purchase of common stock" } } }, "localname": "AggregatePurchaseOfCommonStock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "qron_AmortizationOnDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization on debt discount" } } }, "localname": "AmortizationOnDebtDiscount", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "qron_BalanceAtBeginnings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Balance at beginnings 1]", "verboseLabel": "Balance at beginnings" } } }, "localname": "BalanceAtBeginnings", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7" ], "xbrltype": "monetaryItemType" }, "qron_CapitalStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Capital Stock]", "verboseLabel": "Capital Stock" } } }, "localname": "CapitalStockTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStock" ], "xbrltype": "textBlockItemType" }, "qron_ChangeInDerivativeLiabilities": { "auth_ref": [], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in derivative liabilities" } } }, "localname": "ChangeInDerivativeLiabilities", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "qron_ChangeInDerivativeLiability": { "auth_ref": [], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Change in derivative liabilities]", "verboseLabel": "Change in derivative liabilities" } } }, "localname": "ChangeInDerivativeLiability", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "qron_ChangeInFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in Fair Value 1" } } }, "localname": "ChangeInFairValue", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4" ], "xbrltype": "monetaryItemType" }, "qron_CommitmentAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment And Warrants [Member]" } } }, "localname": "CommitmentAndWarrantsMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8" ], "xbrltype": "domainItemType" }, "qron_CommitmentDateConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment DateConvertible Note [Member]" } } }, "localname": "CommitmentDateConvertibleNoteMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8" ], "xbrltype": "domainItemType" }, "qron_CommitmentDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment Date [Member]", "verboseLabel": "Commitment Date [Member]" } } }, "localname": "CommitmentDateMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "domainItemType" }, "qron_CommitmentDatesMaximumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment Dates Maximum [Member]" } } }, "localname": "CommitmentDatesMaximumMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3" ], "xbrltype": "domainItemType" }, "qron_CommitmentDatesMinimumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment Dates Minimum [Member]" } } }, "localname": "CommitmentDatesMinimumMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3" ], "xbrltype": "domainItemType" }, "qron_ConvertibleNoteAndDerivativeLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Convertible Note and Derivative Liabilities]", "verboseLabel": "Convertible Note and Derivative Liabilities" } } }, "localname": "ConvertibleNoteAndDerivativeLiabilitiesTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "qron_ConvertibleNoteDerivativeLiabilitiesInterestExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest expenses associated with the convertible notes" } } }, "localname": "ConvertibleNoteDerivativeLiabilitiesInterestExpenseTableTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ConvertibleNoteInterestTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of intrest on the convertible note" } } }, "localname": "ConvertibleNoteInterestTableTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ConvertibleNoteJuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note June [Member]" } } }, "localname": "ConvertibleNoteJuneMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7" ], "xbrltype": "domainItemType" }, "qron_ConvertibleNotePayableAmended": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Convertible Note Payable, amended" } } }, "localname": "ConvertibleNotePayableAmended", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4" ], "xbrltype": "monetaryItemType" }, "qron_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "qron_CubesquareLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cubesquare Llc [Member]" } } }, "localname": "CubesquareLlcMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "qron_DebtDiscountDayOneAmendedConvertibleNotePayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Debt discount, day one, amended convertible note payable" } } }, "localname": "DebtDiscountDayOneAmendedConvertibleNotePayable", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4" ], "xbrltype": "monetaryItemType" }, "qron_DerivativeLiabilitieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities [Member]" } } }, "localname": "DerivativeLiabilitieMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2" ], "xbrltype": "domainItemType" }, "qron_DerivativeLiabilitiesConvertibleNoteCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Balance at beginnings]", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginnings" } } }, "localname": "DerivativeLiabilitiesConvertibleNoteCurrent", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails2", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7" ], "xbrltype": "monetaryItemType" }, "qron_DerivativeLiabilityAssociatedWithWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Derivative Liability associated with warrants" } } }, "localname": "DerivativeLiabilityAssociatedWithWarrants", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4" ], "xbrltype": "monetaryItemType" }, "qron_DerivativeLossOnDerivativeConvertibleNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in fair value - convertible note" } } }, "localname": "DerivativeLossOnDerivativeConvertibleNote", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7" ], "xbrltype": "monetaryItemType" }, "qron_DerivativeLossOnDerivativeWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in fair value - warrants" } } }, "localname": "DerivativeLossOnDerivativeWarrants", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7" ], "xbrltype": "monetaryItemType" }, "qron_DescriptionOfConsiderationReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of consideration received" } } }, "localname": "DescriptionOfConsiderationReceived", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "qron_DetailsOfOutstandingOptionsForEmployeesAndScientificAdvisorsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details of outstanding options for employees and scientific advisors" } } }, "localname": "DetailsOfOutstandingOptionsForEmployeesAndScientificAdvisorsTableTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanTables" ], "xbrltype": "textBlockItemType" }, "qron_DisclosureConvertibleNoteAndDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note and Derivative Liabilities" } } }, "localname": "DisclosureConvertibleNoteAndDerivativeLiabilitiesAbstract", "nsuri": "http://f10qqrons.com/20230331", "xbrltype": "stringItemType" }, "qron_DisclosureConvertibleNoteRelatedPartyAndDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Related Party and Derivative Liabilities" } } }, "localname": "DisclosureConvertibleNoteRelatedPartyAndDerivativeLiabilitiesAbstract", "nsuri": "http://f10qqrons.com/20230331", "xbrltype": "stringItemType" }, "qron_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employees" } } }, "localname": "EmployeesMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "qron_FairValueAssumptionExpectedDividendConvertibleNoteRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected dividend", "verboseLabel": "Expected dividend" } } }, "localname": "FairValueAssumptionExpectedDividendConvertibleNoteRate", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8" ], "xbrltype": "percentItemType" }, "qron_FairValueAssumptionExpectedDividendRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected dividends" } } }, "localname": "FairValueAssumptionExpectedDividendRate", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "percentItemType" }, "qron_FairValueAssumptionExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Expected term", "terseLabel": "Expected term", "verboseLabel": "Expected term" } } }, "localname": "FairValueAssumptionExpectedTerm", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "durationItemType" }, "qron_FairValueAssumptionExpectedVolatilityConvertibleNoteRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Expected volatility]", "terseLabel": "Expected volatility", "verboseLabel": "Expected volatility" } } }, "localname": "FairValueAssumptionExpectedVolatilityConvertibleNoteRate", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8" ], "xbrltype": "percentItemType" }, "qron_FairValueAssumptionExpectedVolatilityRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected volatility" } } }, "localname": "FairValueAssumptionExpectedVolatilityRate", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "percentItemType" }, "qron_FairValueAssumptionRiskFreeInterestConvertibleNoteRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk free interest", "verboseLabel": "Risk free interest" } } }, "localname": "FairValueAssumptionRiskFreeInterestConvertibleNoteRate", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8" ], "xbrltype": "percentItemType" }, "qron_FairValueAssumptionRiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk free interest rate" } } }, "localname": "FairValueAssumptionRiskFreeInterestRate", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "percentItemType" }, "qron_FairValueAssumptionsExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Expected term]", "verboseLabel": "Expected term" } } }, "localname": "FairValueAssumptionsExpectedTerm", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3" ], "xbrltype": "durationItemType" }, "qron_FairValueOfCommonStockIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of Common stock issued" } } }, "localname": "FairValueOfCommonStockIssued", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4" ], "xbrltype": "monetaryItemType" }, "qron_FollowingAreTheDetailsOfStockOptionsGrantedToOurOfficersTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Following are the details of stock options granted to our officers" } } }, "localname": "FollowingAreTheDetailsOfStockOptionsGrantedToOurOfficersTableTextblock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanTables" ], "xbrltype": "textBlockItemType" }, "qron_GrantFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant 5" } } }, "localname": "GrantFiveMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "qron_GrantFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant 4", "verboseLabel": "Grant 4" } } }, "localname": "GrantFourMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "qron_GrantOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant 1", "verboseLabel": "Grant 1" } } }, "localname": "GrantOneMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "qron_GrantThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant 3", "verboseLabel": "Grant 3" } } }, "localname": "GrantThreeMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "qron_GrantTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant 2", "verboseLabel": "Grant 2" } } }, "localname": "GrantTwoMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "qron_IdoMerfeldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ido Merfeld [Member]", "verboseLabel": "Ido Merfeld" } } }, "localname": "IdoMerfeldMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "qron_IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Intellectual Property License Agreement and Sponsored Research Agreement]", "verboseLabel": "Intellectual Property License Agreement and Sponsored Research Agreement" } } }, "localname": "IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreement" ], "xbrltype": "textBlockItemType" }, "qron_InterestExpenseNetAmortizationDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Total]", "terseLabel": "Total", "verboseLabel": "Total" } } }, "localname": "InterestExpenseNetAmortizationDebt", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails6" ], "xbrltype": "monetaryItemType" }, "qron_JonahMeerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jonah Meer [Member]", "verboseLabel": "Jonah Meer" } } }, "localname": "JonahMeerMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "qron_LicenceExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Licence expense" } } }, "localname": "LicenceExpense", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_LicenceFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "License fee" } } }, "localname": "LicenceFee", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_LiquidatedDamagesPaymentDaily": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Liquidated damages payment, daily" } } }, "localname": "LiquidatedDamagesPaymentDaily", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_LongTermDebtNoncurrentE835F90DC0D7": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price exercisable" } } }, "localname": "LongTermDebtNoncurrentE835F90DC0D7", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "perShareItemType" }, "qron_NetLossPerCommonSharesBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common shares (basic and diluted)" } } }, "localname": "NetLossPerCommonSharesBasicAndDiluted", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "qron_NoteDescriptionOfBusinessAndBasisOfPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Business and Basis of Presentation" } } }, "localname": "NoteDescriptionOfBusinessAndBasisOfPresentationAbstract", "nsuri": "http://f10qqrons.com/20230331", "xbrltype": "stringItemType" }, "qron_NotePayableOriginalFaceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Note Payable, original face value" } } }, "localname": "NotePayableOriginalFaceValue", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails4" ], "xbrltype": "monetaryItemType" }, "qron_NumbeerOfOptionsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numbeer of Options exercisable" } } }, "localname": "NumbeerOfOptionsExercisable", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "sharesItemType" }, "qron_NumberOfOptionsBeginingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options begining balance" } } }, "localname": "NumberOfOptionsBeginingBalance", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "sharesItemType" }, "qron_NumberOfOptionsCanceledForfeitedOrExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Canceled, forfeited, or expired" } } }, "localname": "NumberOfOptionsCanceledForfeitedOrExpired", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "sharesItemType" }, "qron_NumberOfOptionsEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options ending balance" } } }, "localname": "NumberOfOptionsEndingBalance", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "sharesItemType" }, "qron_NumberOfOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Exercised" } } }, "localname": "NumberOfOptionsExercised", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "sharesItemType" }, "qron_NumberOfOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Granted" } } }, "localname": "NumberOfOptionsGranted", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "sharesItemType" }, "qron_OptionToPurchaseSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Granted an option to purchase of common stock" } } }, "localname": "OptionToPurchaseSharesOfCommonStock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "qron_OwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership percentage" } } }, "localname": "OwnershipPercentage", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "qron_PaymentOfAdvances": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payment of advances" } } }, "localname": "PaymentOfAdvances", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_PreferredStockSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Series A [Member]" } } }, "localname": "PreferredStockSeriesAMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "qron_PrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Principal amount" } } }, "localname": "PrincipalAmount", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_PrincipalAmountRelatedPartyConvertibleNoteModifiedTo6PromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Principal amount - related party convertible note modified to 6% promissory note", "verboseLabel": "Principal amount - related party convertible note modified to 6% promissory note" } } }, "localname": "PrincipalAmountRelatedPartyConvertibleNoteModifiedTo6PromissoryNote", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "qron_QuickCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quick Capital LLC [Member]" } } }, "localname": "QuickCapitalLLCMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "qron_QuickNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quick Note [Member]" } } }, "localname": "QuickNoteMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5" ], "xbrltype": "domainItemType" }, "qron_RedemptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption description" } } }, "localname": "RedemptionDescription", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "qron_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties:" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "qron_RelatedPartyDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Debt [Member]" } } }, "localname": "RelatedPartyDebtMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "domainItemType" }, "qron_RemainingContractTermBegining": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Remaining Contract term begining" } } }, "localname": "RemainingContractTermBegining", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "durationItemType" }, "qron_RemainingContractTermEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Remaining Contract term Ending" } } }, "localname": "RemainingContractTermEnding", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "durationItemType" }, "qron_RemainingContractTermExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Remaining Contract term exercisable" } } }, "localname": "RemainingContractTermExercisable", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "durationItemType" }, "qron_ResearchWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research Warrants at 3% of issued and outstanding shares [Member]" } } }, "localname": "ResearchWarrantsMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "qron_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "the following common stock purchase warrants were outstanding" } } }, "localname": "ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfConvertibleNotesDerivativeLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "carrying value of these convertible notes" } } }, "localname": "ScheduleOfConvertibleNotesDerivativeLiabilities", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfConvertibleNotesInterestExpenseWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest expenses associated with the conversion" } } }, "localname": "ScheduleOfConvertibleNotesInterestExpenseWarrants", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfConvertibleNotesWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The carrying value of the Quick Note is as follows" } } }, "localname": "ScheduleOfConvertibleNotesWarrantsTableTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfDerivativeLiabilityBasedUponManagementAssumptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of derivative liability based upon management assumptions" } } }, "localname": "ScheduleOfDerivativeLiabilityBasedUponManagementAssumptions", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfFairValueAtCommitmentAndRemeasurementDatesDerivativeLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "the commitment and re-measurement dates" } } }, "localname": "ScheduleOfFairValueAtCommitmentAndRemeasurementDatesDerivativeLiabilities", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfFairValueAtCommitmentRemeasurementDatesWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "fair value at the commitment and re-measurement dates for the Company's derivative liabilities" } } }, "localname": "ScheduleOfFairValueAtCommitmentRemeasurementDatesWarrants", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfFairValueOfConversionFeatureDerivativeLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "the fair value of the derivative liability associated with the conversion feature" } } }, "localname": "ScheduleOfFairValueOfConversionFeatureDerivativeLiabilities", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfFairValueOfConversionFeatureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of derivative liability associated with the conversion" } } }, "localname": "ScheduleOfFairValueOfConversionFeatureTableTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScheduleOfFairValueOfConversionFeatureWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "the fair value of the derivative liability associated with the conversion feature is summarized as follows" } } }, "localname": "ScheduleOfFairValueOfConversionFeatureWarrants", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "qron_ScientificAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scientific Advisor" } } }, "localname": "ScientificAdvisorMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails" ], "xbrltype": "domainItemType" }, "qron_SeriesAPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Shares [Member]" } } }, "localname": "SeriesAPreferredSharesMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "qron_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted Average Exercise Price Exercised]", "verboseLabel": "Weighted Average Exercise Price Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetails" ], "xbrltype": "perShareItemType" }, "qron_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Canceled/Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetails" ], "xbrltype": "perShareItemType" }, "qron_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted Average Exercise Price Granted]", "verboseLabel": "Weighted Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetails" ], "xbrltype": "perShareItemType" }, "qron_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted Average Exercise Price Outstanding beganing]", "periodEndLabel": "Weighted Average Exercise Price Outstanding Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding beganing" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetails" ], "xbrltype": "perShareItemType" }, "qron_StockIssuedDuringPeriodSharesConversionOfUnitsUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unvested" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnitsUnvested", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails" ], "xbrltype": "sharesItemType" }, "qron_StockIssuedDuringPeriodSharesStockOptionsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisable", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "sharesItemType" }, "qron_StockIssuedDuringPeriodSharesStockOptionsVested": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsVested", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails" ], "xbrltype": "sharesItemType" }, "qron_StockOptionsGrantedToOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options Granted To Officers [Member]" } } }, "localname": "StockOptionsGrantedToOfficersMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "qron_StockOptionsGrantedToScienceAdvisorAndBusinessAdvisorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options Granted To Science Advisor And Business Advisors [Member]" } } }, "localname": "StockOptionsGrantedToScienceAdvisorAndBusinessAdvisorsMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "qron_StockOptionsVestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock options vested [Member]" } } }, "localname": "StockOptionsVestedMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "qron_StockPurchaseWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock purchase warrants [Member]" } } }, "localname": "StockPurchaseWarrantsMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "qron_TermAdvanceFromThirdPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unsecured Short-Term Advance from Third Party" } } }, "localname": "TermAdvanceFromThirdPartyAbstract", "nsuri": "http://f10qqrons.com/20230331", "xbrltype": "stringItemType" }, "qron_WarrantsCanceledForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Canceled/forfeited" } } }, "localname": "WarrantsCanceledForfeited", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetails" ], "xbrltype": "sharesItemType" }, "qron_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetails" ], "xbrltype": "sharesItemType" }, "qron_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]", "verboseLabel": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8" ], "xbrltype": "domainItemType" }, "qron_WarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants:" } } }, "localname": "WarrantsPolicyTextBlock", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "qron_WeightedAverageExercisePriceBegining": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price begining" } } }, "localname": "WeightedAverageExercisePriceBegining", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "perShareItemType" }, "qron_WeightedAverageExercisePriceCanceledForfeitedOrExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Canceled, forfeited, or expired" } } }, "localname": "WeightedAverageExercisePriceCanceledForfeitedOrExpired", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "perShareItemType" }, "qron_WeightedAverageExercisePriceEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price ending balance" } } }, "localname": "WeightedAverageExercisePriceEndingBalance", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "perShareItemType" }, "qron_WeightedAverageExercisePriceExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Exercised" } } }, "localname": "WeightedAverageExercisePriceExercised", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "perShareItemType" }, "qron_WeightedAverageExercisePriceGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Granted" } } }, "localname": "WeightedAverageExercisePriceGranted", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "perShareItemType" }, "qron_WeightedAverageFairValueOfOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average fair value of options granted" } } }, "localname": "WeightedAverageFairValueOfOptionsGranted", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails2" ], "xbrltype": "perShareItemType" }, "qron_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(basic and diluted)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://f10qqrons.com/20230331", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "srt_MaximumMember": { "auth_ref": [ "r181", "r182", "r183", "r184", "r218", "r296", "r311", "r317", "r318", "r333", "r338", "r343", "r369", "r406", "r407", "r408", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r181", "r182", "r183", "r184", "r218", "r296", "r311", "r317", "r318", "r333", "r338", "r343", "r369", "r406", "r407", "r408", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r176", "r297", "r334", "r342", "r365", "r366", "r372", "r414" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r176", "r297", "r334", "r342", "r365", "r366", "r372", "r414" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r181", "r182", "r183", "r184", "r210", "r218", "r244", "r245", "r246", "r295", "r296", "r311", "r317", "r318", "r333", "r338", "r343", "r363", "r369", "r407", "r408", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "label": "Range Axis" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r181", "r182", "r183", "r184", "r210", "r218", "r244", "r245", "r246", "r295", "r296", "r311", "r317", "r318", "r333", "r338", "r343", "r363", "r369", "r407", "r408", "r409", "r410", "r411" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r94", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts payable and accrued liabilities related party", "verboseLabel": "Accounts payable and accrued liabilities related party" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r327", "r364" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion of debt discount" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r7", "r341" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r248", "r249", "r250", "r356", "r357", "r358", "r400" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising and Marketing Costs:" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r25", "r34", "r85", "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails6" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Potentially dilutive securities net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r99", "r115", "r136", "r167", "r170", "r174", "r179", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r263", "r267", "r274", "r341", "r367", "r368", "r404" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r112", "r119", "r136", "r179", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r263", "r267", "r274", "r341", "r367", "r368", "r404" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date Axis" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/StockPlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/StockPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r243", "r244", "r245", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type Axis" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Financial Statement Presentation:" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r40", "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "Description of Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/DescriptionOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r36", "r114", "r321" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash Equivalents:" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r30", "r36", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r30", "r84" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r116", "r117", "r118", "r136", "r150", "r151", "r154", "r155", "r158", "r159", "r179", "r185", "r188", "r189", "r190", "r194", "r195", "r202", "r203", "r205", "r206", "r207", "r274", "r319", "r348", "r352", "r359" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r2", "r91", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "[Commercial Paper]", "verboseLabel": "Unsecured short-term advances" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/UnsecuredShorttermAdvanceFromThirdPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r356", "r357", "r400" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common Stock, Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r53" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r341" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value: 100,000,000 shares authorized; 13,439,789 shares issued and outstanding", "verboseLabel": "Common Stock, value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Plan" } } }, "localname": "CompensationRelatedCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Carrying value", "terseLabel": "Carrying value", "verboseLabel": "Carrying value" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "The carrying value of these convertible notes is as follows" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes, net of debt discount" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion, description", "verboseLabel": "Conversion, description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unsecured ShortTerm Advance from Third Party (Details Narrative)" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r86", "r88", "r196", "r282", "r329", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Face value of certain convertible notes", "terseLabel": "Face value of Quick Note", "verboseLabel": "Face value of certain convertible notes" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r19", "r197" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate per annum", "terseLabel": "Interest percentage", "verboseLabel": "Interest rate per annum" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r85", "r88", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "[Debt Instrument, Unamortized Discount]", "negatedLabel": "Less: unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositLiabilitiesAccruedInterest": { "auth_ref": [ "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued but unpaid interest on deposit liabilities.", "label": "Unpaid interest" } } }, "localname": "DepositLiabilitiesAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r72", "r73", "r74", "r75", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument Risk Axis" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r120", "r121", "r273", "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "[Derivative Liability]", "verboseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r120" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liabilities", "periodEndLabel": "Ending balance", "periodStartLabel": "Beganing balance" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCreditDerivativesTextBlock": { "auth_ref": [ "r76", "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of credit derivatives which includes information by sellers of credit derivatives, about each credit derivative, or each group of similar credit derivatives, including (a) the nature of the credit derivative - its term, how it arose, the events or circumstances that would require the seller to perform under the credit derivative, and the current status of the payment/performance risk of the credit derivative; (b) the maximum potential amount of future payments (undiscounted) the seller could be required to make under the credit derivative; (c) the current fair value of the credit derivative; and (d) the nature of any recourse provisions under the credit derivative, and any assets held either as collateral or by third parties. A credit derivative is a derivative instrument (1) in which one or more of its underlyings are related to the credit risk of a specified entity (or a group of entities) or an index based on the credit risk of a group of entities and (2) that exposes the seller to potential loss from credit-risk-related events specified in the contract. Examples of credit derivatives within the scope of this paragraph include, but are not limited to, credit default swaps, credit spread options, and credit index products; also includes a hybrid instrument that has an embedded credit derivative (for example, but not limited to, a credit-linked note).", "label": "Disclosure of Credit Derivatives [Table Text Block]", "verboseLabel": "Convertible Note Related Party and Derivative Liabilities" } } }, "localname": "DisclosureOfCreditDerivativesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r12", "r89", "r355" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Demand loans, related party" } } }, "localname": "DueToOtherRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r12", "r187", "r188", "r189", "r193", "r194", "r195", "r287", "r355" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued liabilities - related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r20", "r187", "r188", "r189", "r193", "r194", "r195", "r287", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to related party" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and Diluted Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r53", "r110", "r125", "r126", "r127", "r137", "r138", "r139", "r141", "r146", "r148", "r157", "r180", "r209", "r248", "r249", "r250", "r260", "r261", "r270", "r275", "r276", "r277", "r278", "r279", "r280", "r283", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r272", "r292", "r293", "r294", "r329", "r330", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level Axis" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r198", "r211", "r216", "r272", "r292", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r198", "r211", "r216", "r272", "r293", "r329", "r330", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r272", "r294", "r329", "r330", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Table below reflects the potentially dilutive securities at each reporting period" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r198", "r211", "r212", "r213", "r214", "r215", "r216", "r292", "r293", "r294", "r329", "r330", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.", "label": "Changes in Fair Value", "verboseLabel": "Change in fair value" } } }, "localname": "FairValueOptionChangesInFairValueGainLoss1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails2", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableNonaccrualPercentPastDue1": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Percentage of nonaccrual financing receivable balance outstanding that is past due.", "label": "Interest due penalty" } } }, "localname": "FinancingReceivableNonaccrualPercentPastDue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FiscalPeriod": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.", "label": "Fiscal Year End:" } } }, "localname": "FiscalPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r24" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intellectual Property License Agreement and Sponsored Research Agreement" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant", "verboseLabel": "Grant" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r124", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes:" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r33" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase in accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r33" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase in accounts payable and accrued liabilities - related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r33" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "negatedLabel": "(Increase) in prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r87", "r98", "r128", "r166", "r281" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseCommercialPaper": { "auth_ref": [ "r319", "r320", "r413" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on commercial paper.", "label": "[Interest Expense, Commercial Paper]", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpenseCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r25", "r199", "r201", "r331", "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "[Interest Expense, Debt]", "verboseLabel": "Interest on the convertible notes" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "auth_ref": [ "r149", "r152", "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.", "label": "Interest on the convertible notes", "verboseLabel": "Interest on the convertible notes" } } }, "localname": "InterestOnConvertibleDebtNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails6", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r130", "r133", "r134" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalCreditAssessmentAxis": { "auth_ref": [ "r47", "r269", "r325", "r326", "r328", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by entity-defined rating.", "label": "Internal Credit Assessment [Axis]" } } }, "localname": "InternalCreditAssessmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_InternalCreditAssessmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity defined credit risk rating." } } }, "localname": "InternalCreditAssessmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investment" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r23" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal and transaction expences" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeFinanceLeaseDiscountRate": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of finance lease payments.", "label": "Discount rate" } } }, "localname": "LesseeFinanceLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r136", "r179", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r264", "r267", "r268", "r274", "r323", "r367", "r404", "r405" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r93", "r103", "r341", "r354", "r360", "r401" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r113", "r136", "r179", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r264", "r267", "r268", "r274", "r341", "r367", "r404", "r405" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Expiry", "verboseLabel": "Expiry" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "dateItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r24" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Advertising or marketing costs" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r132" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r132" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash provided from (used by) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r30", "r32", "r35" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r22", "r35", "r96", "r106", "r111", "r122", "r123", "r127", "r136", "r140", "r142", "r143", "r144", "r145", "r147", "r148", "r153", "r167", "r169", "r173", "r175", "r179", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r271", "r274", "r324", "r367" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "Net loss", "verboseLabel": "Net loss for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoninterestIncomeOther": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the total of noninterest income derived from certain activities and assets including (for example): (1) venture capital investments; (2) bank owned life insurance; (3) foreign currency transactions; and (4) mortgage servicing rights.", "label": "Convertible notes extinguish" } } }, "localname": "NoninterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r167", "r169", "r173", "r175", "r324" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "[Other Accounts Payable and Accrued Liabilities]", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r26" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "[Other Nonoperating Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Conversion price of common stock" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r202" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Series A Preferred Shares, par value", "verboseLabel": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Series A Preferred Shares, authorized", "verboseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r202" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Series A Preferred Shares, shares issued", "verboseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Series A Preferred Shares, shares outstanding", "verboseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r341" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Series A Preferred stock: $0.001 par value; 10,000 shares authorized; 2,000 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaymentFeesOnAdvancesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.", "label": "Advances amount" } } }, "localname": "PrepaymentFeesOnAdvancesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Issuance of common stock shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from loan" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r28" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party advances" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r107", "r108" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r111", "r122", "r123", "r131", "r136", "r140", "r147", "r148", "r167", "r169", "r173", "r175", "r179", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r262", "r265", "r266", "r271", "r274", "r310", "r324", "r339", "r340", "r351", "r367" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r217", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r217", "r286", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r284", "r285", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible debenture agreement" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r69", "r109", "r412" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses", "verboseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs:" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted common stock valued" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r60", "r102", "r315", "r316", "r341" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r110", "r137", "r138", "r139", "r141", "r146", "r148", "r180", "r248", "r249", "r250", "r260", "r261", "r270", "r312", "r314" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r129", "r136", "r164", "r165", "r168", "r171", "r172", "r176", "r177", "r178", "r179", "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r274", "r310", "r367" ], "calculation": { "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r23" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "Royalty percentage of net sales" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockTransactionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.", "label": "Grant date", "verboseLabel": "Grant date" } } }, "localname": "SaleOfStockTransactionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "dateItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r61", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Summary of the activity for the Company's stock options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Details of the valuation shares of common stock" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r4", "r5", "r6", "r50", "r51", "r52", "r54", "r55", "r56", "r57", "r58", "r59", "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "verboseLabel": "Stock Plan" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r349", "r350", "r371" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A, Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Warrants Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number]", "periodEndLabel": "Warrants Outstanding Ending", "periodStartLabel": "Warrants Outstanding beganing" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Weighted average excercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r243", "r244", "r245", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r222", "r241", "r242", "r243", "r244", "r247", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock Based Compensation and Other Share-Based Payments:" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Common stock exercise price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "Term Advance from Third Party" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/UnsecuredShortTermAdvanceFromThirdParty" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type Axis" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r40", "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r116", "r117", "r118", "r136", "r150", "r151", "r154", "r155", "r158", "r159", "r179", "r185", "r188", "r189", "r190", "r194", "r195", "r202", "r203", "r205", "r206", "r207", "r274", "r319", "r348", "r352", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock Axis" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r53", "r110", "r125", "r126", "r127", "r137", "r138", "r139", "r141", "r146", "r148", "r157", "r180", "r209", "r248", "r249", "r250", "r260", "r261", "r270", "r275", "r276", "r277", "r278", "r279", "r280", "r283", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative", "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1", "http://f10qqrons.com/role/StockPlanDetailsNarrative", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r137", "r138", "r139", "r157", "r297" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative", "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails5", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails7", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetails8", "http://f10qqrons.com/role/ConvertibleNoteAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails1", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails3", "http://f10qqrons.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsNarrative", "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative", "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1", "http://f10qqrons.com/role/StockPlanDetailsNarrative", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails", "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r53", "r60" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of common shares issued for warrants" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r48", "r341", "r354", "r360", "r401" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets", "http://f10qqrons.com/role/CondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "verboseLabel": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesAndLicenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production.", "label": "License fees" } } }, "localname": "TaxesAndLicenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/IntellectualPropertyLicenseAgreementAndSponsoredResearchAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtCurrent": { "auth_ref": [ "r3", "r92", "r100" ], "calculation": { "http://f10qqrons.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.", "label": "Unsecured short-term advances" } } }, "localname": "UnsecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r43", "r44", "r45", "r160", "r161", "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates:" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "[Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage]", "verboseLabel": "Ownership percentage" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_WarrantExercisePriceIncrease": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "[Warrant, Exercise Price, Increase]", "terseLabel": "Exercise price", "verboseLabel": "Exercise price" } } }, "localname": "WarrantExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/StockPlanDetails", "http://f10qqrons.com/role/StockPlanDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://f10qqrons.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921842-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r345": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r346": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r347": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(7))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953659-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5291-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708773-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4L", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708777-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 68 0001477932-23-003520-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-003520-xbrl.zip M4$L#!!0 ( *%TKU;Z%.Y6$Q( )35 1 <7)O;BTR,#(S,#,S,2YX M=7VX7.,=QG*1MT.S"B>TV>TF\.CXYX& M+=TVD+6^[#FD#XB.4$\C%%@&,&T+7O;VD/1^_^WO?WO_CW[_SZO'6VUBZ\X6 M6E2[QA!0:&@OB&XT7G0'"(6XW_>H/[OM7&@G1Z.CX[?!\RM &)=M"1Y6. Q* M)JP^S5YI.J]9L!Z?#89G@Y/CDU% M+!7] 5@J &L;Q"%.G4P,#4#$K2V-":X MYBITH8W_J6N3#D.U7_1?-=Z,=M._GRZU M*X<@"Q*B+6S3X:*0?VDWEGZDC4U3>^0<1'N$!.)G:'C5$7W#&M&8A2UR\6I> M]C:4[BX&@Y>7EZ/7)VP>V7C--#D>#?Z\1=;7GD>)X2J3]'S 2GU"W<&8@;4/ MJ 4E@?K1VGX>^*7<5B<^"T-T#<"N#R@-N%: /(GZO<(!*\3HR:$,9X^-(#V] M$580JQ^^ZIMT2EX2(T76,R0TG=@M8^3#4?]XV!\-?28+KGD/R[3/NP&V33CP MR (N@'22WI(H2IJ([G>0I-I'E,3("=WA#-NPDBAI3.B7D2_RU"=)5> MT%=8=T@C'[Y[]VX@2GU2B3+>L7CQ$QM=0,-A6 1[;ZB?XF)RI MPJ>YC&QW$27^AODTXE,.C[_Q!^1(M[?"91^/^% ._,O,QML)7 ''9'(XUC<' MF&B%^+B%)N0S2HP@4DP!7D-Z#[:0[( .52TR9ZQI[X%EV53,(N(W?[+;(6ME M>S_9 SY<+CAR2V8QC?_QZ?$FHW;A:*YM-G?V-,0\DOMG4)=?FP%7R$*BU6/^ M;ZCUPPFSKPFN]X,D:;(6ATV0<^LW\3>;N@AC%IKP>^I;KY91+0-:K/8K8')GM-A 2(EOY=0RI=E/F*T7S&;0M_O\?C*]7TPG MVM7X=GQ_/=46'Z?3Y:*#H@ 4#RS8LN@&4L34R,,E3J@$:500).V76,6_=J"E M@Q;8DLQ7\QW$0G+RR0*.@41X%$-.1:V$[S03OL5RO)S>3>\9=/.9-G^8/HZ7 M-_-[!F10?0=B 1"O-\!:0W)C+:BM?]W8IL%65&R"1#JB16 MQJ\$^JP@T-?-1FM_,OW0#.AG "B8[1CCFPS.\ M1> )F4PL&"[N2C.JH!L>)Z&+M*+Q9C2O'4TT)!QBV)06::N#.0_F4M!6AW.H MA+,#L"" GUC,J#,C&HN-C>D2XNW8>.:+]QFVM\L-PN[01T_&B7&ITF,HVUJ?J.:UZH6U"P<;-"PYK<<$G0](KYRX+F6!Q-X@6?X4XG0 MF13_5RU88=L#63O <8B"*B <,BK1%I*L51! M.FBO0SS[!7"DZP*'Z@*CNEU@I.X"ZJ11 M^2XPZKK H;I (IX[1$7*+B%EJP[0);H0L5[:."\LK!L*CN3\6)G$<1?\'0#8 M]("O=I WDE)H5:#MPKIZX*:'>PNJQ5#=#C'P;2K \#TT&ORJP$7'Z3 7 MIE;B*B6QLC],[%#\_A\KIL-]^&J5_4+*?QWJ8\:N%Q7?&!W? )I\JL10WB$6 MV1K=O5HH9/MANO'5KP=.Y:_Q9.MWV7^5_4_2[:_.X)_*']:EV+]+T"OLG]S, MFEFLQ$/^)BX%CVY.*/#-1OR%=4J!"HLS.1D3_VJCFQR*@I!<=.=1*&&1TRBI ML/Q_C1+^'S]R_1&N-'%4^P4_?ONR1]!V9_*#U<6SC3CEG^/5]X^I_HNI>_2Z M-7T27G_.4>T"X:2%O(;]*E@H*]4B'27/*A'1,8)DX O?TP8'4\L$3V758BS0 M;*L^K&^5U2?1'=NH%>OX9;6*CY7#*_5^$#V@G?V*'^#^GNED8ZI9TC'P>?<: MN)=RW-JZJ"B'A?_J^WQ]_J@_/.F/AD>OQ/!E+"-"J%\Y$7R^TB*D7]90L'&? M@;=Z5J*]]%L2S^#]X_3ZHT'[_\I%C[49[@5U4)PDL="C7ND_,_2C19 MX*J'(H!'.>]=1@[\.][=AN>U1*DF1D49LFZ<*01!0"_^J@J"N)'$N3\S]*-)EY"TUNH]+U+P-H4A+6456 Z(T[5040==1V MBM$;?+(D47&*WZ0*].%=4,6P]^G%7U6,[Y *X$>O]''M[U=3483R\*>*4+8' MI%QF5+7S5=,[L)(2][.>7( M-/F!%Y<]BAV^/.#7@UT\N5>X7/9T# U$_<VL13K"3XAO;4)>8#XVMZR6A<;P-;P_ 1^G6]Y0*8CYF17QZ+$J;KF*<4"+%XN MZJNMTA?(KS^$QO@98K"&+(!\@GB^W4?50\^ SXUTD&+GD0%7^F5*8[;]'0MSU>^VXJ+[BZH7T=M96N_J9;,<- : MFS=0[(PE"?*,PN;%CDQS_NF6>TE\%5'S:GSAB7.+9BF07=R\Z EWP(<%<[I4 MG*^E\AV9Q,VKQ2]J-1P3SE-BF=,I&) MRYL_,7=V!RPV?0O_1HBS%5<-$5GW*E6TR02)ODIR@]3R;,VKFI T55!_A$Y? M=WQF*S2J*U74O#F*C=J"O:!*%:TTP9CR%0FB7CCSR#@ ?PDL=N^!XL.B?H5M M,D]RD/L3M&H^*,S79F430]G70:UM-F.;U$WMJ7(WS5:[? 6M5#_%45GMFG:+\A:CUD$MH'>SI7Y2JQMYFX@\H&+"XVE/7?P?+5BBSH3HQ)9#ARWI0>C+(JJJYX)*M31OB-"_!;$[]^@ZZ^03](P,R&9UYN"",5*8 MO&IV4V?B?0^M'A'Y.L,P6*8JM,H@;YM6OO$_VWRC$E^6%41+8FBK9OR;KP+Z M>&05D\O^T]J*S%\L-B-LT.[!M0Q;&/O"IQ^[ MH\1*[A[2J!)AK$B5E.Y5,340D>N2UV#U(PY"W#$L[7\H7B->21U*6B_;2 MN=L63"2CN7(Z%^-NF\YRI%<-:15_V_0F!2/')%W3H2,WJ3=KSC%:(PN8,Z!# M(76PM22?IIT^*!$9B#T&*^"8] $R^>F>3Y/B=T8HDE%+UU21,6(3,H]LNTLXAY1!I61H_6(DH4&. \FF;*>2B5D\D@;/F.?C%"WM MK1DIH,-E?KYS+!:DJKRW%#&/)R>T,JB:W<-[B[XYR.!3Z 1LP1H2%C:X;V*1 M&>SB51&U%!_W'C7B1X.6X0V2E/T8!6E;JJAAB(^0V8CQ/G1XA#ID?BV8E',I MVNGRO"XV7_D2!^XAI:"=*HA=SSJ<01@.I,B35@OMI243@H=/VRG\!!(=(Y&2 M$/LM"#*@VV!R1!2BK.J:*9O!UO7?JX>!\\3A-3Z(EMW/0L+-)//5)PM1\HG] M)I&/2BIS-SL?Y8H=W3WRN;BVJ6P_B9K35XAU1*()@(J\S2KL?]3DB2864^*3 M)M,]E<++R:FH6J6$MX$I0_BPM%5">YTB4^QH>:L$O^9=P(3&S,8KR#B-.6;3 M$<*9FN0RM$JUJ?=Y7]Y82-*T0 &YUT3=5#Y)L^(GOKCT^SQ;>>K0=SK!-T;% M:%OU!6I,R(2;*D;:7G4D!U:4N+TJJ5U;9>[V*IWJ],HP-*O:K6VM^=M._CKF MWK;')]/'D3K)V*4+8*IT@./SW4*4'?K&*/< N$AV8K'HJ! M+HZ]3WIX%5'3;[-3Y9O&TK_Y).U40 X9"M UK8K;OY>VG\WU#FE(R_P6(VTX M$/+>?$AS2##2 #39?>!XU\D8G;Y(,D@0_M,F*.Z\/X^,/H:J8K\B-Y:92?I2!2[7:[$1Z M"'4]W^'P(?6#+5V^Z9_?W('_^]'&+MMPTR&B =U=C)%W F%$DE[8[)L!]S"! MR N,*X<@"Q+^R2 _)(H%&0^1<[''K!$L#MX,=SY68T^H#;R2ALP0GKR>W$T; M^5(BZQBFI%$.5=E/8J+:9OGI3+',NELMJ7(1PE:HYF^7@2N(^0UR?$6Q8&TR M$.X@3Q[WHGMM$> M=@:QOI%DSR=K5@/I7:XL?29)\Y(G/VA/%SZ+JN%Q&LZ#/)69,D[3"1J5.FV. MDB3/(VK8R_C'I/"345)\3%IQLQ([3Y!\"TTD;E_<.VP.8.0BS) M*I4T*N>-8=]!MH8U97\G%S4JZ7\)DS?=N\U_4$L#!!0 M ( *%TKU;KM*LF*PP /:0 5 <7)O;BTR,#(S,#,S,5]C86PN>&UL MU5U?<^(X$G^_JOL..N[A9JJ.$"#_:[);!,@,=0Q0(;.W;U..+8)JC9ADD!WJW_=4G>[)="7W]\7+EA#0I&'[VO-L_,:@-CV'(1? M[VLK6K>HC5 -4-_"CN5Z&-[7/B"M_?[;W__VY1_U^I\/3T/0\^S5 F(?= FT M?.B -^3/ 7_KNT5]2.KUD/J/S3AWH'76/CN_V;W^8%'&Y>& A[W9W+W38_* M-P,VEQRPGE\VFI>-UGFKO2.:>C/_S2(06,2>(Q_:_HI8+G @1:\8,,7!!M = MZ/S+!KVY11;6DL"%A3DHT%G[9SM976_Y0=#KW >?[,^ #P,&]5'_&3RL*,*0 M4C#UW!57A?X;#+!]!CJN"YXX!P5/D$*RADXHSD7XKSO^WPO#!YBA,;U[I^B^ M-O?]Y5VC\?;V=O;6/O/(*\-SWFS\^7TXM>=,KSK"W. VK&VYN)0HON;M[6TC M>'=+*E&^OQ!W.T:[L56'D5-T1X/AAIX=&%>##<12\+_J6[(Z?ZG>;-7;S;-W MZM28-0#8V(-X+GR",\!__G@:[,:<-<]__2+,K&>VMVCP=QM=CTU,IFC -R=P M=E_C%'7NE?/V1O0_#XC\CR6;H!0MEBY#V,@Z+'8@9C/RP7*Y$Z9S"'VJUB.) MJT#%)FSF8W\.?61;;C8M(T7DJ_+49RN9!PDZGHV7D 03CO[ ULIA*];1UEM3 M3G'*=^<6?H5T@*>^9_\U]UR'!;4>G"$;^:?!226Y0( 6G3^ZWMN)SHD7DXOJ M/4AM@I;<^^/9-C9W,)O7%+'1)X2%8NP'LT.E?@91N4"8KA8+BWR,9U.6IA!S MLX7]CFU[*^RS9#7Q7.9XJ(P[Z:3DHOA7CTEF3K7#CR M?,;E\M*#13+_@_FN!PE:,Y>MX1!9+\A%OH8I3Q!9!*2<8)2B^@^V_.T582%@ M[A'_&9)%QUGS!/-(O,7S')&-&56JIQ23B^JBFY^)A:EE!SE%I:N*+Q?E!MB' MKLLK6LN=$(\E//]CB&P>;3NO! ;!ECEXNF1<'K,;KT!Y%;Q[4X4BMP'R"8D\ M\TU89:*,>L>$^2Q :XE\RPV$*U=9!&U.:>&%PE\K9MK^FJ=2=0*(IB\Q1^6; MJPK)67I#/ULL:.8$XU"6J9RGA^ADP67FOTR02H2QBTV:LRF://> IFFV6(X2 MEV$/^A9R;2.%VR M88#*19.#:,,06\5!;%4$8KLXB.V*0-2.*CD.46:UE2W@& PR.0<6D\$DYP!B M,FCD'"A,!@?%V!?Y0KDP".4R7RB7!J%%=J+80MOY:;&DE5.-=G]:E(4-F&\G3;;?TU0WQ\-%'[E!_+ZF-%^@ &>>601'JTH3L7$ MDUF"SBVFYNX,"_N].Q[U^J-IOP<>.L/.J-L'TV_]_O-T$")NNKO4"W6#$GR'=$5G#@*;\Y _+&?Q'_]>*538NWY;L^%TV0S\0?OW# M"!T'7E7$@6F, MDIL_Y5J0Z#K@VZ(!D[:NV>'8-J1Y\\97K))I: MQR,WYI=$$M3J..2H^;G-FDK7J/ATG'1KWDEZ\*OCKLC.M#K?)'+IN*IY;MY7 M.MBKXZF(@_V)#Q.:?FB6X8<8!_P_F%W\J!9_R(_,^"%Q%*T)G2=,#"1\EX8K MI.C&1!)K39WBFB_Q1C^:00E(JS.%NMYBX6$=7\B46HXHK@FC[8@XC-7Q0L=Q M$ =LN1,+.0,<=M@3>AEQ#%H^*:YQH>T3!>+JN.:);W!@Z/0M@A%^I1W;7BU6 MP6-'^.G8>"_I\&HYK+BNA;;#].U0'=\).9QO(Z?(EFI.+;^5TJQ(A!9?U:1Q M5PR\4EH!:> E$":@_-(X!CED?Y>Z'QC]'0C"YF!;3 >,5P[@9]-;("&P/!K_WW)42<\YT20 MFDE8LI>4197+^NCB5\P,JRZ MJ;G/-Q]''O8.42ECE8K/!!9^")A JJY,)$*SNY5Z/CB:7#%@\YM:,3O$FV_W M&N#$[^(YVB96\)C=F4QG?0TX54MO(^CK)+8C,K,[D9$ZQX77",KLG8CB=NRT M,.E-QLJU(+)__Y_P+'^I^2S?_=89?>U/P6#$WAAW__-M/.SUGZ:@UW\<= ?/ M!P_XY38M$KXL4,!YI8NS,_T&'H?C_QKO6;"IRZ&Q9Z\U8C9Z^/C!@ _P;@5V M;!8%%9NV:628>G1&?G*,%&G,]B_2>R3B.?H0;H6J4G[T%'(C*$LYF=)L&^-D MO\1!+_KD7WQ1$W?X+Y'#;*LBNQ>4P*I6W;$"@4"+PA[<_!S@"8%+"SD:3T$J M3K-M@Y.7DJYI*A3X9)5USN6G\;&>/+,ME@(\G\:,55[<$4?^TW@_DMUL]Z, M9R<8J3J^C<']B+"%[=-JZD@9AFIJ&T)'.F'/SW8G5MD)7&:[1>F])M?=2I-4 M9Y)RK$ICM?IFQ^M%$S1"7*S-M8W0?X#6SVFFQ-5*&X=+@LU/Z-(6 M=YZ_RK9,RC)5:0EGN85$Z(U>\V_80-1V/;HBD/^QE\_>7ZLOB 7<,$@E P"T<&$V@L'$8_#A4-- Z^IA&<"4-J+3P1 K6- .UD@ M$%;GTD H#O"X#0*!X. 3Q_E#4MZ/(F!H'V,XG&*'[$4IG-]5* *RBV-DXBA@ M.PP(QP$[6<$LW T%MF,!8;#"PK5TMXJ YU**R)P:;,@+6^Y1=ZT(2EU):WK# M $*.XA);S-4K@FY28MXS@2V7V<2;D(";)R1@\&G[6X&[R9FN8A'P2;DZ#;Z- MV&+WRD^\EF4/M95?7B\?>7JTIZ3Y$O#%7?HB()#R^C[2EN& ^'M@!!VEO'T0 M>,NP8Z8K8 0$4GY.$P!"N57!UXP"*"?L] !!LRH0Y6^Y%*!*94 6J+L1"H2L M=<&, $RJ(0Z>*,O5/8>;901D4GUQ0E(J?C7F<>>, %XJ/DX'7^A*S>,^FCW\ M=IX%R19^JY+PVU'PU15*>OCM2L)/BFUMJ6BZ5 7D5!5)=6NF O*H,R.L(D!?J DH'Y'5E0-Y$@3RMD;,%>5,9 MD$G%T(6Z&*I*^7/J53\":*D..MK 2MR_*A=UZDN!!)A2+12_QU4NJ.+N !+0 M2T527OM@Y=HJ]H8A :KE9!V+[?K%WD8D:"GO/D5H M663AK+Z<2-!6WDN*T+:41].$FXOV^E[*Y<-A\[Z$)TR=:XP$C>5:(%)CR6%#M+=;I+WNYU MCV.I+2>WWU(T"4FH4*1"4+;5OWX +A)) 2!(@00ALQ]NQR*6\YV#[2PX^.O? M7Q>.\0Q\!#WWRU'OW>F1 5S+LZ$[^W*T0L"[XD#,P"V\0*#N4$^?351 /SCX[CT]ZB? MST;_W>#=ZX8W-2S2>3DY>7EW>/\-X3GLG__IZ-['FF*YCZ!*&6^ HJ45:H=7K??KTZ23\FA3=*?GZY#M) M'X.3A)Q-R_BK'6PJI N?G40?<5$$/Z.0LCO/"N4@T(/!+$'^.DZ*'9.?CGO] MXT'OW2NRCS#C#"-BG>\YX %,#?+_WQYN-WU.>Z>_?OE8 N\L;W%"OIY<>G@, M8T+#>G,?3+\1+@24_6$S2:CI; #P<<^N:: M*QM/;EN8;L%VZB/^\*3*$%@_W@E&JY1H FFM\X MWLN>PF$W(X7T*X L'RZ)]$?39!D?NGA<(XA['_MXU7:#<'04D5^A*2D0)JO% MPO37H^D$[V@0B]ET@Z%E>2LWP/O:V'.PX$'ANE.N%2F$_^[AEK'0+> 7,I=6 M5M;8Q0M_ )\<<.\%N)9#3BEX)0O66'97P(?/6&3/X Z:3]"!@0 K]VBR#DB2 M8#1"^C<\_:V5CY> N><'C\!?#.UGLL'<^-[B<0[]B(U%I)=L1@KI:3$_^J:+ M3"O<4XIH+:HGA;A;-P".0PZ_IC/V/;SA!>L[:)'5=CCS0;C88@%/EKB6A_E& M#JODP+SY6(1"6@=RED2R\XWQR:1PU$/BU MPJR]?B9;:?$&0"_?X!XE=Z^J9<\2Z_K1Q(NF)!C9ME3M>6*(]FZXR?VO$J0& M86S6)L'11"\N?4$39!NS1H/3\ H$)G0DS<-<8\W#Z$G%T5,'Y-[T_7#^2 6T MTZIT':4L^2)U5:WG@E-C_Y85 RR<-!*:5@RQ7Q_$?DL@#NJ#.&@)1.%516(7 M39ZVJBTX"A<9R0N+RL5$\@*B $%SV)RYQ0&ZB;ZDU7Q[:W,&%)DG=KUTYOV,_Q BR>2-!;*6*S5>NF MU'2<JFRO6"85G"DCH-CD4P-5=.4'DP)M73%.,?H0O)">8._YFA&KP& MP+6W\5FD.>&PS &I/1I]+^><;P-'#XVPI+&V)P!X]:=>OXB"J(*R4H()*$&/SYCO9M[SB0T@"1GNDW^0Y;$?L1' 'V&_PR<4^/C0EK3D MF$_ "=O_@/MZ![#VC38,*1R\:,ID&>"("__&-[_?CTQ;N_QA]'E__TQNKNZ M?I@85]WCQGD>\[QJ8F>PF5NA8YGIKF,)CIP I3\LIWQ\0\_-A P>\$M M_B>B3/VX,*WLB4J:0U^[ +UQN2RMVY$U]+-4X]TA:33>* 1WXJC.%.OMA7R+ M^_.X!'L^'HU?CO!N=XIKA%O?9\O#VN=K<.V$!?'V"69Q1%G\W?'P$/]R%/BK M'<@-B^?ZUPH&ZTMO@15A,MN&KU!D=-&KU2D\ZC&Z2)B9P<<2)!W+1JYJ!)0C MZBH^A[,$PRA>IT!VE80B:?#&6DXX##RQ4 8:"^5';X?XVN22G)?K%DR(*9;- M>X%E4(7L,,D++SI!?(U519;<*$5K%5A6@64(BSOV8VT= MW2*TVBJ1E)-OII1ZQHOK*QG"8UY7VP4D:!U;_3T:.3Q58[>L3FRGD)\,=#7, MOP?!K6MY"W#G(8Z*ERNF$Z@DI;J."]X93)ZES49#6<_&'0M]3W3O/4I]HU2,-& MW+(1-AV.IFWC1J;U9I"60=35M&V-@Q:G((PR$/(CJ]L]9KHE7>1.07L?1Y8NAN1B=@G.VLQ23TD94O*Z93KLGG:+I?&%O)2&HIW6XYVVYOCVW7^"WY5WTGI4IWJ%/P=G;H,O"B9FMUS^YYG7J+ MM"]O-V\<>'FP^VSN]<-C7=5. =C9S;=+; /L9U_>3I&XLUMG5MP&N%CIVG8* MP,ZN7&;NQ^UV$0I=A,(A1"C_/,/"'QRW%S?@6?@\$,51.MK M%;,@"DIQ\,*&MJ_ )"M9: ';);C(?UZRF58$.Y0;MBSQB@%6' VA0LHMBIYH M3M(ZA%=L:+]UEZL A?A[17Y-;B7UGH=* YPE:!K$_8(R:I%9OXK,^HYUY' K)L0^IE*ZRUE,:F M-I2!Z]79E1RCN$;R82#(QS0TZ&6OF%TN96_9=1N4M[<8O<[BTEE<#L'B,L0C MW(;DN9!G,"&.VG"*7[]:S@K/2N+O)7%^JR@>8S1-POC&P ]CS"[6] ;X9II: M.]7*ME,K)Q0;A.BDW9L+4&0=**[9"K-/ W-':+BD&:/8/%2?S%MD!&J?W'4P M%@U?3-]^Q!T4[ W98GJMYEG:4P)1%N,>OEM&AB/&9T:,\\G%ZE#=OEAORXS- M=1A41"!L<;@V\?6*S-]Z>FO'.D\;N;2(>^GPXQ%TUHV@BKVU:==0-(K2>\-Y M/7L#XZ9@$BCX)TGFA&GG7A)D%59O+1$]TZ2O"K+0)%N"U!N9N3@E/I]9A?7D M,PM-PN=J!GL&G^,;G]MKH.$M*RZW^574\[S.%3XM)SX?$FE5,]6SI$7BOT;A M;1/T': V'Q),8NKEU*5F<'&DW"[VM5+'K?'*[SDX8$BM.!S:VC,[L/U7$N*\1ZNMOI3=C)PIG\K.M88Z.1'%L;NH01JBZ7/D^ MX"E=K/+J!2)\9F!!4!WH]Q1L9_:-:17JO^P:&@F##4)Q%B,/J\X!\ &*D_V, M@CDO])E57B-1L""H37"T]QNE*15TY\[[_BIH%Y;9*:&=$OIVE-!=A4!7W>; ME=##L1:\#25TT"FARI70GB+=YS8^=H[MVR.M.XYH(JCN-RS^-TXX. MW!,YKX+ZXU[94SD/C>*3.?505^@DXM=2+Z#]DA&TQ&&T25H11=QN'J_<_/X[ MY@1YHJ#'%E29-C026QE8"A-+5->G!C1]JCCU:WE]:M#I4YT^U>E3G3ZEVS&] MTZ,6Y@L_0!J[]@.<(8PT0KJU^62BV4I8"M)?'1EP6Q&APXP.0A'.5DP6]ML:R MH /:ZWY/^7GQW<,;,O%OK*O-C'Q]C>7!@I2_Z%.S1,BSO.7E$-4Z .Y'0!+; MB%;N1UX"D\'. XX2W)"I9">=.[)S1^KOCF0]#GZQSDQ#KE&^3!MZV-(J %/L M#\NH^07F95K95ACURP]&CL!:D@MD/\&TP;A7GW#4Y?ZXQ*L$^K4R?7#G6'P[ M%:VD^E,?>UAE+%4TXA4G^G@ RRB5*AI-+>#.#4TF]-(0/#5P<=1@%1B\N M\-$<+L=X:\3]FC.6RDDMJ0-KF<2K3=R132B2-CF$D&RN0#;&?O$V=!!5!5A[ MV0*D"#&:IV2/O +(\F&H//-EQJBBF8@8*/*6@H:#**(TJFALKLG)?>C:^!>L M/MF[@?'XV[WG6D67!*JWJ)$\JX-,_ 8R=Z6Q#UT++DTGRK&4/LSDC$%?/1M. M(; ?O?,Q!@\1\OPU^<#8Q:2TK(-WKY%-F#0:'IO$N* MW9G(WXB)O+NQT]W8Z6[LM%!0+3*.ZW=CI\N 0#L"MCH#0I>7F9:7NK,HG]&)M^QZI;>KY9L9;MJI35)/H?1<5A$U1"[= =&734&?HKR-, M"NN4^,3_[^B]6I?T0U0"GLN24T$'!A=AJ.-25$Z:]R!(4\ 8R:2F2$5=F"Z" MI3T/'55)IWXF1:'N-_:<<)44ASN//E?"V"4U[(P&AV,T>(O9NU09#=YP]BY5 M6G:7O:O1W(%=]B[)0_UM9^^2>OVOR][5_(6]+K-4Q0M[0@Q%1:FD=JG+5]&0 MP7D(":.E6CWR71;DF*)1V9J<4]493NE) M(#E8/A/.7JG3J(VI7SRD95*CXE.46&TOP0DUIK'@A/ IR\(F9Q\ 01 M-I2R#57+V88.)FD;XF=MZS+E-98I;W,V:*UW[CW-<_5!BN?J?5N\<'9.TBT07%H;V,XGK8T?D8E =JYJ@JCK5D5&B%%X\[ MKHH$TI+T?+)$T@8[OCRQJ+/S_W,%K9]A;@6>@72G5 L.E_R!E#YA[E"O."-? M=[.P53<+LW1]<\TH/I 8OI@AJ51(U*K:"HB*1FV*O^X.:/X.:/M#5L]I"N,G M*0KC>5N4X@\4C.]/I6#\T"G%G5)\"$IQ=\^U<4U+]UN*+5&[NWNNVHZ@%ED) M#OB>Z]X#+:&8OS5D2VFU,V1)5VR"$YV0K5R,:4.%P>R6O$)>C=TM6KE*L[R! M%\B[J_42K]8/) BLR%"? &OEAP/]^M5R5GA>WF#ND#/[*HBR^DRO M33\\K(R!'YW8U_0&"JS@=7:JE>6D5DZH3BI!)4W$5E!TLZ_U7E(]_.0JHMFUGT$M6G7:(&'M*;@ZR[A6]6$ M;ZIF]AM.^*;*4=HE?&O669JS%?*=IJS"Z@VXHAH5QVE7KT.T5? !9/X\6HJ5YTI;-Y,9 DW&\J&467-"DO MIBYITN$(KDN:I+'PVI4TJP\F8U-I@B'MRN"&?:$$1?2E!$9LNNN"(+CCB M$((C1)[AYKTQ3JNEE=&2#T5Q?('\%^!;8MV4_/J[D?$&UR"8J65CJWFWD MO55//>3Q*J@_WXD,NJ(0V):\T1AFQ@@/9&1$7@%D^3 \BO(F#[.*>M&4RMC" M0*$VI\XHF -_:(598]#87),M%)^_\2_XK&*G#L=L"95H0B.)E4"E-M=.-AG0 MK6OYP$0@IC,QDO#GET!UC20GB*@.&T.ND]$J0 '6-Z$[8^P\O HZL+P(PUYI MF/>>&@^8'!\2$\X[-N*,7-U>M M-1VDN!? ?-;GAB]M^YX%@(U(K"JADMQ%'$V)6\9S0Q1L>0I4U4AX FAB29VW M8Y^*5@MB[PTQVF.L\.,/YHQC/2K3AD:R*P,K%N('1:$_ @>B^'H=_G;ON591 MZK_J+6HDX.H@8W%_5"/N6ZRQH-"]S=D7,X4T$DJ&[IC/G]3P^0[,3.<&\+2L M5!&->)RB>C\;*^/ /?:A:\&EZ3 3\Y)B.Z5TX""5<,7VFSN $ WT"6GBSNB M5B499QF.[LTPX-?301Z"4!()20T]&,YF/IY) 1BO?&N.^RPZXH9Z64$E'9@N M@B/AN,PW$TO,B4O'1&@TC4/N1OX#G,V#ZU=\9(,(X E,CN%)/%[\%?784Z5B M?JF: L:"5,<5"(_J4]'WL%? M*V@3'>G*7&#]",4!M%*#I*K!"R1Y4;I;S VZYN+R%T-/,').QX!\!=# M^YF+6#<);(VS?"#N@!F?5E57^ M 3BAW85T_(@W(F1:X1N#(BC?YU'&C<4PTLUU 6==P-F!!IRQ9M#%.OV%'WY6 MI@VM@M'* %,UAEKKW1B-_/-LE@Z#_PJ7C^%0"?R\R=4KHP@:6'8)!R[Y4(R"JLJEXL)5S;A6@4 M/RJX H]>:I21E 0";NN":CI)B(^D7<&-7=#(/D$CBA;#[Z8/B3:4T'CM!C!8 MCUYA?*H)SX93".Q'[WR,(4*$/'_->0Q!2LLZ2$\:V+V")PO= M^D)A+.SBNDB"C6"OL$:Q:/PX^*Z*^&DN*DKH^WX]:"-$F:#WBF]DR[W*=:88 MVX%<8Q)'LU?H(TL$MAUR!$_PR)^'(D?GU@679SRG@C;LYF!0;,8?^V 9A0>0 M8,R1FQ!X#S@Z+K>2#D(1P5&+U3(.Q1A-DZY8Q[#=_A('JSOH$6.ZD-\Y@!Q8KS)$M?R?& _ 0P6^:;CR*N_;.\:S_= MJY%T:\3]&INVPYPSFZZ-I.]4@2:#&\)(+9)0,.Z3AO0\CS2L9)!:&UJ[4(4N M5.$00A7"@RS>M"_QW(3!$"& 4+A<<(,3^+6T"D?@0U'LYV815^3S+JK7BL $ MD:$G**R6/+10C[A:%*X@763*7C5 ?I"2*/YK*TW\![E9;:^L8.1/@/^,3S2, MY1 7I9?48PEDDE]'CGTQCB-R3HU(0\EAJ$%?8PX+/ B$R7THZ/*=H3/DIU>5\OEHZW!@5O1.V4TO&DM ,B M8:BB7#EWT"69"4+Z;TPK?-S@^G4)_?#!'_(\#.>BJU!E]5(2SY(A@D=MX&^< M8B"3>"!)%LD6%+^61A+B ZGC_930A11E$KQ:^="=C8$//3O*,+A-%S":?L-, M0]_"[$S,>(&JC>D@H7WPU9'5E$M+^'$4YC)&WRM+C-;*08B*!DQM+._$=/#2 M'-*5NFYWQ3? MBD]>531AYY.OY),_K!"*-GBYFO#)UY1 H//)5_;)2YU'G4^>SGJ.3UYJ;%'G MDZ_JDZ\I6.C0$G&4MRRSDG+T.]][8[[W?N=[W]_WWN]\[_O[WON=[UV6[[W? M^=ZE^-[[4GWO&F>'*K^W,S-%]16]J'/7N8T[M[$^$FJ9VSCM7HMI8MCS2WGJ M,DWI()WJZ-2FANJ O?.@ M'I0'=?AB^C993?@NTUPQ/1P$=-H5.T4WU!2YU78*ML+M21TO+(:WQ+%9E>5M M< 949[NZ[.;I0V1HFR YO<(;:Q:(KZL-7?MBA? *BU#\"S\4?;\FU1_W&$-P MYUQ>&6(M^8FH)(VF4ZS,59%7OJ:^8LDCJ24=>]3IHY>\9QAI:")/.@K55,]] M,7U5"(Q:8T](T@6FS<9$D;RO9L1(/%QF(<"+];9(G!$K''I8]0X__ G(\X7 M'CX#WYPEKQM&2!/*=+GY8NGCW&%KW&%IK%/WN,;3N,;1& M8IFK[%_QV^#A@8"_'G*J:+7\<7 H3N67)JAH4M'*MF*U*QQ9],?I,T#J2 77 MF!Q:M+CM+XOT6G;6J.GSGRMH_8SUE;N[2ZZ-C%%6O9(M]I@>@_QD-5)EB@$^ M>3QNC%L#/GF.G(R*HJ!H;B7U\F#/[/PFP<.1"*::C7+_Y6EKKHN,*,-5,/=\ M^&^>88M;2;U@A/53+@ZUMLL4:7C"C_SH5;COIK,"B2E,2#[LRGK*B8U'[5.' MT?B)XK="HV2QE#A5-)(-!X7:X+2=R1W16&)52RIH) TF!K592U)DA;-62 AQ M23VY'Q._U[N"\J? :!6@P'1MZ,Y*S(-,+3W%00&RUY. $FPFG'#?>_ 2?N(: M4,3J:R0N44A[/38HXRVNU"E>_,Q<5$\C015!V>M50,D"*G]X%JVOK< *C]#5 MWA*L9685G=EX=;05$/7DIO#MP1W2A(X1A14UEP_M,"$WSN\!V& 1AEE= 63Y M,/PGPVK)**L#CSGD"[])&/]._O-D(O"W_P=02P,$% @ H72O5B7@A\\P M2 8K # !4 !QI?OSA(!@\ M!!E! -DS'V:Z4N$./@ /E\/=\:__]G6W!:\H3H(H_,-WXQ]&WP$4NI$7A$]_ M^&Z?O(.)&P3?@22%H0>W48C^\-T;2K[[MS_^S__QK__KW;O__/#I!EQ$[GZ' MPA2BD8!/*$'Q*_*RXK9!^-N/ MY/\YN'X -W28_/@U"?[PW7.:OOSX_OV7+U]^^#+](8J?<'U&X_?_^?'FP7W& MN-X%(6EP%WV7:Y%2>'KC]7K]GOZ:BS8DOSKQ-O_&]'T.!XLGP8\)_=Q-Y-+& M55 #0@GRKW>YV#ORIW?CR;OI^(>OB?<=;@T 6'O$T19]0CZ@H'],WUXPHY)@ M][(ED.C?GF/D\Z%LX_@]T7\?HB="-/*9-?G,>$$^\T_9GV^@@[;? 2+Y^=.U ML%;K2EF9TGM%J-T*OT=Q$'F78?Z5$U6T7JPJ^)-^_B&%<=JKR9OZFBOP&*5P MVPMZ65,SZ%O4K[4/>KI;&<_ZJ%\KES0' )TV 7=N6EZ;;LF?;O!_50"BKRD* M/>3E$$D!DAF7ED\G=EIR47;D5DK=DKD[BIOU3G"IM,0$N3\\1:_O/12097-" M_N,=^0]:9?R/7\\CO '8.$D:0S?-2Z*5^,-WG-_?5P$1N4V[^7? M+.AN#IQZ+Q='9"*CM6LW^+,>^?35%CYQP-=^U].Y7%!Y[U9^M*![>7CJ_5O( M "*DM8//]W%,P 6)"[=_13#&YT%B-N%M4X2BFO9T+5"+[9U S@(RM$!K;/J8 M.&#R@"@ K &(BH%%_V$'M]O;1[@:%XWU<5TLH!#KP:!4H2]C"@"4I$ "(),E$#_7^Y0_%3$#[] M%$=?TN(4(WI(8;H7 MKR(B<:WG1RGDVC&2*VL-=:3P1(?*;/=1* &F9>1L65Q6"#:G CF]ITTNR/JQ MLR)D 4%DN(0'429L1.K(V@E#[AGYZ9#ND:+>+PH(:X4>[V M*?5;PAL?\;9*JJ1UKZH O[9CE6A80"5ED*+=*]4$5!4P75!2-C(!_7D/XQ3% MVS>VI98,H(:DW@E( +0^ =7$+&"-')EP BK$L\..F>NS&(9)0%SI6NG1%-5\ MK2: VKABJ\E9Q! !-/'56R%O@B.'G?GM?N>@6#AAED5TGW:JT)I''?:[!1P0 M0)(<<@ 3--#GUZ$;Q9AOU,>6&�>;0/TQ@OC9[8":=%2R:K&VC+2GL8S^OB6QJ=O[YR@4FTV:(GKZ6 0M[^?Z[Q;TM0!2O;^I M&*!R)LTF*2*!4L$KNH IS'Q9)&=YOKA>0XD,+0>NR3=T\0OC &H6V:Y'\Y4"G[PZ]T.T,LP'?^51#"T WP&(B8 M)5@0]=A-=7B*]:D*H5L7/=*WOZZ7OC-!!AG8'W%CT;J[O;B\?;B\ !\V-YO; M\TOP\*?+R\<'PVS<) E*DQ;>U87T,8P/K\REJ@3M@]5D-4N1_ M+O^V#U[A%D-+-NDYC..W('SZ&6[W]<-01UU]Q.I4F3+1E!1IK\XGZ_G(LX!X M/2 WB(AU65HC\A_H4(J8D[IFA=;9@-9LLAY-H*^I,])2JI;VJ:"*K][R-.T+ M<&V:"+C-+ZNAL15#C1MS"\8H'U6=#+\PL;/\F"/)Z#%X$XO;EJUI+O0]71LT MQ0%7!=88:7>/FQM@T1Y-6A?]8ZJEPQ?6C*("CF#XG#(/3I_>O0F@$VSQN1(E M>%FFSJ;/T=9#<4*6Y_2M95.NKJZ/(5VK5.:0JB[MUMD:>M"&/UY0/8W%Z A\>[\__XT]W-Q>6GA]^!B\NKZ_/K1WOHJG9JE"D8H:3" M^5$LS1;C^1C.;-C+J^(4G22W!WW3:YSK$N>UY!Z^06>+\"#"?XGWR&M6433; M=RE!XVK9O6*5)55=G7:Y.T7(HP^ MH2W-*PKC=K[*%/31LQUVF8UB:;:PC:8NG%A /E67/J.X5NX^1MX%7&9YFBZF-IQ=VQ'6"51H@.0YBM-W*8IW &:L,GTO%86O"$^:>/6^C5*4 M[S_E9&I3TG@3I02_<@4EU6 SP9O# MP[P%7I#0O9OIK1B*@U=(/)"4#ZYR%8T;+@7HE3V61)YMLY$S&=MPG:*.M+F3 MRC75CII:+5AJEBMVH;ARU\NI+?C)20M+<[.<^L%7.LR*W<9I%5T_-%IY:ALKYJA<:A"A_'2KI%W "4; M=4&6]W^']O1^X@>F=_3TN!N'% MA-WNRMP;N9+ZJ"0!6N801XQVRF@*%^N9!>1I!=A@#=ZLHP1L0*$)$J+Z(_C? MHQ]&HS$Q<8%74LZ_@/'H;#0:@81E]8+[]#F*@[\C[U_ I/Q#D"3$]$^LJ=$@ MF;_ZF3B*C&92+]N&F$XS!A]BU7!1E6$GL!?7)T3>,$315'Z7;&Z%;F MVX^8;Y1P(M*-IV>SZ?ILN5I;S;R-Y]$ &+B]AX%W'9[#EP!O_D17P")IC;?O M83I]0"H,0>9AUQP=9\03.H*.HCF7HURGQKUV+A0^[4139,B%WQR [;&L;YZ M#&/B8).F<>#L4^H?DT;@'EIA8..ZW;:86;@Z;!9;S5;>RI9QW@TR/Y+A&_,M MEG9GQ^:QR?6]-R,G-NP!U)'*3(3T4,,43%L+JS8&/)7=Q33PWZ-GOGL4T[3? M2@8*L;(ITT];=<36()%F-M&L1BL;O GZ8%:P&;%,[V>'T[M5'&7H-H7M0*EM MFDJF."F"+^9B78/VYW+F+<+S]>WCX^@+LK<'=_ M^6GS>'UW^P"^_QS"O1?@G=SOC7LJO*)P+W0H/ORLT^N@"JGJ6\!^HST QR,? MVG![P$=5Y\4M2D$"M\;=R.]>$'E<*WRZ_/J"P@2UIC\8GD03A%B39-R_P4-A&+V2VS&HE'#-2'9W3C0+X MZAPD46".O*/U:F9#KIH.4.LLRU7IG:9W4"Y(9]RF&ODH2:CWWQ42+F!-,9U6 M4S[$JIFT*D,[Q7/=I;:DDG*[J Q=G3)E:> CXQ3Y"85XIMR2#$W>+@@#,KF2 MB%?YQ-2JI8] BA4H\ZE%A;G1>6BMS0=(1J].8.MLRY19)J.*NL(4I7.GHK1# M8?=TU];( M6.W''!O671DVR8AETN![(O][TPZ.-)G<;11&U;IDLTJ;24-162.K.E6G0C0E M37;8FZW'2QL<'/M@;IA!2!D@R#B9[38DYM1!S=XIPDTD,QK41-CTO%K U>#N M5VO6'2%Z(IX#LF5$BK'>_+EPOL\S?E7"[0)Y#?5>C?3BR-@&,X 06&.Q*%B1 MB1ZY2@C25>?:@-"MK%H>03%EV#AFPKVY1*C_^5038+.BMQS-K3 82?+Q[ZRV6 M,CRZN4TNJY7.L=N##V,;HJ8%L!H#D7"@;P7:?-GPZNRAJVO]UJD:Q#U328A=S:+5R33KD]<4KFG$ GO6!F_GH M,>>\[QU2$+N49D69WG7\!05/SQC'YA4O44_H=K]S4'SG-SP16TQ2W8O1-[OU MK6)Y NQ:!C-(3GU_94.BY>/0U_F=EP8@*^[DGJ>">52U%@HS:^^B-,VU1U:U MF'U[EL-BH,MF\:+IQT<=6Z9TI5TM69CJ=#9:H9>A04V79_ M/AV-;E6 GB9GC3,8V,8R#K9F@-Y,%OU!IT]>H &"-&!R M25)(,5OCQ$%S&T[#;?@D9"$:@*I8PQ@V@^)#V$L4XG\FFZ]!*WGX.@9X) // MI11/@?7>V%G,;+""=H!:)UJ6H>Z@ GXA2J:I5@J\^XC(ME)019?&D MB\EB:7)*Z8:RZ:=?Y"DAFJ!(8/(+TS8]K0AR04NGF!8=XXFYQ5./5($M"\N) MO[+!;[ #5$FJ;J+[[CH$YU:FZI:R3"1L+B6WF%=\21:BBM#*MR-PMAUC,S"- MZ8!<"7Q?SL"=I>PVXPC8EK*CD0+#FWN>JVMHO^!Y/L*K!8Q3V=6P&&2]*S[ M+7D9-<^<8/K@TY[@Q516E\Z\L.*\P@/53*6=I3IC\7E'L1 GJYA13(!1>4?M1#-)G!%C/?ANK MSA3"L:Z+OW.8/%]M MHR]M&4WD*D:N^830!;=[#7G692LTLR+ 1QVI\EW>YN%/X.KF[B\V94_"JP"I MWGT\CZ\?4X0/A<7(7,;-PU>V:L" MQ":"9ZE7<[.MA?71G;I&F0(V7-UR(+4[,9^1?V[WQ/L)W$2DEH M8/$]TSGR-JX;(S+#R,/1FF(:!XH 8H7D-1EFEYJZ2\^&8X<<'>?A3B8-(A]X MR$F!%R2N=@-:2Q1MQ;;0)LNN3I;.=*K+@BPQJW4#>[K@X$$BR^MO]+6+&X\J M[\Z(/+,NS6 B MU\F>$IG"Z>#;V2YI;[J ;D3"Y.J_)UWYPC1M27ZHVH<=6\3L+',B&MK@4*4, ME)-HAVF [W-=RK],_43I=P;@']YSDPUV<@_?B(6%I'[%N_ ]'J'"##['%F:2 MJUVJ*V>P2DG9M=T8;C^%4U]%3)3-.+_"\"Z96J^0W5]] O:.;0AQ M[8.9>S]&+Z7S8@AKORB1K7U47(2PB^T@GQ[0(Y(B;+5;3Z>K5"KWE_">79E:X[ MG7HV6*#4D7*>,J.:;&:MG, MC<>#B293\L F]ZA]*DO[W\FOGIXO^@%^>?\(1\Z?N(OX'2BR#+ M?# >CW2=,EKG2I,-P)MO@^*ZTBM?5])IF-C!Z7^@ P33B8V,,-AH'VI-R?1? M<8(8VW R,U7OIL\>+OJ,+6>E+YR!P\LZ\I5,07""6O%-2? %#CH*0A)"AGB__V&8/PMKSI# M-.,WLR8,,RS&-KB(G:@:@TW _SV)YLT\\9?0JJ0:)ZR3: I%F!QX\FQ+?J(G M$<3^Y65+DP[ +<%'#,;7H1_%._K <5M."%5MC>DANE6HDBE"3949RIS);&E# M>&$OT(V,!(P0D?KR7.TL:906)G'^%7E+21HRFHU?-3 +/F MYEF38IF*(7+&-N3P:,/'<> DZ0)2HG "LHC>-XM2?)Q.W#AX(1/=G?]AGP0A M2A*\0)-G69([_QZW!)D8)2O9<47I>@/MN*H>7D7K5PYSV5RN%MK\37EL/%T- MZGPM%4CV97F1=!-/"R5_+1=K9/>>PRJAY5?Z$7U-/^"1]!MOKNE>"@L']\>^ MKVLN4D@Z>&PU!J2 EO6O/QF.;DB=ZZ=1SMN03O8(Z(T$A#FGRUP7\AO\0DH$ MM$C3_LI9!%00/MU'V\!52+XC4=":&:0%=BU'B$":/2JW=KVI#4<&59R-(^9^ MMX/Q&^'90_ 4!G[@PC %A^) 7IZ9[*0'3,T:2F<7-9^A:E[NT#?8A^ MU6/IZM3#O5I*JYU+!V%M6 ([PFWP4TY*F]:Y3T'R&SG(?,:='Y/W&A0\NUMT M-+ZQH0*^\M2&3('EK1F/'&V'#AD%.T"MT^^GB+#MG+1?;.;<^+!WR&NU:0"W M%]'>23=.M$\IK R5?+)0UF9A0S,X'^FZ%%=9X7K"[]F-FJYLNG9H[T;1>W&C MD:=6+&S=(3[\\QAY07H )]_)JVG2MD)S.->6$%YA M8>X#74,W:UG NW5XKX;3N7!KX:\-"W9'N(T[AD*=&$M8 26")MGCZ<#8:GW2 M%=K^5?ET*['2:C5&SFQA,B/$*>O0.A5;LL:R_+AJ->5.5;T*8);PQ6RJS3^\ M-:'T4348I+>/23C=LT./:1%]J:F-L-7XP]R]43>=M-79.,:]5@QK71U/%-NLSVP5IGU^Z>/@/_',7I M.U()%NSQF@UU?50 MI-2ZIX"Q3BZ;R52VSCS&,$Q(PHN-_Q3=:G1*D71P M_S:R8:(9B+DVV,;Z8%8G*BC9SBQRV/@IBKPOP7:+#RO788JK0LX<&_HH< ,5H'/,Q8]B M$\7IBF:3R<0?KVPQM0U5-_W$.L($ 3C-X M3.] SJ,=>;.(AFQDVZ?S*$G;3N7M:AISF"A6H9)XHD6'+496B_'+]%A\U3JK6]VUVH"'89L-)V15G UR97HTPH82S7D#5/?D#B-'\X^DPA%> M.!:N#*LR>S7^,"X2LA5O1ZW-F.)((Q@\CT2_&!GB*J%? GES@_P86EDXPM7"MBHLLNE2*TLN M4HNU?F/_OS6=C**RQA0RG:I321NCI,F>7IZ/5E#7?E7&Q3Z8Z^S,WL2@NQB8 M,CMH.37,CX8)>A4D+MRR#.:"9JB*Z",;#UJ94N7?F4/]=.Q9<>,I1M:D!Y$$ M?T4P!I>A9YH-GQ-TYU\F:;##7!4E]*X+Z6,$'UZ9$U4)=JR?+<=6F!QDV!J> ML0DU4172IHF1Y6JN/\>@M(PIZNI-]*Y4)*KA%6VC%[*J7GXEUT*(U4SH5Z6@J=.S3;DB58^V5C5F4%NM M5XX->_K.@)N^;-E5,0L^*8H ].;/-!\W'HV026BNB41U5FS5TIA;3ZT"E01[ MNYJX-CW!V EOG7DF9TN\CC']#*GF&,\*F6N$PWP *PPRUV&2QOO=83LL.LRKZ6JT MBW2I3,5@HJ+([!7^Q)G8D"RP!^2&B047 6@9Y$1]L,>5BAED#?\+C&/8>DB6 MBVI:MUN@%BNV0(Y90-%DOC9I9E%'6&=(KF1ZEBJ>!E$[08C%#;S)HG!F$,GF M[WS-UC:$&JNAE+W28II&ES F3TJ2QU+I6JS&IE8MC9YE:A6HN)K)5;)(\?E" MFY>LU/>L"]C&RP,P"5QF" FV>W*XN(F2A+Q!RW9>ALEWB[Z4[LOPE(S_TT6E MQ5J-C=V+T4?/OE4L\[5K&8P3<+9T;7C#^3CTS4,R.85LW\!UDNPQG\N)Q2ME MVW*(*.6\^8@@B5[T[L)/))-)C$'36^,V?O.+@5E$0+CT<2& M!W!/4(5&"H!^/@,7J(4T13$>#QX9((G299HEASZ6?KB M*72?L=)+%-,Q8L7+IZ4T431%"ZE>Z[V@7$=GT)0"^&K$E$2!=CP?0IC_RW*-5L:SV!T/7T9=[Y L<9OM M'][P5)E$;D#OAKX$Z7.)U,G1[R&VTKF9"_*-FNL_OT3A1QC")Q85CG?C.WI3 M4'<$.[XX[>3N764.QSN7Q2Z8O>G5-IEB$=G)WJAJ'T$KZ;*^(YK.5\;W%4X>K8TW+QYWNG MS&&J\WZW3Z%F]L+]JR_:)W6NX-'Z9=>*Z\'(>T4TU8KJ)9%L$V\DN46I]!HR1N]*!0,/'KU&G#)S3^$ E[FB;;[ V*->;,P++B%-15W8 M2D<=)?/UJ3]B)"_0"9M'D$;H!%]@KA=+.%[:<'L_9-T:KURA% ;;)%^Q7O/B M0$(^3?].1B/YPV#)4<2GK=QOJHL)5+4,XX=H>>443M'\ IC=T''1TJ(EHP]T MY=LB\.=]X/[&'H\9_I)(7*G:22FO8[>6$19BG*\MU5,@K* $%APX'HLSQ8H^G2 MIINF[L 'M]^0C0C>D.]@'/P=2YYJ3S+(P;4<9E4^6VQ<7'58%<%9)^CA$T0#WN->T>&) MCQ:;&.&31G8NSK+_9G7\B\'+A[S17T=T='T5"5K6DY.VQ#% M,G.:8EGLZ'*\-AKV/UB%&I&%^3< 'G[9DE38:RIC CRQ3X$T KB.^'?VM6&> M),_K>K=/DQ1O]S#"K,9747RY>]E&;P@EY-4'-R#.QAC+QGL-DBA6,.6X M$8E85^FD<8_;]QD>; NEQNEF .U3H@'S4O^*DPZ$VMB![$FW8@U*?67.X>KI0U!;\I ^<2:V$RL:6=B3>T@UK0;L::E M_O+7H_',JG1$;4#YQ)I:0ZP\"U+)\:NHF_)KRYU+T9D[O%<%J^G%.Q7!''GF M[G1M0\K+H\ WR*MR]S=@9[9Z=4H%L_ /?SW6U3$*+Z8H(&U:2TY_&7OT1*+B M?]PBJV]2. &/;'A=0(ZN\8I6B3=%I)_I]6<3ID&>W>*A2&YQ^=7=[CWD7>%> M(Y=+>_9$QIU?3YCTX8U?@,38,.@7-:9J'K[A*FF>A_L2?!N3;H/1Q<.>#_/.'K%_$^B(JR@+3"W6,?L0?D(W0JHS&,<4# M5QD%98',8=N;C7P;>"N&UF :$05$]@2,$.8M9XGZN> V]QS(HCI%' M5SH),>3RNJY0%4 ?+D@EPFQ'[SMC:#[A@C+,A@\9U00;4.BR_G1F8Y-QL=U@,A_52#W^WBE>AH(4K_ ;^&(2%PG M3>20JTSAR[)(^?5BO#*Y?^V&DL^7IG>$)=;U(P^3FQU)?SO,034O^YNQ6%0; MXX2V"58P2VJUGHR=?P K!*]*]:%SWY)?-D0IV)*$XB\H9OM^(R9_Z9-Q/#9( M%6B3+.%JL=(5PJAP!= !L?0]/*_T'IY+GB0S//L5#Z3ABI4>3ZOU7:TQVI3T MS5=J\,O4DVNP2+T5M./I@2Y892_A13'8%0_AV<"Z^SAR$?(2,DG>1+"1LU(B MIX];0I!E.C6$V%R 7+2P88UJ@==8;S)Q0%H"KRSPR"CJ$]Y8'AZ ^A0DOTDL MTW(5$_>78NC\:\RF/+,5SR9P98/#ECI2R:WX0140W2&MW,6#D&\DJ;K,RLV7 MU/\>)PX*NG)[@5A41ADB7'8JW;T65=! M0XB$-;[&)85;>7.+*\DLT^YZ-+-A>E+!*+N48V^QH*_D7+8/DF?C+UJRNMR% MM7GW%J5W_B/\*F@&!3V=;UPJ5J+ZV&6+$K-PSWWDV[ ![PA7F$E+\#[+4('N M34=(\5Y<)JTM$+T-<"FP7"3*]BJKV6AI_%Y8%:3DT%9R8578GVLY7)<@23:[ M,GGVKM%B-/-T)7EDC\ ]I/BP([,YJX-N/#N*GB"Y; .Q']W3>^"#SFEZ*7Q M^3/&2K( %G__"6^MR,.H8T%+="G Q-/NJM7BO^_>IDW[&BTG4V@RI^.QN!L; M(:8(\*;Z$(G\CS&93+S53%M@$9M,+D/OJ*FD@%SOIDOF5&C'1$*]8DEJQ3;/ MY(.,9L_D.KB&9W(ND+TX"AW?AB.R!!K?,YG(#N:KGL1IB0WX7PY8$B/5WY@::DF#C3Z9H<$4L,82\2&,\@?,J82$LD\AWERVOR& MQ2!+7L--(>;-[:(E,IX'IQU>TSA1))ZE WQ(&WS+(/\8A,%NO^/2@_.[GL'. M!94/^,J/+"7&?.G,3!H,6F#5NS\3-=KM\*N\VZN_:^IV'JBBV\L_LO;UI@O? MY.AO@=7H=B8ZK _O(65V\;@&\6-Q4^1=!*^!AT+O$YYR>/.8LJJNK)[=JG)( MVZFFQXY-GC>"QGU^>R%NG" R#>!E*@,EG6UB)8X%5S$JWK/N0#"^JCF"R:HB M(QA/CUU0^,LU,IYWO!?BQGZ5^(_X6 7DMS$@A@,],RX9$3]'6WS")@'[/2:R MNK+YJ8Q?'97)K*J9Q;FN9T8=XH[!+)S07@LEW5Q[1/&N8PV9BGE>E:&KL(G( MLYMZ9[J8&@_$[(14R!P\3>T,V]+*;EJ/,0P3DC(^"I,/;^5?)(:V+@7HL\)U MKU8U,$%5FWE?N_,1M.%U@;ZXY7YXY9)(SHKJK\,9B/8.2OZVAS&ZV;H2^Q!/ M3)=Y2 SQ8!UJRC!3NX_6KF-Z'FM%U[ -%0H :]CBGOD)O;#7')/*,V/$&4(X M5"0:.N>I5N#5B4DHSI:XS"?W\(V\ED$"4ETWWB.OZ4^"?[O%/2X-E.E?G$9_CB.K M7'']Z%D62P^P\D8YL<8]9$R1)%+^1'W@[H),4JVF_><(F M*/:G)RB3G1W68V]J?#][\MHTH["S#P!(OP#>5:G?<-@'N^Q#Y,6ZQ3^#E^)C M].=!ALKF"9_,GC"H6G/P6DPLJXG4;6 +IHH$,W=KUT4FHU5W*3U^\+@Z?ODD.M#]=V!JL59P=#-RO% M]7.^DQEL:&FS"1P1_[M>>0MM.0Z57G%0 7OR,. !N^HDP?X3QW,FNCR-%+I) M!>J0,?^"%:D][:2A3),MR24YF1H=;P)]XQ?I,F#U_OV+>L[( 8=;OI!D^;=$ M5S4<,3;%C.#8U>4#HS#06G%JCAL^6?PZIW_:JVXB1KTGD6PP!T!*>3"72NO;UK8 /VW2A*&M[%^]/3;Y5 MVPED8Q-=TB,SC$>20'F9JM;YGE:C1O!;E)8!UH>LH@J;7R?3V5B7&4&R#O3" M7.^UQRB%VT$&LGH'=*N/MH$]'(-,WFYUQ=E8#"AC]&[@A.DODIH!@'."ZJJ; MN:J[ZYFNF;@EF\1Q%6ADEF!QX.01&@<]!2%-::TM7TQ+?_6LL=&,,D-1T/CY MK@_@QF3!I9N9TY_6;!\>+N>8?81RNX62I M[:]]99@M?$G :8/]%8DCB>Y7D#=$'%'T?ZLPFT%]UYE: M1QPQS';B**<+&*"#>F3AF,Y=?AHETR97"*85';(W]E-.OXR2K0FD?#5!J-_E15 M*LF>)!L]J:I0#+ONGH\GK0'M&#OVG0Z5D#T=.1M*"6/#0>N'XMESV MG*8F%J;#4.K04[2$#0NI1O8:OV@Z&GW#HLQAJX'+*$Z]DJX)4BH*["RQ@%!; MO&^/R4:">,!,*>K3";<+NM3)Y/1P O[8N!?AHQ0/:\(7.P;TT0F/UE,/K2QP M&.P.6/]H)A-_YN!_%P=/00BWQ'.;(N951RZO:12K@"X8(Q-F!T\1_GKZ1ES8Z+]YE>V@;"9*J+TZ MHA@@L686+S'V'/.^AOTPM\;OL)>ZJ29X844QET3ZIX%N2BJ;V#S$>H="#WF\ MNKE6MY+#129_=HJX7*]_D8SO'(V^^XE5RISX#'B0SVH&5 MS=#$+(91DV_?&]Y61FY 8B7_$J3/><"/F@N+4-F87U]+=23>1 )-MG6:S-R9 M\:ODGI@5GI5[ [ H"'S!)8$O65'#++G4&:WDQ,9="II"NI96$;S#+PH0W0WA<;TR^>))!XAU+E$50'1H5"(@6L/E-O[S/G!_ MH[DFA#YP#1%-4XP 6C&KU'YG.8S@?.H:WRA+D=7[FPJSHYGA)VQ/E&=CO/3\ MN:X$#BF*C\BR44"59]DX=)$%/?,YA"RVC;CN- -SE968&]IL@=S!KUG6K*]" MFO"IY5W03JCKW7:#DN1'L#^H*03L&LC7*^G"KNUA+COO27EH,HM9=Z2-VSZZ M4!]TST!)&^3J9J;UD^3D@>N5IVU9;9W258 .F9'G^.2UY90$?MFL=A^C7;"O MW_5WT-.8CE:U$I6\LVU*F0_ZTK$B97)'N/(4$K[!%!+U-"EW86T0W:+TSG^$ M7WF=UJK$3"F^,QVMS7L']$1]PN1"0QV(ADO@,(>CYKP'"CDFFSV M7*V72->92<6!H@MFE5PZX%WCX*29?XJ>.T(MXXQ3\=41J+",+X.K2SD#==^\:#.#NC;4E!TSCJF#OEF,]W MX:WA:&1!VI63U>.(M!<:>UESJ@AO.796%N2#/%D]_CMCA##_BP?16)<52GXW M<)IZ')4OPD!?]X[7A:NEN]:U@>O=@N7UEK(R,W[XCJ?MZ5N%WNN)ON^3MX;O53MW=-_6TGDC MJY&]-GC9=4?1VZ,8()JD6*2R9G!5U3 M+J ME1&[@0H4V23E>D-L"^75DC+C;ITD*:0ITWDY,)FTF)P0' ML"@)1$F411=[J^74^/V)*LC6- _10=/PI/4)PXD#LNFF,7!TZ_[P##%*%@Z7 M^]"1\-KG:.MQKGJ/*TK?E'9,5_?&WP-^Q6PEG!?ME2H2.M__;0"KQG\4/S-#[=)QUB:#K%N! M-6>*7- P!6[0$]Q>(:&%JO2[ONYO@"IW?O$C:V%O[(U-9OQI@=4,",9B=')( M8Q@FT*6A6(C$EKC'FC,%Q_'[. C=X 5NJ^'SY0-C0T33P5L K3AMUWYGVZKE M'$V,NVQ(D37B/W)A '<6Q'Z3H'2$KH*0;$)OB TI#R+D9(-75=(Y.ZC KTX9 M,@TV8!T]/<4T:<(]KO,S!B<[GRIIZ#+Q*0$_ MF/FDXNPF8#:>^B;CT#H#;>Q9&G6P/6$5 MFCX;3!N\$'7CEC[D(WRJ9';-DH/0P8N!UE)H?U)5UVGWZU:EJOE/39I95; ?N@%ONM,&:>=@H6+.,WP=_V@4?L$!=P!Y\0,88P]^-@^\9;9EH4 M-"WB2K"+-5PJS=(V^0X>F::7\ XX&Z?)0A5X3)?8GUC&'X^H&Y[GV#8V")\^ M(1<%KY"Z0(;4+ :WF57U'B;IQ1Z)UNUN1>B;[_I4K?+>?0=]%DX[7R^U&2;#?[PWE0-OMR'84CQ?X4@U?$H@PCW%_ L<6/-2LA%'<40GIJ'?$=QI MUE.F_3@%_2&OKM;#83_"F-S;M.%J>%$>! &5'"8@\M_Q4O7\$:%8'/S8$-&T MO15 *S:TM=^SG$/(UQ92(=S"2I'5.YH* R(];.CKM1=]1+&/MIZXJYLRFOI: M!.Z0**TFP'92R)N[QE\ND$-K;/*\"&3B)^KO$VSR7J(D2$L7_JK>SZUZ.K=^ MBI6H[@);E-@:[B[GG@UK1T>XS2W'"PQ.Y>Q\/.OVZ#'ZQ-P_R'84UZ;I=E-O M +F.1K:I@*\P3::0A=>-9MI"EZ0L4X?:N''#!]DLC+;ASN+M;8+ M'X4#94_T]9XL%)2Z4LODW[E3^[:,SD5!(U-M"$?HCKAQQLV+ ,5DPPHY W_> M0[S#8<^]13'Y)_F!_?LZ]*-X1_,-GX$#N0\?-)/)OY896<%&(==@H1OCT6AE MD;MP%\C"%04Q9>/NOBK]U:G^>IV"!Z";#1?)BC ;D\EA#F&*9Z"#"4V32V=I M6UU/A/(Q\@(_0-YCM+C'^D&21/$;-X?E" M5<\IS1=M=]F'R)%F\<_@I?A82Y[,X9WV6OR$18+LZLB=(&A+ C UI!)/O6^_ M4ZL6G"P,IP_]QTT>G*YLEHW+G4#/ECS;@U6N-0P\CVGZ%KG6*8N)LA);E'UG M[NCR %9@1T?49G+NB'-&=$VBTT%/7QZ) >DV-G[-UPUJ8[^J2K!AK@,WGA>0 M$S1><3.G ^:_Q'_36B:MBTVM@ \<$HJR+:*[G#LF+2B=0#;FI4*OA(-;1Z:[RQL"ND*QA3!.YS#ZQ)L0S$>KT-N? MQ@=-Z&GODLA>S$8>Z/*OVGSHZX!*#O/Y3RR1_7KJKXSWJPA4TQ7>)38PX"/3 M9M9'^!4E>&^4(1)%UC?%]$W_(HCE.;\NP\)8IFB^MN'Q/3DZ"3E,NYI^BMZ( MFWMFLA74KBZD,?D8%UXEK5A%@FW='.3XNOR29:R086ND F.RI[F;D<_^_,[F M2NA=!3C=S/F9!5;"Q7J]M&0UX +C#GH7#=K!I?34)/ Z3 (/Q?2B5G:X5-'2 M]LR3:@5*SSRUJ3#O#&\YG9B\7NL%MN'@==!GD9FE$FPYA3[ +;KS:13JP27@ MSB\39O1A]RU+?*I87KJYE9#Y&H]'"AI??CT,O6OP._E&$ MW2%*08*_8WJ/1*\X0K@]CY$7I)L$[^\2^N"6^/EJN8IF)X46Z T7!8$\>^EX M,5OY-B2F44?*=8,AYCNF"@ZZX!>B/4@X0!*G):KA?QUHAO]!4GAZ>S>]BQ]0 M_(HW"AQJB<6&IU,;1$(AD4R6>6X^@R9IHX:NZ;- ->C-0*9T$HX(MF\/;H!9 M&/B!N_%>@R22!(4)135MU%J@%KLS@1RSAJU==VQ\#Z^$L$Z,@Q+(M RO43^1 MY#-Q:Q+ M:!K\?&#%F*_^S,P>TQ$<&S]]R8!QNQ6,A^O8QR]12\>6)'1V; -8M6.+GYF/ MV'0V'9LE7>CHS?N[,!>S=X;1N_91&MO=N M5NO=XG<6]#-U7&TN@2V]*T#&[]WY(+U[N7O91F\(21ZI;XAHZET!M*)W:[]G MIY/Q=&S\=2 9RU8%L MM^0JC+T#=[&/@_#I'L5!Y+'WX0Y9=>_\SV&0)I_I@RO\Z_B^)>FR_!Y5T8-A MN%4<>"Y.=^U.0580,GQ553(V-3G\6K M>4L/&H]B. IYG7X_GX!\IW0?*?D/7(B?@I$I&'$)$< 6.'_4I)E5>@*71F>X MKCCYIWA/^N[+4)-!G[R5,Q\N'5U7D6VQDU* XO251LXV':_W?'<]<2Q(>="* MK^,MGSTW;6MW/M66@;6-R3)\G2_<[+GTFOLK;ZYKZ5=J8P&^SG=?=MT]+9?^ M:F)7.XL0=KZ"LND2:.6N5MK":)3:602P\UW04,W<+V'R>#Q=KG5=IK8UM!RA M)&^RD8W&S;"&[ODR,X#GSB?&L]\?#%["3"!J9-DYJ01F-UHXV"XK" M?*X*MX\AY8CIXG9/5OX[/^/*!_04A)A+'^"6Y"#@\:Y-0],4H :\&.QR\6SG M@]9+X]X478#6N<)T2>14I@V<3!TX3%\'ARAC^=<'(DDSG*D!%7$E$V/GD.5D M-;&-(UR [=S(U'10(M_WJ)"B)&N&%@VP(F(4@BR&:.PL/9.>,AT@MI.C4-1! MCW,R-6V1=Q7AXV6 .7D7T].+$E]DRF8(U%X=$:/$FFSBGZ[7T+@W9T_,[9S+ M2SH#?E[6&*"%DU99F)DP%^OYTKJ)2PRSG4B( M*@^_YVE.M*+3M%1<)VODD*NDX'6V967 +(B M:HZ(Q:%,.\\D)S,E-0M8)CJS*>AD]_NKD;8G%WIQC(NV*\6&/-O)P$L/>HJ* M%K!,? 14TLK,K/[:CC(WD3A MTR.*=^35TL,KLY>KZ?QJ/;HX'UTL>?57T=*5.E2Y H=THJTJS+4"NO.5\?FP M*]C.'--[\+V"0?PSW.Z1RGV1NJZ96:ZU,J))3JC(UK'58HV,1Y;T@RRD'\SH MY^-RP"LIB)A?HLS\\C3@@>43VD%ZX#Z/PC2&;DJ&D\SFTJ*@B6M*L N"2:69 M-6RR'OO&#R0=<#:2A.:J(-<%*58>UI["Q.7JY>(FB5.%+*<-DV41ME,7 MSDVF4N^&4I4R3%37 ^TZ1JDCN2AH4V!I?Q=K:TDD@JK*I*&W3V5/OFS! M?8QH]DD799DG-Z'W89\$(4J2["^2_#;'E:?3O_/(2E?]/'L6QC@Q7\RUQ:S) M_3U/4HU&+E-2JWO?!^?7#JS MO*YFDLS\*L@Y6]5AE^)C9[ZTDYHRM,H,S L9EF3LPX_1/6Z19Y@@YD--WF?8 M[:*0@N-56TE-$\DZ5*$@F8).EE)I,9T:?^RS,UJN)S4YB(;9J9.\"OR2E<8> MTR E@80493H' JGW@TCV=MSF"XR]>Q33 M'VJ'=VKJN?-9F^4M6#>YZ/ZXQMP,6INS$J6@Y:G=!7 M5RWVRD8:WD8AF_XN_[8/TK?K,$GC/?DUN=NG20KI:9;YP9V4A!V^FSWA/A]- M=1WT7EB\4PKC]&8(-O:N?(.++%XP 24]8K2"QQNMS"TT/2AIH&.^B47F6QG= M)OT]C52VD5J0%OV.E@W*WP#CB7B\-_C44.C?SQY)O>6W:LIW -']2S,OM(P\V) M>STK%M9U&=X&]W#[+9)DGHT;0IIYH3$ M@[8NP3;/RSFNIBT<$& 3]CUJ=X']ME8:NS:>2S2?>'J/E9>A9\6ALJBZTJ&R M[5I[L"N.MN9(6MNC7'^9=V7SJD3?MYE]>8S&GJ[5JL7&8;8!NGH:GM[\(;HT MU$]'0QVB[Q+SO] (-_\BJ8$*-Y]1Z#&:):8*FXE)SW3)=<@R:&GGIOKGV5%D MZ?;&M_&@YL,U;GS"I2-YX$'?L+];&$Z@8KWW?0-WW5^U&5IMI6Q@8 MC9&V$X+L#;^EL]1E^-"Q[SRB">S*D6",D49[Y)M:I[[% 3\V[O-KL-Z==Z/% M=[Y1(\BW8IT;.U,XUVM_%UP&F:W^,=;W4X0_'N]7E,*4MM#Y%B9)EAM]\S5( M1'=N8GF-7CUMH"L7I")AMID8C\>>R2OOCC";03N9&J!ZX,X'+(Z'J ZRS_GS M/G!_.X&XAAYE*=<^BAI:)QNVH%7)ARQ.$NMX"W]F153CBK0 MQJ1#%<'F#!2Z;-8QXGE3BCUCT2F;??H.N] MQ!19QYPQ;VC<9X6RZ;ZZA_%=3)..6OI,I,:626>-M*7_[]9W:KCE M?8C+( GQ6"F %@-P.:QO3<_NE%_L*22ZUZWW)\]YBR^OV3U91,]W\C LE^X+2^"C)9T^\ MKE=0EY-OGT$B!*PR4BJ17:;72]G+@;?H"_U);(514]9IDNE2G:I]1D4S3UWB M(9..@<=@%K^8DJ>\8+-Y0(LE.9#!E\R]W,C<4CT6JIRLY!HLM&LY=UR+YI ==#0-XU([ M-7JDR+V]P1,+0WCY]06Y)-$>BG>-OFF1_Y4?#WQT7WB12V,984:86OMR.JD= MZ!_9_A:DSP@$1;3D&8!)@E*R1FX#Z 1;DD@C((&X3)FD=G,0B,K9-((0_.X^ M_&OX,;QX#/^$_^?A=V2KNX,I??8#Z\+=RQ:=8:GQ7^"&(+?X M% #^9Q23XGV2_Y6D+P\1>$,PQB4$KPC@O73ZC,]Z^)-8/L"B"%,)OB4_-$A4 M_L,-_B_\Q_Q/^/\Y,$%__/]02P,$% @ H72O5AM0?LAS/@ E88# !4 M !Q 5 ]:S-=F5F M " ^_W"X.QR.?_[7'\^;U2M.TC"._O*3^K/RTPI'*/;#Z/$O/VW3#S!%8?C3 M*LU@Y,--'.&__/2&TY_^]5_^^W_[Y__QX<-_?OKZ>745H^TSCK+598)AAOW5 M]S![6M&??H5IAI,/'_:E?]M]Y\\K[6?]9\4Y_/LGF)):<937(3^JAU^N2'NK M.%@AVG)>53$_JN9'3='T0Z'[.,B^PP2O8(*>P@RC;)O SJKKNA_S7XNBM9(_O&13?$/_6'2'%$_#/Z?YYS['*!21Q!O\%0R !- MP^>7#4'X<>AG(Q]'9$1^@AM*POT3QEG:W0]6K1D[=D=&?I0]X2Q$<#.LEXU- M3-OE^XS,9+I(I.M@_8*3?,"EWR*X]I"5+'LC MW%WA)'PEE+WBSR'TPDV8<8AR1)-S0)H(QEFZ_HU,?[1-R!+P%"?9 TZ>+_Q7 MNL'<)/'SPU.8[,38U?6>S4S2]3+-#PF,4HCR/:6KKUWU)NG<;93AS89JM'!S ME\1DP\O>/H>(KK87CPG.%UM"\/T+J143N5$-E&K!AQ^[4$SV@6F61+KSW1'- MI'/5JQ:<9@+"ES"#F[SQSEG64':B;<%+\1];(MKK5[J5=F\ S>7/N$=-NU?- MLF?Q??H!DD5S(ABG;8G:\_@0C6[XG/O?($AGA'%8FSA'4W/QR152;\Q#FUK6$+CL!%9N*%1>1B,O$" M(G+1F'BA$+DX='S;F!:*(1"*.2T44R 4:UHHED H]K10;(%0G&FA. *A#-4# MA.S]IW[VK,W/WA?:R&9G=>?WQ=*W'3G<_7U1SO;!:3UIO ZAEO*S=*;;K=-6 M89;N="J#K15FZ0Z_KZBKXN2.4%Z+IKW*7%WBWT,XZK9W\J44T?"9_,-)!?PC MPY%_C-:@?>4.TLK"C)96=O]/77TXQ@9^6.4E5W?P$:]NHR!.GGWN3M U*F4N3C['VZCHBHWK[BQY!^,\J^P&?O3>OL3'ESP2[ -Z"C>'$1"0S;M-4GNYQ!W=+8N/ M?.I\$KXD:!*XN24C^L>_XS>6B&M%N62L"I-Q"[2S"KF8W0^DQ6;9GI;@$JDF M0*1-0,XJR0OR=9_VX&8#'YM%62G")4M=@"P;H9Q5F)?;A&*X"5,$-_^'**S7 MQ,@BVGS+XM]:FDO$A@ 1=P$4L-+>/\/-IHB>9*VSE8)<,C:%K;*-L$2(]XG8 M:9?Q\PN,F+O8:3DNX5KBA-L 2H!LKY]Q\AA&C[\D\??LB4/(+16XI&T+DS83 MI@C=;+>(?<4O<4+C FCT^):Y=+35X!*\(TSP;*!"%+8[G(2QS]P66XIRR=H5 MJ,(U0A,PO&_"#4XN21\>XX2YFE0*\ID=XFR[1EQ"!O%._=GQ?4/^K67M8!3G MD[4(&Z\3HT")4X636]ZEPGS2%FG^M> 3L3G&S\_Q[B;8_1.!EZZW67X)E^P? MS"V268^/ 1%&(S]J(0/_/[8PR7"R>=MMXNR!7RO,)W81AF0'/C'.)'K:%E+I M\ B[7II/VB),RBZ$@K24+]MG[^C#;U-1BE)\XA5G5-81"1#K;83BA%";RR6_ M%GM)HY\3LL+Y3$=_1T4^X8NS,;EP"^#C ?ZX]0G /!B=]JU[S+=6X>- G+G9 M@56 ]"]\/Z%WJG?_^1Q&6&5)OK$XG]1%&)Z=&,5)_)+\<9T\Q-\C#GF7"_,= MU(@S0EOQB9-UOMJMD[LD?@UWJ5NZ!%ZKP2=U<4>.;*3B1'\7$R-A\W_#EZ[= MM;D\G]A%V*7=*,][KD8[DV#8+N;3$GR"%6%N-B$YJRAISJ7-W5,<,;7O>BD^ MD8HP)=L0"=&^B2U+XS5?\17,X-[_SE:[FVOPB5O<\20;:4WT__RQAH-H*K_/ M%QO&S(E5"A;35A]6A^Q!-%9L_>7J^LO]]=7JT\7GBR^7UZO[OUY?/]R/C18+ M8.KE9&S3#X\0ONR&$=YD:?$OQ_&T_P=PZ-V>^,L+)]=9[: M0'=UJ"CC)\@0>!=I2DCI!G):#BB:;ZJU.5V=(;5Q..T\&2+CTYG$!G<,\A+' MS'Y.\Q)4*0XLG8A3DX.G%BDS&&E#YG%Q#3)2XIDL(LZH+C0Q9)L6H,Y.Z X M!L%L JNU TU\LX;UQ'D/Z!!/+K;6TUP&J MZV//EH.\WDQT\=D&]A@F*&0=W67I2>_@&TW^1*"2?TFV9&&I]9RQV/(W G2- M+&:>=!RWL=.\+ _ >PQ*%$'SU18_Q*4;KCRLMM]?G!!+,9Y"-K&F5"?=^Q:C%G"1 MYR@U@V=9Y'$!+,6)RF'<]3'J0&";GKIPFABP2F&EBW7&7Q> 0!QK#@6%B2W$6;I%SP"O%RHH@[:X88GE7.PZ,&@H#[ 6V+
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